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Abstract 
Reaction of a range of protected β-aminoalkyl zinc iodide with 3-chloro-2-
(chloromethyl)prop-1-ene under copper catalysis, followed by cyclization 
using sodium hydride, gave enantiomerically enriched 5-methylene 
piperidines in good yields (55%-85%) (Scheme A). 
 
Scheme A: Synthesis of 5-methylene-2-substituted piperidines 
Application of this general method using the cyclic reagents 129 and 138, 
followed by cyclization provided 6-methylene indolizidine 128 (Scheme B). 
 
Scheme B: Synthesis of 6-methyleneindolizidine 
Hydrogenation of the previous piperidines (Scheme A) gave two 
separable diastereoisomeric 5-methyl-2-substituted piperidines: 
hydrogenation of substrates with a TFA-protecting group was more 
stereoselective than hydrogenation of the corresponding Boc-protecting 
 VIII 
 
group derivatives. Heck reaction were carried out with these piperidines, 
and hydrogenation of the Heck products gave 2,5-disubstituted piperidines 
(Scheme C).  
 
Scheme C: Hydrogenation of piperidines and Heck products 
2,6-Disubstituted piperidines were formed by reductive cyclization of 6-
oxoamino acid derivatives (Scheme D), prepared by conjugate addition of 
organozinc reagents derived from L-serine to enones. Stereoselective 
reduction of the intermediate imine produced two inseparable 
diastereoisomeric 2,6-disubstituted piperidines. 
Scheme D: Synthesis of pipecolic acid derivatives 
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Chapter 1: Introduction 
1.1 Introduction 
Piperidine ring systems are important components of a number of natural 
products and pharmacologically and medically active substances, and 
have therefore been the subject of much synthetic effort.1-3 This project will 
focus on short diastereoselective syntheses of a range of significant 
substituted piperidines, specifically 2,5 and 2,6-disubstituted piperidines. 
1.1.1 Importance of 2,5-disubstituted piperidines 
2,5-Disubstituted piperidines have been found to be useful for inhibiting  γ-
aminobutyric acid (GABA) uptake. For example, nipecotic acid derivatives 
1 and 2 have been synthesized, and have shown reasonable activity as 
GABA uptake inhibitors. Other 2,5-disubstituted piperidines, for example 
compound 3a, have been synthesized and studied biologically. The cis-
isomer of compound 3a was found to be more active than the trans-isomer 
for dopamine transport activity by a factor of 3. This activity could be 
increased further by replacing the fluorine atom with a cyano group 
(compound 3b) (Figure 1).4,5 
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Figure 1 
1.1.2 Importance of 2,6-disubstituted piperidines 
The 2,6-disubstituted N-arylsulfonyl piperidines 4 have been reported to 
be γ-secretase inhibitors, used for the treatment of Alzheimer’s disease 
(the cis-isomers 4 were more active than the trans-isomers). Introduction 
of a cyclopropyl ring, compound 5, gave the most active γ-secretase 
inhibitors.6-9 The N-sulfonamide 6 derived from cis-2,6-dimethylpiperidine, 
has been shown to inhibit acetylcholinesterase (Figure 2).10 
 
Figure 2 
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1.2 Preparation of disubstituted piperidines  
There are a significant number of methods for the preparation of 
disubstituted piperidines. This section will summarize some of the most 
important methods for making 2,5 and 2,6-disubstituted piperidines using 
a cyclization strategy, rather than starting with the piperidine skeleton.1-
3,11,12  
1.2.1 Preparation of 2,5-disubstituted piperidines  
There have been a small number of synthetic methods reported for the 
preparation of 2-substituted-5-methylene piperidines, either as racemates 
or in enantiomerically pure form. 
Shipman and co-workers reported radical 5-exo cyclization of 2-
methylene-N-substituted aziridines containing a phenylselenide group to 
give 5-methylene piperidines.13 The aziridines 10 were synthesized from 
the aminoalcohols 7 over three steps (Scheme 1).14-16  Alkylation of 
compound 7 with 2,3-dibromopropene gave the alcohols 8, and was 
followed by introduction of the phenylselenide group. Cyclization of 
compounds 9 with sodium amide gave the aziridines 10.17,18 
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Scheme 1 
The aziridines 10 underwent radical rearrangement upon treatment with 
tri-n-butyltin hydride and AIBN (Scheme 2).19  This rearrangement 
proceeds via the aziridinylcarbinyl radical 11, which undergoes a 5-exo-trig 
cyclization followed by ring opening of the aziridinylmethyl radical, 
releasing the ring strain present in compound 12 by breaking the C-N 
bond, giving the piperidines 14. 
 
Scheme 2 
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Desmaële and co-workers have disclosed an alternative route to 5-
methylenepiperidines involving sequential palladium-catalyzed allylic 
amination and Michael addition (Scheme 3).20,21 Reaction of commercially 
available bromo-acetal 15 with diethyl malonate in the presence of sodium 
ethoxide gave compound 16, which underwent saponification to produce 
diacid 17. A decarboxylative Mannich reaction gave 18 which was 
esterfied to give 19. DIBAL-H reduction of the ester 19 and hydrolysis of 
the acetal group gave hemiacetal 21, which on treatment with methyl 
(triphenylphosphoranylidene)acetate provided the unsaturated ester 22 
which was acetylated to give unsaturated ester 23.22 Palladium-catalyzed 
reaction of benzylamine with compound 23 gave the piperidine 25a, 
presumably via the η3-allylpalladium complex 24. A less nucleophilic 
amine (p-toluenesulfonamide) gave a lower yield.23  
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Scheme 3 
Ring opening of activated aziridines with palladium-trimethylenemethane 
(Pd-TMM) complex in a formal [3+3] cycloaddition has been reported by 
Bambal and Kemmitt.24 Harrity and co-workers have applied this approach 
for the synthesis of functionalized piperidines.25,26 The enantiomerically 
pure monosubstituted aziridine precursors 27 were prepared from the 
corresponding amino acids in three steps (Scheme 4).27 The cycloaddition 
reaction of (Pd-TMM) complex 29, prepared by heating 2-
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[(trimethylsilyl)methyl]-2-prop-1-enyl acetate 28 with catalytic palladium, 
with monosubstituted aziridines 27 provided 5-methylene piperidines 30 in 
excellent yields. 
 
Scheme 4 
Sun and co-workers have synthesized 5-methylenepipecolate 37 through 
a sequence involving allylation, ring-closing metathesis and palladium-
catalyzed formate reduction (Scheme 5).28 Allylation of 5-
phenylmorpholin-2-one 31 with allyl bromide furnished 32. Acidic 
deprotection of the Boc group gave amine 33, which underwent N-
allylation with compound 34 to produce secondary amine 35. Protection 
and ring closing metathesis (RCM) gave unsaturated pipecolate 36 in 
excellent yield. Regioselective palladium catalyzed formate reduction gave 
37. 
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Scheme 5 
1.2.2 Preparation of indolizidines 
Najera and co-workers have reported a synthetic approach to the related 
indolizidinone 43 (Scheme 6).29,30 Treatment of (S)-pyroglutaminol 38 with 
p-toluenesulfonyl chloride under basic conditions afforded tosylate 39 
which underwent nucleophilic displacement by p-methylthiophenol, 
followed by oxidation to give enantiomerically pure sulfone 40. 
Subsequent addition of 2 eq. NaH and 3-chloro-2-(chloromethyl) propene 
41 gave tosylindolizidine 42, which was reduced to the indolizidinone 43. 
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Scheme 6 
De Kimpe and co-workers developed a novel synthesis of indolizidines by 
dialkylating 2-methyl-1-pyrroline with a 1,3-dielectrophile (Scheme 7).31 
The pyrroline 44 was deprotonated by LDA and consecutive reaction with 
1-bromo-3-chloro-2-methylpropane furnished the intermediate 45 as a 
stable salt, which  was reduced with LiAlH4 to give an inseparable mixture 
of the diastereoisomeric indolizidines 46 and 47 in a 1:9 trans:cis ratio. 
Scheme 7 
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Daïch and co-workers have synthesized indolizidines using the reductive 
desulfurization of benzothienoindolizines (Scheme 8).32 Preparation of 
(S)-N-benzothienylmethylglutamic acid 49 was achieved by reaction of 
aldehyde 48 with L-glutamic acid, forming a Schiff base, followed by 
reduction. Refluxing compound 49 in ethanol gave the γ-lactam 50. The 
carboxylic acid was then transformed into an acid chloride, which 
underwent an intramolecular Friedel-Crafts reaction to give the expected 
tricyclic keto-lactam 51. Reduction of the ketone provided trans alcohol 52 
as a single diastereoisomer. The reduction of alcohol 52 was achieved 
using triethylsilane/trifluoroacetic acid furnishing lactam 53. The use of 
BH3.Me2S to reduce this lactam to compound 54 was successful.  
Compounds 53 and 54 were each subjected to reduction with activated 
Ra-Ni in anhydrous methanol in the presence of hydrogen gas. Lactam 53 
gave an inseparable mixture of the two diastereoisomers 55 and 56 in a 
7:3 ratio cis:trans. Compound 57 was the only isomer observed when 54 
was reduced under the same conditions.   
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Scheme 8 
1.2.3 Preparation of 2,6-disubstituted piperidines  
Due to their potential biological activity, the synthesis of substituted 
derivatives of pipecolic acid has also received attention, and has been 
reviewed recently.33-35 This potential for biological activity engaged our 
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interest in the synthesis of pipecolates from amino acids and, due to the 
relatively small number of reports of structures bearing mono-substitution 
at the 6-position, we focused our efforts in this area. A number of routes to 
pipecolates substituted at the 6-position with saturated alkyl chains have 
been reported. 
Bailey and co-workers described the aza-Diels-Alder reaction between 
imine 58 and 1,3-pentadiene (Scheme 9),11,36,37 which led to the 
stereoselective formation of the cis-isomer of the unsaturated piperidine 
59, which in turn was reduced to piperidine 60. 
 
Scheme 9 
Shono and co-workers reported the anodic oxidation of compound 61 
derived from L-lysine, which on treatment with acid gave the key 
intermediate 62 (Scheme 10).38,39 Treatment of 62 with allyltrimethylsilane 
in the presence of TiCl4, followed by hydrogenation, exclusively gave the 
cis-diastereoisomer 63. 
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Scheme 10 
Davis and co-workers developed a method for synthesizing 6-oxoamino 
acids, which can be cyclized to give piperidines (Scheme 11).40 The 
aldehyde 65 was prepared by reduction of the ester 64. Treatment of 
commercially available (1R,2S,5R)-menthyl (S)-p-toluenesulfinate 66 with 
LiHMDS, followed by addition of the aldehyde 65, gave the sulfinimine 67. 
Introduction of the nitrile group in 67 was achieved using the reagent 
generated in situ from iPrOH and Et2AlCN. Treatment of 68 with 6 N HCl 
resulted in removal of  the sulfinyl group, hydrolysis of the nitrile to an acid, 
deprotection of the ketone, and finally cyclization. Hydrogenation of 
compound 69 occured as expected from the least hindered face to gave 
70. 
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Scheme 11 
Takahata and Shimizu applied the Sharpless asymmetric dihydroxylation 
(AD) reaction to the synthesis of enantiomerically pure 6-methylpipecolic 
acid (Scheme 12).41 Selective AD reaction of 1,6-heptadiene gave the 1,2-
diol 71, which was converted into the epoxide by the Sharpless one-pot 
procedure followed by reduction using Super-Hydride® as regioselective 
reducing reagent to give the alcohol 72. A second (DHQD)2-PYR ligand-
derived AD reaction gave 73, as well as a small amount of the C-2 epimer 
of 73. The triol 73 was selectively monoprotected at the primary hydroxyl, 
followed by tosylation of both secondary alcohols. Double nucleophilic 
substitution reaction with benzylamine gave the enantiomerically enriched 
cis-piperidine 74, contaminated with the trans-isomer. Deprotection of the 
benzyl group, Boc-protection, and desilylation furnished separable 
alcohols 75 and 76. The last two steps to produce target compound 77 
were an oxidation and a deprotection. The same procedure was followed 
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to synthesise the trans-isomer 78, but the synthesis started with the 
(DHQD)2-PYR ligand-derived (AD) reaction. 
Scheme 12 
Blechert and co-workers reported a short diastereoselective synthesis of 
6-substituted pipecolates, applying a highly selective cross metathesis 
reaction followed by a domino reduction-cyclization reaction (Scheme 
13).42 Commercially available allylglycine 79 was converted into protected 
starting material 80.43 Cross metathesis of allylglycine derivative 80 with 
methyl vinyl ketone using the Hoveyda-Grubbs catalyst 81 affording the 
aminoenone 82. Hydrogenation of compound 82 achieved three things: 
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hydrogenation of the double bond, deprotection of the amine, and 
cyclization to furnish cis-pipecolate 83. 
Scheme 13 
1.2.4 Preparation of piperidines in the Jackson group 
Extensive work has been carried out to prepare enantiomerically pure 
substituted piperidine derivatives by using amino acids as chiral pool 
starting materials.11,44 Some enantiomerically pure substituted piperidines 
have previously been prepared in the Jackson group using organozinc 
chemistry.45 The Jackson group first reported the synthesis of piperidines 
derived from amino acids in 1994.45,46 Cross coupling reaction of the 
serine-derived organozinc reagent 85 with propenoyl chloride gave 4-oxo 
amino acid 86 in a 39% yield, in a reaction catalyzed by Pd(PPh3)2Cl2. The 
addition of HCl in diethyl ether furnished benzyl 4-oxopipecolate 87 in a 
quantitive yield (Scheme 14).46  
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Scheme 14 
In an approach to 4-methyl pipecolates, the zinc/copper reagent 89a 
prepared from the corresponding zinc reagent 88 was treated with 
enantiomerically pure (η3-allyl) iron tetracarbonyl salt 90 to give the adduct 
91. Addition of LiOOtBu gave the epoxide 92, which gave 4-
methylpiperidine 93 on treatment with Zn/TMSCl (Scheme 15).47  
 
Scheme 15 
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In later unpublished work, Jackson and Gulati48 developed a method to 
prepare 5-methylenepipecolates (Scheme 16). The allylic amino acid ent-
94 was cyclised by treatment with NaH to give the pipecolate ent-37 in 
good yield. Unfortunately, it was demonstrated that the final step 
proceeded with racemisation; the observed specific rotation of ent-37 was 
-4 compared to the value of +61.8 for 37 reported by Sun.28  
 
Scheme 16 
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1.3 Organozinc reagents 
Formation of carbon-carbon bonds is very important in the synthesis of 
natural products; organometallic compounds are significant tools to 
achieve this transformation.49 The reactivity of organometallic compounds 
depends on the metal. Organolithium and organomagnesium reagents are 
very reactive reagents due to having highly polar bonds, due to their 
electronegativity (Li 1.53, Mg 1.27), in turn resulting in low 
chemoselectivity of these reagents. In contrast, the zinc-carbon bond is a 
less polar, covalent bond. Organozinc reagents have a lower reactivity and 
are more tolerant towards functional groups. 
Transmetalation of the unreactive functionalized organozinc reagents to 
more reactive organometallic reagents, which can react with different 
organic electrophiles, is possible. Cross-coupling reactions of the 
organozinc reagents with a variety of electrophiles has been successfully 
achieved.50-52 Negishi reported reaction of organozinc reagents with 
different electrophiles, aryl, heteroaryl and alkenyl halides in the presence 
of catalytic palladium (0).53-56 In addition, organozinc reagents were 
transmetalated to copper reagents57-60 (Scheme 17). 
 
Scheme 17 
Preparation of organozinc reagents by direct zinc insertion into the carbon-
halogen bonds of poly-functional alkyl halides can be achieved using zinc 
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dust, provided prior activation to remove the oxide layer is carried out.50,60-
63 
Functionalised chiral organozinc reagents were synthesised from naturally 
occurring amino acids by the Jackson group.45 A range of protected amino 
organoiodides derived from commercially available amino acids were 
converted into the corresponding organozinc reagents using a variety of 
zinc insertion methods (Figure 3).64-68 
 
 
Figure 3 
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1.4 Copper chemistry 
Organocopper compounds are amongst the most important source of 
carbon nucleophiles.50,69 Organocopper(I) reagents can be generated in 
situ using catalytic copper(I) complex and organomagnesium, organozinc, 
or other organometallic reagent, or may be prepared as stoichiometric 
reagents. The organocopper(I) reagents are shown as RCu, R2Cu
-, 
R2CuLi and R2CuZnX.
70 
These reagents are very effective in a variety of reactions such as 
conjugate addition, carbocupration, alkylation, allylation, alkenylation, and 
acylation (Scheme 18).71 
 
Scheme 18 
Kharasch and Fields reported a conjugate addition reaction of a Grignard 
reagent to an α,β-unsaturated ketone in the presence of Cu(I) salt.72 
Gilman and co-workers reported in 1952 that the reaction of 1 eq of MeLi 
with copper formed a yellow precipitate and addition of another equivalent 
of MeLi gave a colourless solution. The latter type of reagent, formulated 
as R2CuLi, is known as a Gilman reagent or Gilman cuprate.
73 
Costa and co-workers isolated phenyl copper(I) from the reaction of 
copper(I) bromide and phenyl lithium.74 The synthetic chemistry of 
organocopper began to evolve rapidly since this report in 1966.75  
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Knochel and co-workers developed a method in which organozinc 
reagents were prepared by zinc insertion into carbon-halogen bonds, and 
subsequent conversion into cuprates via transmetallation with CuCN.2LiCl 
(Scheme 19).76,77  
 
Scheme 19 
In 1983 Gaudemar found that the reaction of Reformatsky reagents with 
allyl halides was catalyzed by the copper salt Cu(acac)2. These reactions 
gave excellent yields, although SN2/SN2’ selectivity was only modest (60% 
: 40%) (Scheme 20).78  
 
Scheme 20 
In 1987 Nakamura and coworkers reported the allylation of chiral β-ester 
organozinc iodide with 3-bromocyclohexene under CuBr.DMS catalysis, 
providing two diastereoisomeric products (Scheme 21).55 
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Scheme 21 
Yoshida and co-workers carried out the reaction of β and γ-ester 
organozinc iodides with various allyl halides. These reactions were 
catalyzed by using CuCN, and generally resulted in gave the SN2
’
 
products accompanied in some cases by the SN2 products (Scheme 22).
60  
 
Scheme 22 
Knochel and co-workers prepared a zinc/copper reagent containing a 
phosphonate group which reacted with allyl bromides to produce the 
corresponding terminal alkenes in high yields (Scheme 23).79 
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Scheme 23 
In order to distinguish between direct displacement of bromide SN2, or 
attach at the double bond SN2
’ labelled allylic halides were used. Yoshida 
and co-workers used a cyclic secondary allylic tosylate which they treated 
with an organozinc iodide under CuCN catalysis to furnish a mixture of 
formal SN2 and SN2
’
 products. The SN2
’
 product obtained with a cyclic 
allylic tosylate whereas when an acyclic allylic tosylate was used, only the 
SN2
’
 product was obtained (Scheme 24).60  
 
Scheme 24 
Goering and Kantner have proposed a mechanism for the reaction of 
organocopper reagents with allylic acetate (Scheme 25). They propose 
that the copper coordinates to the alkene before the acetate group is lost 
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forming an allyl copper complex.The alkyl group could now attack at either 
the α or γ carbon giving rise to the SN2 and SN2
’
 products.80 
 
Scheme 25 
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1.5 Jackson group chemistry 
The first report of the use of the zinc/copper reagent 89b, previously 
discussed on page 17, described its reaction with different allylic halides to 
give SN2
’
 products of protected unsaturated α-amino acids (Scheme 
26).81,82  
Scheme 26 
Related zinc/copper reagents derived from L-aspartic and L-glutamic acids 
were reacted with allyl chloride to furnish unsaturated β- and γ-amino acid 
derivatives in good yields (Scheme 27).83  
 
Scheme 27 
The use of catalytic CuBr.DMS has been investigated as an alternative to 
using a stoichiometric amount of CuCN.2LiCl due to the latter’s toxicity 
(Scheme 28). Allylation of L-serine-derived organozinc reagent with bulky 
allylic electrophiles in the presence of CuBr.DMS and CuCN.2LiCl 
provided nearly equal yields of a mixture of  SN2 and SN2
’
 products.84  
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Scheme 28 
However the use of catalytic CuBr.DMS generally gave higher yields of 
substitution products than those obtained with CuCN.2LiCl, especially for 
less stable β-amino organozinc reagents (Scheme 29).66 
 
Scheme 29 
The precursor ent-94 that was used in scheme 16 (page 18) was prepared 
by the CuBr.DMS catalysed allylation of the zinc reagent 88 using 3-
chloro-2-(chloromethyl)prop-1-ene 41 (Scheme 30).48 The product of the 
bis-allylation ent-95 was also isolated.  
 
Scheme 30 
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1.6 Aims 
The main aim of the project was the extension of the approach to the 
synthesis of 2,5-disubstituted piperidines already developed within the 
Jackson group. 2,5-Disubstituted piperidines may be derived by 
hydrogenation of 5-methylenepiperidine. Alternatively we envisaged that 
Heck reaction of 5-methylenepiperidine, followed by hydrogenation, would 
lead to stereoselectively to the 5-benzyl piperidine (Scheme 31). The 
required 5-methylenepiperidine may be obtained from the organozinc 
reagents and allyl dihalide.   
 
Scheme 31: Retrosynthetic approach to 2,5-disubstituted piperidines 
The retrosynthetic plan can also be adapted to the synthesis of 
indolizidines and indolizidinones which may be accessed from 
hydrogenation of 6-methyleneindolizidine and 6-methyleneindolizidinone 
respectively (Scheme 32).  
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Scheme 32: Retrosynthetic approach to indolizidines 
2,6-Disubstituted piperidines especially 6-substituted pipecolates will be 
targeted using a short retrosynthetic pathway (Scheme 33). 
Diastereoselective reduction of imines should lead to the pipecolate, which 
is potentially accessible from a range of enones and organozinc reagents.  
 
Scheme 33: Retrosynthetic approach to 6-substituted pipecolates 
 
 
 
 
 
 
 30 
 
Chapter 2: Synthesis of 2,5-disubstituted piperidines 
2.1 Introduction 
 Amino acids are an important chiral source of starting materials for the 
preparation of optically pure piperidines.11,33,44 Amino acid derived 
organozinc iodides have been used to prepare protected 4-oxopipecolic 
acid,46 4-methylpipecolic acid derivatives47 and 5-methylenepipecolic acid 
derivatives,48 as mentioned in section (1.2.4). 
The planned approach to the 5-methylene piperidines 96, precursors to 
2,5-disubstituted piperidine derivatives, involves a [3+3] annulation 
reaction between 1,3-bifunctional electrophile 97 and 1,3-dianion 98. 
Suitable synthetic equivalents were identified as 3-chloro-2-
(chloromethyl)prop-1-ene 41 and a range of β-amino organozinc reagents 
99 (Scheme 34). 
 
Scheme 34: Retrosynthetic approach to 5-methylene-2-disubstituted piperidines 
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2.2 Results and discussion 
The initial aim was to develop a general synthesis for 5-methylene 
piperidines. The synthetic approach had been previously established for 5-
methylene pipecolic acid derivatives,48 and involved three steps; i) zinc 
insertion,  ii) copper-catalyzed allylation  with dichloride 41, and finally iii) 
cyclization (Scheme 35). 
 
Scheme 35 
2.2.1 Preparation of organoiodides 
The initial goal was the synthesis of a range of protected β-amino iodides. 
Protected L-iodoalanine was prepared from L-serine 100 in four steps 
using a literature procedure. This first involved protection of the carboxylic 
acid as methyl ester 101 and Boc-protection of the amine group to give 
102.85 Following this, the alcohol was tosylated to give 103, which was 
further reacted with sodium iodide to furnish the iodinated product, 
protected L-iodoalanine 104 (Scheme 36).86 This procedure was also 
carried out with D-serine. 
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Scheme 36 
The synthesis of the iodides 109a, 109b, 110a, 110b and ent-109a was 
carried out using the established procedures in the Jackson group.87,88 
The reduction of the carboxylic acid group of 105 to the alcohol was first 
carried out according to Meyers’ procedure.89,90 Two protection strategies 
were then considered. The reduced materials 106a and 106b were each 
Boc87 and TFA88,91 protected at the amine group to give compounds 107a, 
107b, 108a and 108b. Iodides were prepared using the 
triphenylphosphine, iodine and imidazole method.66,87 The iodide ent-109a 
was prepared by the same route (Scheme 37).87,92 
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Scheme 37 
Five steps were previously employed to synthesize organoiodides 109c 
and 109d by Dexter and co-workers62,83 and organoiodides 110c and 
110d have also been synthesised by Rilatt and co-workers67 starting from 
L-aspartic 111a and L-glutamic 111b acid. After esterification of the 
carboxylic acids at the β and γ-position,93,94 the amino groups were 
protected with Boc or TFA groups.67,94,95 Reduction of the α-carboxylic 
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acid groups via the succinimide esters formed the corresponding 
alcohols,96 which were iodinated using standard conditions to furnish the 
required iodides in good yields (Scheme 38).97,98  
Scheme 38 
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2.2.2 Investigation of pipecolate synthesis 
The organozinc reagent derived from protected L-iodoalanine 104 was 
used in the copper-catalyzed allylation reaction with 1,3-dielectrophile 41 
and gave unsaturated amino acid ent-94 and bis-allylation product ent-95 
(Scheme 39). 
 
Scheme 39 
As already discussed, addition of NaH to a solution of unsaturated amino 
acid ent-94 in dry DMF gave direct access to the protected pipecolate ent-
37 in a straightforward and efficient manner (Scheme 40). The specific 
rotation of the sample of ent-37 was zero (c 2.5, CHCl3) and -4.1 of the 
previous work within the Jackson group. The reported specific rotation of 
its enantiomer 37, prepared by Sun and co-workers (section 1.2.1), was + 
61.8 (c 1, CHCl3).
28  
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Scheme 40 
Therefore, the pipecolate ent-37 gave two signals by HPLC (Column: 
Chiralpak AD, mobile phase: 5% IPA in hexane, flow rate: 1 mL/min, 
retention time: 4.6 min one enantiomer, 5.6 min other enantiomer) (Figure 
4). These signals indicate the presence of both enantiomers. 
 
Figure 4: HPLC of the pipecolate ent-37 quenched by 1.5 mL of water 
It is possible that this is due to rapid racemisation during the workup 
caused by the formation of sodium hydroxide from the reaction of the 
sodium hydride with the water used to quench the reaction, which then 
has the ability to deprotonate the acidic α-proton (Scheme 41).  
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Scheme 41 
Attempts to avoid the epimerization were made by modifying the work-up 
of the cyclization reaction. Different aqueous work-ups were investigated 
(Table 1). Increasing the quantity of water from 1.5 mL/ 1 mmol to 10 mL/ 
1 mmol gave enantiomerically enriched pipecolate product ent-37 (ee 
94%), which was established using chiral HPLC techniques. Saturated 
ammonium chloride solution gave similar results. However, phosphate 
buffer solution (pH=7) can be used to improve the enantiomeric purity (ee 
97%) (Figures 5, 6 and 7). 
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Figure 5: HPLC of the pipecolate ent-37 quenched by 1.5 mL of water 
 
 
Figure 6: HPLC of the pipecolate ent-37 quenched by 10 mL of buffer phosphate 
 
 
Figure 7: HPLC of the pipecolate 37 quenched by 10 mL of buffer phosphate 
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Table 1:   
Different work-up ee% [α]17D c 1, CHCl3  
1 mL of water 0 0 
10 mL of water  94 -57 
10 mL of sat. Ammonium chloride 94 -57 
10 mL of pH 7 phosphate buffer 97 -59 
 
2.2.3 Boc-protected piperidines 
Since the previous approach gave satisfactory results in the preparation of 
5-methylene pipecolate from protected L-iodoalanine, attention turned to 
the use of other amino acids specifically L-phenylalanine, L-valine, L-
aspartic acid and L-glutamic acid (Schemes 37 and 38)   
The Boc-protected β-amino iodides (109a, 109b, 109c and 109d) were 
each converted into the corresponding organozinc reagent which then 
underwent copper-catalyzed allylation reactions to give the corresponding 
mono-allylation products 117a, 117b, 117c and 117d in reasonable yields, 
with small amounts of the unwanted bis-allylation side products 118a, 
118b, 118c and 118d. Addition of NaH to a solution of the allyl chlorides in 
dry DMF gave the piperidines 119a, 119b, 119c and 119d in good yields 
(Scheme 42 and table 2). 
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Scheme 42 
Table 2: 
RI R mono-allylation bis-allylation piperidine 
  % % % 
109a Bn 117a 69 118a 10 119a 85 
109b 
iPr 117b 59 118b 13 119b 72 
109c CH2CO2Me 117c 65 118c 10 119c 80 
109d CH2CH2CO2Me 117d 60 118d 13 119d 80 
 
Although there was no obvious mechanism for racemisation of these 
piperidines, it was decided to directly determine the ee for one example. 
So, ent-119a was therefore prepared starting from D-phenylalanine using 
the same approach (Scheme 43). 
 
Scheme 43 
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The piperidines 119a and ent-119a have equal and opposite specific 
rotations: -33.0 (c 1 in CHCl3) for 119a and +33.0 (c 1 in CHCl3) for ent-
119a. However, this was not enough evidence to prove that the two 
compounds 119a and ent-119a were enantiomerically pure. Chiral gas 
chromatography was employed, which enabled separation of the 
enantiomers due to the difference in their retention times. A deliberately 
prepared mixture of compounds 119a and ent-119a with a 2:1 ratio gave 
different retention times, 37.4 min for the 119a and 39.2 min for ent-119a 
(Figure 8).  
 
 
Figure 8: GC of the mixture of the piperidines 119a and ent-119a 2 : 1 ratio 
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Injection of compound 119a and ent-119a separately gave the 
enantiomeric purity of 119a as 98% and ent-119a 99% (Figures 9 and 
10). 
 
Figure 9: GC of the piperidine 119a quenched by 10 mL of water  
 
 
Figure 10: GC of the piperidine ent-119a quenched by 10 mL of water 
We are therefore confident that the remaining 5-methylenepiperidines 
119b-d are also enantiomerically pure.  
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2.2.4 TFA-protected piperidines 
Amino acid protecting groups have been generally categorized into two 
main classes: acid sensitive, for example, the Boc-protecting group and 
base sensitive, for instance, the TFA-protecting group, which can be 
introduced and removed easily. It was decided, following the success 
synthesising the Boc-protected piperidines, that the TFA analogues would 
also be investigated (Schemes 37 and 38). 
The same approach used with the Boc-protected organoiodides was 
successfully followed with the TFA-protected organoiodides 110a, 110b, 
110c and 110d giving the allylic chlorides 120a, 120b, 120c and 120d in 
reasonable yields. Cyclization using NaH/DMF provided the TFA-protected 
piperidines 122a, 122b, 122c and 122d (Scheme 44 and table 3).   
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Scheme 44 
Table 3: 
When the cyclization reaction using the TFA-protected derivative 120c, 
derived from L-aspartic acid, was worked-up using less water (1.5 mL/ 1 
mmol) the yield of the piperidine 122c was much reduced (25%) and the 
major product was the diene 123 (56%). It is possible that the piperidine 
122c undergoes an E1cB reaction during the work-up. Increasing the 
amount of water to 10 mL/1 mmol improved the yield of the desired 
product 122c to 60% and the yield of the diene 123 was reduced to 19% 
(Scheme 45). 
RI R mono-allylation bis-allylation piperidine 
  % % % 
110a Bn 120a 60 121a 12 122a 58 
110b 
iPr 120b 60 121b 12 122b 55 
110c CH2CO2Me 120c 57 121c 12 122c 60 (25)
a 
110d CH2CH2CO2Me 120d 55 121d 21 122d 79 
a 1.5 mL of water/ 1 mmol was used in the work-up 
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Scheme 45 
We had now successfully prepared a range of 5-methylene piperidines, 
and the final goal was the preparation of the TFA-protected piperidine 127 
(Figure 11). 
 
Figure 11 
We did not explore the use of the TFA protected L-iodoalanine 124, since 
previous work had shown that it was not especially stable, decomposing to 
give 125 (Scheme 46).  
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Scheme 46 
Therefore, Boc-deprotection and TFA-protection of Boc-protected 
pipecolate ent-37 were carried out in good yield (80%).99 Alternatively Boc 
deprotection of the unsaturated amino acid ent-94 and TFA protection to 
126 followed by cyclization also gave the desired product 127 (Scheme 
47)  
 
Scheme 47 
All the protected piperidines showed rotamers in the NMR spectra, arising 
from restricted rotation of the N-C bond of the carbamate. At 25 °C, the 
TFA-protecting group has distinguishable separable peaks for each 
rotamer, but in the case of the Boc-protecting group, the peaks overlapped 
and were broad. In order to coalesce them into one signal, energy must be 
introduced using elevated temperatures to overcome the barrier to rotation 
(Figure 12). 
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Figure 12: H-NMR spectra of piperidine 122d at different temperature 
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2.2.5 Indolizidine synthesis 
The next target was the preparation of indolizidines, using the protected 
organozinc iodide 129 derived from L-proline (Scheme 48). 
 
Scheme 48: Retrosynthetic approach to 6-methylene indolizidine 
Reduction89 of L-proline and subsequent Boc-protection100 provided N-Boc 
L-prolinol 132 in an overall yield of 51%. Iodination101 of the hydroxyl 
group of 132 to give iodide 130 was achieved in 50% yield using 
imidazole, I2, and PPh3 in ether (Scheme 49). 
 
Scheme 49 
Conventional Negishi cross-coupling of the Boc-protected organozinc 
iodide derived from L-proline 130 with aryl halides to give protected 2-
arylpyrrolidine 134 has been reported to be unsuccessful (Scheme 50).68 
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There are two reports of the rapid decomposition of organozinc reagent 
129, producing alkene 133.68,102  
 
Scheme 50 
Therefore, the Jackson group explored the generation of the organozinc 
reagent 129 in the same pot as the catalyst and aryl iodide.68 The 
organoiodide 130 was therefore added slowly to a mixture of activated 
zinc and aryl iodide in DMF at 0 °C with catalytic (2.5% mol) Pd2(dba)3 and 
(5% mol) SPhos (Scheme 51). 
 
Scheme 51 
This in situ method was applied to the allylation reaction of the 
organoiodide 130, giving the desired product 135 (35%), the double 
allylation product 136 (17%) and the elimination product 133 (40%) 
(Scheme 52). However, reverting to the original procedure in which the 
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zinc reagent 129 was prepared first gave a much better outcome: the 
allylic chloride 135 was isolated in good yield (60%) and no bis-allylation 
product  136 was observed, although alkene 133 was isolated (30%). So 
the copper-catalysed allylation reaction is clearly faster than palladium 
cross-coupling.  
 
Scheme 52 
The Boc-deprotection of 135 using TFA/CH2Cl2 gave 137, which was 
cyclised by addition of NaH in DMF producing the indolizidine 128 which 
was difficult to purify. (Scheme 53). 
 
Scheme 53 
The copper allylation reaction and cyclization approach can be applied to 
the organozinc reagent 138 to give the indolizidine 128. This can be 
achieved by reduction of an indolizidinone 43 (Scheme 54). 
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Scheme 54: Alternative etrosynthetic approach to 6-methylene indolizidine 
The organoiodide 142 was formed over four steps starting from 
commercially available L-pyroglutamic acid 139, which was converted into 
alcohol 140 by formation of methyl ester followed by reduction.102,103 The 
alcohol 140 was converted into iodide104 142, via the tosylate 141 
(Scheme 55).105,106  
 
Scheme 55 
Copper-catalysed allylation of the organozinc reagent 139 with 41 gave 
the allylic chloride 143 in excellent yield (84%). Interestingly, the bis-
allylation product 144 and the eliminated product 145 were not observed, 
although the organozinc reagent 138 was prepared then transferred to the 
allyldichloride 41 (Scheme 56). 
 52 
 
 
Scheme 56 
Cyclization of allylic chloride 143 gave the indolizidinone 43 in good yield 
(65%) (Scheme 57). 
 
Scheme 57 
We considered that the indolizidinone 43 (and the indolizidine 128) could 
be simply accessed from the piperidine 122d (Scheme 58), by TFA-
deprotection followed by cyclization under basic conditions. Refluxing a 
mixture of the piperidine 122d in methanol and water with potassium 
carbonate for 2 h gave the indolizidinone 43 (58%) while using sodium 
borohydride in methanol and refluxing for 3 days gave a higher yield 
(88%). Reduction of the lactam was accomplished smoothly using lithium 
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aluminium hydride in diethyl ether to the indolizidine 128 in good yield 
(75%).107 
 
Scheme 58 
Our next goal was to investigate the hydrogenation of the 5-methylene 
piperidines. The successful preparation of both monocyclic structures 
119d and 122d and the bicyclic derivative 43, would allows us to compare 
related structures. We considered that the oxazolidinone 147 would be an 
interesting bicyclic analogu of the pipecolates ent-37 and 127 (Figure 13). 
 
Figure 13 
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The oxazolidinone 147 and ent-147 were prepared directly from the 
pipecolates 37 and ent-37 (Scheme 59). The pipecolate ent-37 was 
reduced using lithium aluminium hydride in diethyl ether to give an 
excellent yield 93% of ent-146 without further purification, after the 
aqueous workup.108 Cyclization using NaH gave the oxazolidinone ent-
147. This procedure was also carried out with the pipecolate 37 to produce 
the oxazolidinone 147. 
 
Scheme 59 
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2.2.6 Hydrogenation of 5-methylenepiperidines 
The method chosen for hydrogenation of the 5-methylenepiperidines used 
Pd/C as  the catalyst, based on previous result in the group (Scheme 
60).48 
 
Scheme 60: Hydrogenation of 5-methylenepiperidines 
Initial attempted hydrogenation of 5-methylenepiperidine 119a using 10% 
Pd/C at 1 atm of hydrogen at room temperature gave a mixture of the 
hydrogenated piperidines 148a/148b (3 : 1, according to the 1H-NMR 
spectrum) and the endo-methylpiperidine 148c (Scheme 61). The 
exocyclic double bond in 119a was isomerised to the relatively stable 
cyclic enamine 148c.109 This suggests that the reaction time was not 
enough for achieving hydrogenation. When the reaction time was 
extended (from one day to two days) only the mixture of piperidines 
148a/148b (3 : 1) was isolated. Hydrogenation of 148c under the latter 
conditions (two days) provided the same ratio (3 : 1). It is clear that the 
catalyst causes isomerisation of the alkene, and the similarity in the 
diastereoselectivity suggests that 148c was an intermediate in the 
hydrogenation of 119a to 148a/148b. 
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Scheme 61 
2.2.6.1 Hydrogenation of TFA-protected piperidines 
The TFA-protected piperidines 122a, 122b, 122c, 122d and 127 were 
each subjected to hydrogenation to furnish two separable 
diastereoisomers (except 122b) in good yields. The cyclic enamines could 
be isolated in some cases when the hydrogenation reaction was stopped 
after one day. 
The piperidine 127 was hydrogenated to give a 1:1 ratio of trans and cis 
isomers; the assignment will be considered in more detail below (Scheme 
62). 
 
Scheme 62 
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The hydrogenation produces two diastereoisomers 149a and 149b; one of 
them is anti across the ring, and another is syn. If we assume that the 
structure of the saturated ring can be considered as similar to a 
cyclohexane ‘chair’ conformation, this gives us two possible conformers for 
each of the products. A, B and C, D (Figure 14). 
 
Figure 14: Potential structural outcomes of hydrogenation of piperidine 127 
Looking at these possibilities, we can see that the C-2 and C-5 
substituents may be in either an axial or equatorial position. With both 
substituents on the oppsite face of the ring, they can be arranged either C-
2ax/C-5ax (A) or C-2eq/C-5eq (B). With the syn isomer, they can be 
arranged C-2ax/C-5eq (C) or C-2eq/C-5ax (D). 
The Karplus equation tells us that the 3J-coupling constants of aliphatic C-
H signals are directly related to the dihedral angles between the 
hydrogens, with angles of 0° and 180° giving the largest values (~13-15 
Hz), and 90° giving a value of approximately zero. The two diastereotopic 
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protons at C-6 and the α-protons at C-2 will play an important role in 
allowing us to determine the structure of all the hydrogenation products. 
Geminal protons also tend to have relatively large coupling constants of 
(~12-15 Hz). Thus, taking into account the coupling constants between the 
protons illustrated in figure 15 allows us to elucidate the stereochemistry of 
the structure with some certainty. 
 
Figure 15 
The isomer 149a show clear rotameric behaviour, and two signals are 
observed for each proton of the isomer 149a. The doublet of doublets 
(3.12 and 3.51 ppm for each rotamer) of one proton at C-6, the doublet 
(3.64 and 4.22 ppm for each rotamer) are for the other protons at C-6 as 
determined by 1H/13C correlation (Figure 16). 
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Figure 16: partial 
1
H-NMR spectrum of 149a  
Considering the signals of one proton at C-6 (3.12 and 3.51 ppm for each 
rotamer), which are a doublets of doublet (Figure 17), with large coupling 
constant (14.0 Hz for each rotamer) due to the geminal coupling and small 
coupling constant (3.5 Hz, and 3.0 Hz for each rotamer) with the equatorial 
proton at C-5. 
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Figure 17 
The other proton at C-6 is a doublet (3.64 and 4.22 ppm for each rotamer) 
with coupling constant (14.0 Hz) is a result of the geminal coupling (Figure 
18). 
 
Figure 18 
Since there is no evidence of a large axial/axial coupling for either proton 
at C-6 in each rotamer, the methyl group at C-5 must be axial (Figure 19). 
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We can delete B (C-2eq/C-5eq) and C (C-2ax/C-5eq) and keep A (C-2ax/C-
5ax) if trans, or D (C-2eq/C-5ax) if cis. 
 
Figure 19 
The α-proton at C-2 (4.68 and 5.17 ppm for each rotamer) is a doublet 
with a moderate coupling constants (5.5 and 6.5 Hz for each rotamer). 
Again, there is no evidence of a large diaxial coupling so the α-proton at 
C-2 must be equatorial (Figure 20). 
 
Figure 20 
Thus, the α-proton must be at the equatorial position and the ester group 
at the axial position. 1,3 Allylic strain (A1,3) may explain this 
observation.110-112 (Figure 21).  
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Figure 21 
This analysis can eliminate the diequatorial isomer D (C-2eq/C-5ax) and 
suggests that we have the diaxial conformer A (C-2ax/C-5ax) of the trans-
isomer 149a (Figure 22). 
 
Figure 22 
The other isomer 149b also exhibits clear rotameric behavior for the 
protons at C-6 and α-proton (Figure 23).   
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Figure 23: partial 
1
H-NMR spectrum of 149b 
The signals assigned to a proton at C-6 is a doublet of doublets (3.80 
partly observed, and 4.40 ppm for each rotamer), arise from a geminal 
proton with large coupling constants (12.0 and 13.0 Hz for each rotamer) 
and small coupling constants (2.0 and 4.5 Hz for each rotamer) arise from 
the vicinal proton at C-5. The large values are a result of geminal coupling 
with the axial proton at C-6, and the smaller value indicative of a relatively 
small dihedral angle with the proton at C-5 (Figure 24). 
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Figure 24 
The apparent triplets (2.55 and 2.91 ppm for each rotamer) at C-6 (Figure 
25), are actually two sets of doublet doublets with large coupling constants 
(14.0 and 14.0 Hz for each rotamer) due to geminal coupling and another 
large coupling constant (13.0 and 14.0 Hz for each rotamer) with the 
vicinal proton at C-5 (anti coupling constant). This allows us to assign the 
C-5 proton of the 149b isomer as being in the axial position. 
 
Figure 25 
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There is an indication of a large axial/axial coupling in both rotamers, so 
the methyl group at C-5 must be equatorial (Figure 26). We can keep B 
(C-2eq/C-5eq) and C (C-2ax/C-5eq). 
 
Figure 26 
The α-proton is a doublet at (4.69 and 5.25 ppm for each rotamer), with 
moderate coupling constants (5.5 and 6.0 Hz for each rotamer). This 
coupling arises from the vicinal proton at C-3 (Figure 27). 
 
Figure 27 
Therefore, there is no an indication of a large axial/axial coupling in either 
rotamer, so the ester group at C-2 must be axial (Figure 28). 
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Figure 28 
So we have conformation C of the cis-isomer 149b (Figure 29). 
 
Figure 29 
The next scheme 63 and table 4 summarise the hydrogenation outcome of 
the rest of the TFA-protected 5-methylene piperidines. 
 
Scheme 63 
Table 4:  
Substrate (R) Piperidine Combined yield % Minor Major 
Bn 122a 75 1 7 
iPr 122b 75 1 4 
CH2CO2Me 122c 80 1 2.5 
CH2CH2CO2Me 122d 80 1 2.5 
The ratio is determined by 
1
H-NMR spectroscopy of the crude product 
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We will now discuss briefly the conformational analysis of the 
hydrogenation products of the piperidine 122a. 
The piperidine 122a was subjected to hydrogenation which produced two 
separable diastereoisomers with significant diastereoselectivity (7 : 1) 
major : minor (Scheme 64).  
 
Scheme 64 
The 1H-NMR spectra of two isomers 150a and 150b showed coupling 
between C-6/C-5 protons, and α-proton with benzylic and C-3 protons. 
The conformational investigation is summarized in the next figure (Figure 
30).  
The major isomer 150a has a large (14.5 and 14.0 Hz for each rotamer) 
and a small (3.0 and 2.0 Hz for each rotamer) coupling constant at C-6, so 
there is no diaxial coupling, the methyl group must be axial. The α-proton 
has a small coupling constant (4.0 Hz), which suggests that the benzyl 
group must be axial. 
The minor isomer 150b has two large (14.0, 10.0 and 13.5, 12.5 Hz for 
each rotamer) coupling constants at C-6, so there is a diaxial coupling, the 
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methyl group must be equatorial. The benzyl group is axial as there is no 
diaxial coupling. 
 
Figure 30 
Table 5: 
Substrate (R) Piperidine Combined yield % cis trans 
Bn 122a 75 150b 
1 
150a 
7 
iPr 122b 75 151b 
1 
151a 
4 
CH2CO2Me 122c 80 152b 
1 
152a 
2.5 
CH2CH2CO2Me 122d 80 153b 
1 
153a 
2.5 
The ratio is determined by 
1
H-NMR spectroscopy of the crude product 
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2.2.6.2 Hydrogenation of Boc-protected piperidines 
Hydrogenation of the Boc-protected piperidines 119a, 119b, 119c, 1219d 
and ent-37 gave in each case two separable diastereoisomers (except for 
119b) in excellent yields. 
The stereochemical assignment will be discussed in more detail for the 
hydrogenation of piperidine ent-37. The crude NMR spectrum of the 
hydrogenation of compound ent-37 shows a (3 :1) ratio of major : minor 
stereoisomers (Scheme 65).   
 
Scheme 65 
As already discussed for the TFA-derivatives 149, we need to consider 
two possible conformers for each stereoisomer. A, B and C, D (Figure 
31). 
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Figure 31: Potential structural outcomes of hydrogenation of piperidine ent-37 
The major isomer 154b has a doublet of doublets (2.41 and 2.54 ppm for 
each rotamer) which have the same coupling constants, and a doublet of 
doublets (3.84 and 3.99 ppm), arising from the protons at C-6. They allow 
a determination of the local conformation. These two signals were 
identified as the C-6 protons by 1H/13C correlation. 
The signal for the proton at C-6 (3.84 and 3.99 ppm) appears as a doublet 
of doublets with large (13.5 and 13.5 Hz for each rotamer) and small 
coupling constants (4.5 and 4.5 Hz for each rotamer) (Figure 32). The 
large values are a result of geminal coupling C-6, and the small values 
derived from a coupling with the vicinal proton at C-5.  
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Figure 32 
The signals for the other proton at C-6 (2.41 and 2.54 ppm for each 
rotamer) show a doublet of doublets and exhibits two large coupling 
constants (13.5 and 12.5 Hz for each rotamer) (Figure 33). The first value 
is a result of vicinal coupling with the proton at C-5 (diaxial coupling), and 
the second value arises from the geminal proton.  
 
Figure 33 
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Consequently, this allows us to assign the methyl group at C-5 of the 
major isomer as being in the equatorial position (Figure 34). 
 
Figure 34 
The signal for the α-proton at C-2 (4.71 and 4.89 ppm for each rotamer) is 
a doublet with a small coupling constant (5.5 Hz for each rotamer). This 
small values arising from the the proton at C-3, no diaxial coupling thus 
the ester group is axial (Figure 35). 
 
Figure 35 
Through analysis of the NMR data, the compound exists in conformer C 
(C-2ax/C-5eq) of the cis-isomer 154b (Figure 36). 
 
Figure 36 
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The minor isomer 154a shows a doublet at (3.16 ppm) and a doublet at 
(3.60 ppm), arising from the protons at C-6 (Figure 37), again they allow a 
determination of the local conformation. These two signals were identified 
as the C-6 proton by 1H/13C correlation. 
 
Figure 37 
The signal for the proton at C-6 (3.60 ppm) appears as a doublet with a 
large coupling constant (13.5 Hz). This value is a result of geminal 
coupling with the axial proton at C-6, and no coupling with the proton at C-
5.  
The signal for the other proton at C-6 (3.16 ppm) appears as a doublet 
and exhibits a large coupling constant (13.5 Hz), which is a result of 
geminal coupling. This allows us to assign the methyl of the minor isomer 
as being in the axial position (Figure 38). 
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Figure 38 
The α-proton of the minor isomer is broad. It will be based on the results 
obtained from the assignment of the α-proton of the major isomer, 
therefore the ester group is axial (Figure 39). 
 
Figure 39 
So, the conformational structure of the minor isomer 154a is conformer A 
trans-isomer (diaxial) (Figure 40).   
 
Figure 40 
Hydrogenation of the Boc-protected 5-methylene piperidines was 
summarised in Scheme 66 and Table 6.  
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Scheme 66 
Table 6: 
Substrate (R) Piperidine Combined yield % Minor Major 
Bn 119a 80 1 3 
iPr 119b 78 1 1.5 
CH2CO2Me 119c 83 1 1.5 
CH2CH2CO2Me 119d 84 1 1.5 
The ratio is determined by 
1
H-NMR spectroscopy of the crude product 
 
Hydrogenation of piperidine 119a gave two separable diastereoisomers (3 
: 1) major : minor (Scheme 67). 
 
Scheme 67 
As before, the conformational structural analysis of the two isomers is 
summarized in the next figure (Figure 41). 
 76 
 
 
Figure 41 
Table 7: 
Substrate (R) Piperidine Combined yield % cis trans 
Bn 119a 80 148b 
1 
148a 
3 
iPr 119b 78 155b 
1 
155a 
1.5 
CH2CO2Me 119c 83 156b 
1 
156a 
1.5 
CH2CH2CO2Me 119d 84 157b 
1 
157a 
1.5 
The ratio is determined by 
1
H-NMR spectroscopy of the crude product 
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The hydrogenation of all 5-methylenepiperidines is summarized in scheme 
68 and table 8. 
 
Scheme 68 
Table 8: 
Substrate (R) Piperidine PG Combined yield% cis trans 
CO2Me ent-37 Boc 89 3 1 
127 TFA 92 1 1 
Bn 119a Boc 80 1 3 
122a TFA 75 1 7 
iPr 119b Boc 78 1 1.5 
122b TFA 75 1 4 
CH2CO2Me 119c Boc 83 1 1.5 
122c TFA 80 1 2.5 
CH2CH2CO2Me 119d Boc 84 1 1.5 
122d TFA 80 1 2.5 
The ratio is determined by 
1
H-NMR spectroscopy of the crude product 
 
In most cases the trans-isomer is favoured, suggesting that hydrogen is 
preferentially delivered from below of half chair II which would have the R 
group in an equatorial position. This prouducs the diequatorial chair III 
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which may ring flip into a chair IV to avoid A1,3 strain between the R group 
and the protecting group (PG) on nitrogen (Scheme 69).   
 
Scheme 69 
2.2.7 Hydrogenation of indolizidinone and oxazolidinone 
2.2.7.1 Hydrogenation of indolizidinone  
Hydrogenation of the indolizidinone 43 furnished two inseparable 
diastereoisomers in excellent yield 92% with a moderate stereoselectivity 
(5:1) as determined using 1H-NMR spectroscopy (Scheme 70 and figure 
42).  
 
Scheme 70 
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Figure 42: partial 
1
H-NMR spectrum of 158a/158b 
The configuration assignment of the major indolizidinone 158b was made 
by 1H-NMR spectroscopy. The two protons at C-5 were first identified 
using 1H/13C correlation, since these are important in determining the 
configuration at C-6. (Figure 43). 
 
Figure 43 
The signal for one of the protons at C-5 (3.83 ppm) of the major isomer 
158b appears as a doublet of triplets (Figure 44), with a large coupling to 
the geminal proton (13.0 Hz) and two small doublet coupling (1.5 Hz) to 
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the equatorial proton at C-6 and the equatorial proton at C-7 (W-coupling) 
respectively.  
 
Figure 44 
This means that the other proton at C-5 (2.81 ppm) is a doublet of 
doublets must be axial (Figure 45), shows a large geminal coupling (13.0 
Hz) and a small coupling constant (4.0 Hz).  
 
Figure 45 
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One large geminal coupling is present but no other large coupling, so the 
methyl at C-6 must be axial. 
The appearance of a doublet of triplets of doublets for the proton at C-8a 
(3.39 ppm), the large doublet coupling constant (11.5 Hz) is generated 
from the axial proton at C-8 (diaxial coupling) and the triplet from the two 
protons at C-1 with a coupling constant (7.0 Hz), and the equatorial proton 
at C-8 gave a small coupling constant (3.0 Hz) (Figure 46). 
 
Figure 46 
The distinguishable peaks of the minor indolizidinone 158a are the protons 
at C-5 (2.45 and 4.06 ppm) but the proton at C-8a is not separated clearly 
in the spectrum (Figure 47). 
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Figure 47 
This proton at C-5 (4.06 ppm) is a doublet of doublets of doublets with a 
large (13.0 Hz), a medium (5.0 Hz) and small (2.0 Hz) coupling constants 
(Figure 48). The large value arises from the geminal proton, the medium 
value established from the vicinal axial proton at C-6, and the small value 
derived from the equatorial proton at C-7 (W-coupling).  
 
Figure 48 
The other proton at C-5 (2.45 ppm) is a doublet of doublets with two large 
coupling constants (13.0 and 12.5 Hz), which are due to geminal and 
vicinal diaxial coupling (Figure 49). So the methyl group must be 
equatorial. 
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Figure 49 
As already discussed, hydrogenation of the piperidine 122d provided two 
separable diastereoisomers, cis-isomer 153b (minor) and trans-isomer 
153a (major). The latter isomer was readily cyclised by utilizing the 
conditions employed for the preparation of the indolizidinone 43 to give the 
indolizidinone 159a in excellent yield (82%) (Scheme 71). This compound 
had identical spectroscopic characterisations to the minor isomer from 
hydrogenation of 43. This allows conformation of all earlier stereochemical 
assignments. 
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Scheme 71 
Formation of the indolizidinone 158a occuried during TFA-deprotection of 
153a. Presumably rapid conversion of the diaxial conformer to the 
diequatorial conformer occurs (Scheme 72). 
 
Scheme 72 
 85 
 
2.2.7.2 Hydrogenation of oxazolidinone 
The oxazolidinone 147 was also subjected to the previous hydrogenation 
conditions furnishing two inseparable diastereoisomers in excellent yield 
95% (Scheme 73) with a stereoselectivity (7:1) major :  minor measured 
according to 1H-NMR spectroscopy (Figure 50). 
 
Scheme 73 
Figure 50: partial 
1
H-NMR spectrum of 159a/159b 
The stereochemical investigation of the products was by the protons at C-
5 using 1H/13C correlation and 1H-NMR spectroscopy (Figure 51). The 
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proton signal at C-5 of the major isomer 159b (3.0 ppm) is a doublet of 
doublets with a large coupling constant (13.0 Hz) which is a result of the 
geminal coupling, and a small coupling constant (4.0 Hz) with the 
equatorial proton at C-6. The signal of the other proton (3.56 ppm) is a 
doublet with a large coupling constant (13.0 Hz) arising from the geminal 
proton (Figure 52). Since neither of the protons at C-5 show a record 
large coupling, the proton at C-6 must be equatorial. 
 
Figure 51 
 
Figure 52 
The minor isomer 159a; the two protons at C-5 were also assigned 
(Figure 53). The doublet of doublets of the proton at C-5 (2.40 ppm) with 
two large coupling constants (13.0 Hz and 11.5 Hz) arising from the 
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equatorial geminal proton and the axial proton at C-6 (anti-coupling) 
respectively (Figure 54).  
 
Figure 53 
 
Figure 54 
The other proton at C-5 (3.81 ppm) is a doublet of doublets of doublets 
with a large (13.0 Hz), medium ( 5.0 Hz), and small coupling constants 
(1.5 Hz) (Figure 55). The large value arises from the axial geminal proton,  
the medium value is a result of vicinal coupling with the axial proton at C-
6, and the small value is due to long range coupling with the equatorial 
proton at C-7 (W-coupling). 
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Figure 55 
In conclusion, hydrogenation of pipecolate before and after cyclization 
showed a different diastereoselectivity. It was 3 : 1 cis : trans before 
cyclization and 7 : 1 after (Scheme 74).  
 
Scheme 74 
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2.2.8 Heck reactions 
We next turned our attention to functionalization of 5-methylene 
piperidines, as a route to 2,5-disubstituted piperidines. Optimised Heck 
reaction conditions had been previously established using partially 
racemised piperidine ent-37 (Scheme 75).48 The products were the 
corresponding endocyclic alkenes, rather than the initially expected 
exocyclic isomers. However, given the case of isomerisation of the 
exocyclic double bond during hydrogenation reactions this is not 
surprising.  
 
Scheme 75 
The conditions described by Kimura et al.113 were utilized. A number of 
aryl iodide electrophiles furnished Heck products in low yields (25-40%). 
Optimisation of the previous Heck reaction conditions was carried out 
(Scheme 76). Using a large excess of aryl iodides relatively to pipecolate 
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ent-37 (from two to ten equivalents) and distilled acetonitrile gave good 
yields (70-76%).48 
 
Scheme 76 
The Heck conditions previously developed were used with the 
enantiomerically enriched 5-methylene pipecolate ent-37. The TFA-
protected pipecolate 127 was also subjected to these conditions providing 
good yield 70% of compound 163 (Scheme 77).     
 
Scheme 77 
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These Heck conditions were also successfully applied to the piperidines 
119a and 122a to furnish the enamines 164 and 165 in comparable yields 
72% and 78% respectively (Scheme 78).  
 
Scheme 78 
2.2.9 Hydrogenation of Heck reaction products 
It had been reported previously that hydrogenation of the Heck products 
could be carried out using Pt/C (1% w/w) as catalyst.48 
Application of these conditions to the Heck products (the 2,5-disubstituted 
piperidines) provided two inseparable diastereoisomers of the desired 2,5-
disubstituted piperidines (Scheme 79) 
 
Scheme 79 
Hydrogenation of the Heck product 164 gave two diastereoisomers in 
good yield 60%, with 6 : 1 ratio and one diastereoisomer 166a was 
isolated (Scheme 80). 
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Scheme 80 
Hydrogenation of the pipecolates 160, 161 and 162 gave predominantly 
the cis-isomers with a diastereoisomeric ratio of ~4:1 in each case 
(Scheme 81 and table 9). 
 
Scheme 81 
 
Table 9: 
Heck products Yield% trans cis 
160 65 167a 167b 
1 4 
161 55 168a 168b 
1 4 
162 57 169a 169b 
1 4 
The ratio is determined by 
1
H-NMR spectroscopy 
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2.3 Conclusion 
Initially, we examined using copper(I) mediated allylation and cyclisation 
methodology to the synthesis of enantiomerically pure 5-
methylenepipecolate ent-37 (Schemes 39 and 40). 
Application this methodology with a range of β-amino organozinc reagents 
derived from different amino acids (L-phenylalanine, L-valine, L-aspartic 
and L-glutamic acids) and cyclic amino acids (L-proline and L-pyroglutamic 
acid), furnishing 2-substituted-5-methylenepiperidines (Schemes 42 and 
44) and 6-methylene indolizidines respectively (Schemes 53 and 57). 
Hydrogenation of these piperidines did not lead to the same levels of 
stereoselectivity as for the pipecolate ent-37, and a diastereoisomeric ratio 
of approximately 3:1, in preference of the trans-isomer was typically 
obtained (Table 8). 
Subjecting some of the piperidines ent-37, 127, 119a and 122a to 
developed Heck coupling conditions with aryl iodides provided access to a 
class of 2-substituted-5-benzylic-5,6-dehydropiperidines (Schemes 77 
and 78). 
Finally, hydrogenation of these Heck coupling products proved to be a 
straightforward process to 2-substituted-5-benzylic piperidines in 
reasonable yields, and with diastereomeric ratios of approximately 4:1, in 
preference of the cis-isomer (Schemes 80 and 81). 
Thus, we have successfully developed new routes to interesting and novel 
2,5-disubstituted piperidines. 
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Chapter 3: Synthesis of 2,6-disubstituted piperidines 
3.1 Introduction  
Our retrosynthetic approach to the 2,6-disubstituted piperidines involved 
reduction of imines that might be made by cyclization of 6-oxo amino 
acids, in turn prepared by conjugate addition of β-amino organozinc 
reagents to enones (Scheme 82).     
 
Scheme 82: Retrosynthetic approach to 6-substituted pipecolate 
3.2 Results and discussion  
The first goal was to develop a synthesis of 6-oxo amino acids via the 
conjugate addition of β-amino organozinc reagent to enones. 
Previously in the Jackson group, the iodoalanine derived zinc/copper 
reagent (generated in THF) had been reacted in the presence of 
chlorotrimethylsilane, with methyl vinyl ketone to give the protected 6-oxo 
α-amino acid in low yield (20%).82 However, zinc/copper reagent derived 
from D-aspartic acid (generated in DMF) gave a higher yield in a similar 
reaction (56%)83 (Scheme 83). 
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Scheme 83 
Copper catalyzed conjugate addition of L-iodoalanine 104 to methyl vinyl 
ketone was subjected to optimisation (Scheme 84 and table 10): 
Method A: using the allylation reaction recipe by addition of 
enone/TMSCl/DMF mixture to CuBr.DMS/DMF followed by addition of the 
organozinc reagent 88 derived from L-iodoalanine 49 at room 
temperature/overnight that gave 15% of Michael adduct 170a, and the 
organozinc reagent was recovered as a protonated product 171. 
Method B: changing the addition order to addition of the organozinc 
reagent 88 to CuBr.DMS/DMF followed by addition of enone/TMSCl/DMF 
mixture at room temperature/overnight, increased the yield to 30%. 
Method C: It is similar to the method B, but the addition was achieved in a 
water bath (5 °C) for 10 min and then the mixture was stirred at room 
temperature/overnight, which increased the yield to 47%. 
Furthermore, some other enones ethyl vinyl ketone and propyl vinyl 
ketone were targeted to give 170b and 170c.  
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Scheme 84 
 
Table 10 
Enone Method Michael product Yield % 
Me A 170a 15 
Me B 170a 30 
Me C 170a 47 
Et C 170b 45 
nPr C 170c 45 
 
Unfortunately, disappointing yields (10-15%) of the desired Michael 
products 172a, 172b and 172c were obtained by using the organozinc 
reagent derived from D-glutamic acid with the preceding enones. In each 
case the protonated products were observed 173 (Scheme 85). The 
compound 172c was suggested to allow a very short synthesis of the 
alkaloid indolizidine167B.  
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Scheme 85  
Boc-deprotection/cyclization of the key intermediates 170a, 170b and 
170c was accomplished using TFA to give quantitative yields of the cyclic 
iminium salts 174a, 174b and 174c (Scheme 86).  
 
Scheme 86 
At this point, stereoselective reduction of the iminium salts 174a, 174b and 
174c was straightforwardly achieved using sodium borohydride in 
methanol,114 to give two inseparable diastereoisomers of the 6-substituted 
pipecolates in excellent yields (85-89%) with diastereoselectivity major : 
minor (6:1) (Scheme 87). 
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Scheme 87 
If it is assumed that the saturated ring adopts a chair conformation. There 
are two possible conformers for each of the products, A, B and C, D 
(Figure 56).  
 
Figure 56 
The stereochemical assignments of the major and minor isomers were 
determined using 1H-NMR spectra. The signals for C-2 (3.38, 3.36 and 
3.40 ppm) of the major isomers 175a, 176a and 177a (R = Me, Et and nPr 
respectively) are each a doublet of doublets with a large (11.5 Hz) and a 
small coupling constant (3.0 Hz) (Figure 57). The large values are a result 
of vicinal coupling with the axial protons at C-3 (diaxial coupling), which 
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establishes that ester group must be equatorial (Figure 58). So, 
conformers B and D can be deleted and keeping A and C.   
 
Figure 57 
 
 
 
Figure 58 
The signal of the major isomer 175a at C-6 (2.67 ppm) is a doublet of 
quartets of doublets and exhibits a large (12.0 Hz) a medium (6.5 Hz) and 
small (2.5 Hz) coupling constants. The large value derives from the proton 
at C-5 (diaxial coupling), the medium value is a result of the methyl 
protons at C-6, and the small value arising from the other proton at C-5 
(Figure 59). 
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The signal at C-6 (2.41 ppm) of 176a and 177a are doublet of triplets of 
doublets and also reveal a large (11.5 Hz) a medium (6.5 Hz) and a small 
(2.5 Hz) coupling constant. These values arising from the proton at C-5 
(diaxial coupling), the methylene protons at C-6 and the other proton at C-
5 respectively (Figure 60). 
 
Figure 59 
 
 
Figure 60 
 
 101 
 
Thus, the proton at C-6 must be at the axial position and the alkyl groups 
(R = Me, Et and nPr) at equatorial (Figure 61). 
 
Figure 61 
Thus, the trans-isomer C can be eliminated and suggests that the major 
isomer exists in the conformer A of the cis-isomers 175a, 176a and 177a 
(Figure 62). 
 
Figure 62 
The signal of the minor isomers 175b, 176b and 177b are multiplet 
coupling of the C-2 (3.75-3.83, 3.87-3.92 and 3.87-3.92 ppm respectively). 
If we look at the signals arising from the C-6 of the minor isomers 175b, 
177b and 178b, multiplet signals have been observed (2.91-3.0, 2.73-2.84 
and 2.73-2.84) respectively. 
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3.3 Conclusion 
We have explored the application of our copper(I) mediated conjugate 
addition methodology to the synthesis of 6-substituted pipecolic acid 
derivatives. 
Copper-catalyzed conjugate addition of organozinc reagent derived from 
L-iodoalanine with a range of enones gave improved yields in comparison 
with using stoichiometric copper, followed by deprotection/cyclisation/ 
hydrogenation with diastereomeric ratios of approximately 6:1, in 
preference of the cis-isomer (Schemes 83, 85 and 86). 
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Chapter: 4 Experimental 
4.1 General 
All moisture/air sensitive reactions were carried out under a nitrogen 
atmosphere in oven dried glassware. All reagents used were purchased 
from commercial sources or prepared and purified accordingly for literature 
procedure. All solvents used were HPLC grade or distilled. Petroleum 
ether refers to the fraction which boils in the range 40-60 °C. Dry DMF was 
distilled from calcium hydride and stored over 4 Å molecular sieves. 
Solvent evaporation under reduced pressure was performed using a Büchi 
rotary evaporator. Organic extracts were dried over MgSO4. Purification by 
column chromatography was performed using silica gel for flash 
chromatography. Thin layer chromatography was performed using pre-
coated plates, and compounds visualised by UV light (254 nm), ninhydrin 
solution (5% in MeOH). 
NMR spectra were recorded using Bruker AC 400 or Bruker DRX 500. The 
coupling constant is given in Hertz and are rounded to the nearest 0.5 Hz. 
13C NMR spectra were recorded at 400 MHz. 
Optical rotations were measured on a Perkin Elmer 241 automatic 
polarimeter at λ 589 nm (Na, D-line) with a path length of 1 dm at the room 
temperature and concentrations. The concentration is given in g/100ml. 
Infra-red spectra were recorded on a Perkin Elmer Paragon 100 FTIR 
spectrophotometer (νmax in cm-1) as solutions (solvent stated in the text). 
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4.2 Starting materials 
All starting materials were prepared from commercially available amino 
acids according to the literature method.  
Methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride (101)85 
 
 
Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-hydroxypropanoate (102)85 
 
 
Methyl(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[(4methylbenzenesulfonyl) 
oxy]propanoate (103)86 
 
 
Methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (104)86 
 
 
(2S)-2-Amino-3-phenylpropan-1-ol (106a)89 
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(2R)-2-Amino-3-phenylpropan-1-ol (ent-106a)89 
 
 
(2S)-2-Amino-3-methylbutan-1-ol (106b)90 
 
 
tert-Butyl N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]carbamate (107a)87 
 
 
tert-Butyl N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]carbamate (ent-107a)87 
 
 
 tert-Butyl N-[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamate (107b)87 
 
 
2,2,2-Trifluoro-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]acetamide (108a)91 
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2,2,2-Trifluoro-N-[(2S)-1-hydroxy-3-methylbutan-2-yl]acetamide (108b)91 
 
 
tert-Butyl N-[(2S)-1-iodo-3-phenylpropan-2-yl]carbamate (109a)87  
 
 
tert-Butyl N-[(2R)-1-iodo-3-phenylpropan-2-yl]carbamate (ent-109a)87 
 
 
tert-Butyl N-[(2S)-1-iodo-3-methylbutan-2-yl]carbamate (109b)87 
 
 
2,2,2-Trifluoro-N-[(2S)-1-iodo-3-phenylpropan-2-yl]acetamide (110a)115 
 
 
2,2,2-Trifluoro-N-[(2S)-1-iodo-3-methylbutan-2-yl]acetamide (110b)115 
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(2S)-2-Amino-4-methoxy-4-oxobutanoic acid hydrochloride (112a)93 
 
 
(2S)-2-Amino-5-methoxy-5-oxopentanoic acid hydrochloride (112b)93 
 
 
(2S)-2-{[(tert-Butoxy)carbonyl]amino}-4-methoxy-4-oxobutanoic acid 
(113a)96,116 
 
 
(2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-methoxy-5-oxopentanoic acid 
(113b)116 
 
 
(2S)-4-Methoxy-4-oxo-2-(trifluoroacetamido)butanoic acid (115a)67 
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(2S)-5-Methoxy-5-oxo-2-(trifluoroacetamido)pentanoic acid (115b)67 
 
 
Methyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-4-hydroxybutanoate (107c)96 
 
 
Methyl (4S)-4-{[(tert-butoxy)carbonyl]amino}-5-hydroxypentanoate 
(107d)116 
 
 
Methyl (3S)-4-hydroxy-3-(trifluoroacetamido)butanoate (108c)67 
 
 
Methyl (4S)-5-hydroxy-4-(trifluoroacetamido)pentanoate (108d)67 
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Methyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-4-iodobutanoate (109c)87 
 
 
Methyl (4S)-4-{[(tert-butoxy)carbonyl]amino}-5-iodopentanoate (109d)87 
 
 
Methyl (3S)-4-iodo-3-(trifluoroacetamido)butanoate (110c)87 
 
 
Methyl (4S)-5-iodo-4-(trifluoroacetamido)pentanoate (110d)87 
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4.3 General Procedure A: Allylation reactions 
A two-necked round bottomed flask, fitted with a three-way tap and rubber 
septum, was flame-dried, evacuated and backfilled with nitrogen three 
times. The flask was charged with a magnetic follower and zinc powder 
(2.0 mmol), and again evacuated and backfilled with nitrogen three times, 
with continuous stirring. Dry DMF (1 mL) was added via syringe, and the 
heterogeneous mixture stirred vigorously. Iodine (0.25 mmol) was added 
by rapid removal and replacement of the three-way tap under a stream of 
nitrogen, turning the solvent yellow. The mixture was stirred for 1-2 min, 
until the solvent had become coluorless. The alkyl iodide (1.0 mmol) was 
added by rapid removal of the three-way tap under a stream of nitrogen. 
The mixture was stirred and an exotherm was observed. The mixture was 
stirred for a further 30-45 min, before cessation of stirring. The solid zinc 
dust was allowed to settle before transferring the solution containing the 
zinc reagent into a new reaction vessel via syringe.  
During the activation period, a separate two-necked round bottomed flask 
fitted with a three-way tap was flame-dried under vacuum, and backfilled 
with nitrogen three times. This flask was charged with a magnetic follower 
and CuBr.DMS (0.1 eq), and gently heated under vacuum until the 
CuBr.DMS changed appearance from a brown to light green powder. The 
flask was allowed to cool, before adding dry DMF (0.6 mL) and 3-chloro-2- 
(chloromethyl)prop-1-ene (4.0 eq) via a syringe. The mixture was stirred at 
room temperature, at which point the organozinc reagent was added 
dropwise via syringe, and was stirred at room temperature for 3 h. The 
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reaction mixture was transferred to a separatory funnel with (10 mL) ethyl 
acetate, and washed with a (5 mL) saturated sodium thiosulfate solution, 
(5 mL) water and (5 mL) brine. The organic layer was dried over 
magnesium sulfate, filtered, and the solvent removed under reduced 
pressure. The residue was purified by flash chromatography on silica, 
using ethyl acetate in petroleum ether. 
Reaction of methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3 iodopropanoate 
(104) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
 
This reaction was done according to the general procedure A using (2.63 
g, 8 mmol) of 104 to give ent-94 (1.39 g, 60%) as a colourless oil and ent-
95 (539 mg, 15%) as a colourless oil.  
Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-5-(chloromethyl)hex-5-enoate 
(ent-94) 
 
Rf 0.25 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 3356, 1740, 
1702, 1502; 1H NMR (400 MHz, CDCl3) δ ppm: 1.42 (9 H, s, C(CH3)3), 
1.71-1.79 (1 H, m, CHACHB), 1.96-2.10 (1 H, m, CHACHB), 2.22 (2 H, t, J 
7.5 Hz, CH2C=CH2), 3.73 (3 H, s, OCH3), 4.02 (2 H, s, CH2Cl), 4.30-4.36 
(1 H, m, CHN), 4.97 (1 H, s, CHACHB=C), 5.1-5.21 (1 H, m, NH), 5.15 (1 
H, s, CHACHB=C); 
13C NMR (100 MHz, CDCl3) δ ppm: 28.2, 28.6, 30.5, 
48.1, 52.3, 52.9, 80.1, 115.2, 143.7, 155.6 173.0; Found MH+ 292.1323 
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C13H23NO4
35Cl requires MH+ 292.1316; [α]D
22 +20.5 (c 1.46 CHCl3) (lit.
48 
+20.5 (c 1.46 CHCl3)). 
1,9-Dimethyl(2S,8S)-2,8-bis({[(tert-butoxy)carbonyl]amino})-5-methyl   
idenenonanedioate (ent-95) 
 
Rf 0.3 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2977, 1744, 
1697, 1507; 1H NMR (400 MHz, CDCl3) δ ppm: 1.43 (18 H, s, 2C(CH3)3), 
1.70-1.79 (2 H, m, 2CH2), 1.91-1.99 (2 H, m, 2CH2), 2.0-2.09 (4 H, m, 
2CH2C=CH2), 3.73 (6 H, s, 2OCH3), 4.27-4.34 (2 H, m, 2CH), 4.77 (2 H, s, 
CH2=C), 4.96-5.09 (2 H, m, 2NH); 
13C NMR (100 MHz, CDCl3) δ ppm: 
27.3, 29.8, 30.6, 51.2, 52.1, 78.9, 109.5, 145.5, 154.5, 172.3; Found MH+ 
459.2689 C22H39N2O8 requires MH
+ 459.2706; [α]D
22 +24.9 (c 6.24 CHCl3) 
(lit.48 +24.1 (c 6.23, CHCl3)). 
Reaction of methyl tert-butyl N-[(2S)-1-iodo-3-phenylpropan-2-yl] 
carbamate (109a) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
 
This reaction was done according to the general procedure A using (2.52 
g, 7 mmol) of 109a to give 117a (1.56 g, 69%) as a white solid and 118a 
(365 mg, 10%) as a white solid. 
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tert-Butyl N-[(2R)-5-(chloromethyl)-1-phenylhex-5-en-2-yl]carbamate 
(117a) 
 
Rf 0.35 (10% ethyl acetate in petroleum ether);
 mp 62-63 °C; νmax/cm
-1: 
3299, 1695, 1603, 1556, 1158; 1H NMR (400 MHz, CDCl3) δ ppm: 1.42 (9 
H, s, C(CH3)3), 1.45-1.53 (1 H, m, CHAHBCH2C=CH2), 1.68-1.75 (1 H, m, 
CHAHBCH2C=CH2), 2.18-2.26 (1 H, m, CHAHBC=CH2), 2.27-2.32 (1 H, m, 
CHAHBC=CH2), 2.76-2.83 (2 H, m, CH2Ph), 3.80-3.89 (1 H, m, CHN), 3.99 
(1 H, d J 12.0 Hz, CHAHBCl), 4.05 (1 H, d J 12.0 Hz, CHAHBCl), 4.35 (1 H, 
d J 8.0 Hz, NH), 4.94 (1 H, d J 1.0 Hz, C=CHAHB), 5.13 (1 H, br, s, 
C=CHAHB), 7.27 (5 H, m, Ph); 
13C NMR (100 MHz, CDCl3) δ ppm: 28.3, 
29.4, 31.9, 41.3, 48.2, 51.1, 79.2, 114.8, 126.3, 128.3, 129.4, 138.0, 
144.4, 155.6; Found MH+ 324.1743 C18H27NO2
35Cl requires MH+ 
324.1730; [α]D
22 +5 (c 1 in CHCl3). 
tert-Butyl N-[(2R,8R)-8-{[(tert-butoxy)carbonyl]amino}-5-methylidene 1,9-
diphenylnonan-2-yl]carbamate (118a) 
 
Rf 0.3 (20% ethyl acetate in petroleum ether);
 mp 138-140 °C; νmax/cm
-1: 
3294, 1695, 1610, 1556, 1152; 1H NMR (400 MHz, CDCl3) δ ppm: 1.42 (18 
H, s, 2C(CH3)3), 1.54-1.62 (4 H, m, 2CH2CH2C=CH2), 1.98-2.16 (4 H, m, 
2CH2C=CH2), 2.72-2.79 (4 H, m, 2CH2Ph), 3.77-3.88 (2 H, br, 2CHN), 
4.34 (2 H, d J 8.5 Hz, 2NH), 4.69 (2 H, s, C=CH2), 7.25 (10 H, m, 2Ph); 
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13C NMR (100 MHz, CDCl3) δ ppm: 28.4, 32.2, 32.4, 41.4, 51.3, 79.0, 
109.7, 126.3, 128.3, 129.5, 138.2, 148.2, 155.9; Found MH+ 523.3536 
C32H47N2O4 requires MH
+ 523.3536; [α]D
22 +7 (c 1 in CHCl3). 
Reaction of methyl tert-butyl N-[(2R)-1-iodo-3-phenylpropan-2-yl] 
carbamate (ent-109a) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
 
tert-Butyl N-[(2S)-5-(chloromethyl)-1-phenylhex-5-en-2-yl]carbamate (ent-
117a) 
 
[α]D
22 -5 (c 1 in CHCl3). 
tert-Butyl N-[(2S,8S)-8-{[(tert-butoxy)carbonyl]amino}-5-methylidene 1,9-
diphenylnonan-2-yl]carbamate (ent-118a) 
 
[α]D
22 -7 (c 1 in CHCl3). 
Reaction of tert-butyl N-[(2S)-1-iodo-3-methylbutan-2-yl]carbamate (109b) 
with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
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This reaction was done according to the general procedure A using (1.28 
g, 4 mmol) of 109b to give 117b (616 mg, 59%) as a white solid and 118b 
(114 mg, 13%) as a white solid. 
tert-Butyl N-[(3R)-6-(chloromethyl)-2-methylhept-6-en-3-yl]carbamate 
(117b) 
  
Rf 0.41 (5% ethyl acetate in petroleum ether); mp 44-45 °C; νmax/cm
-1: 
3300, 1676, 1535, 1171;  1H NMR (400 MHz, CDCl3) δ ppm: 0.87 (3 H, d J 
6.5 Hz, CHCH3CH3), 0.91 (3 H, d J 6.5 Hz, CHCH3CH3), 1.39-1.62 (1 H , 
m, CH(CH3)2)1.43 (9 H, s, C(CH3)3), 1.62-1.72 (2 H, m, CH2C=CH2), 2.12-
2.19 (1 H, m, CHAHBCHN), 2.21-2.28 (1 H, m, CHAHBCHN), 3.40-3.47 (1 
H, m, CHN), 4.03 (2 H, s, CH2Cl), 4.95 (1 H, d J 1.5 Hz, C=CHAHB), 5.13 
(1 H, br, s, C=CHAHB); 
13C NMR (100 MHz, CDCl3) δ ppm: 17.5, 19.1, 
28.4, 29.7, 30.5, 32.1, 48.4, 55.1, 78.9, 114.6, 144.8, 155.9; Found MH+ 
276.1737 C14H27
35ClNO2 requires MH
+ 276.1730; [α]D
22 -5 (c 1 in CHCl3). 
tert-Butyl N-[(3R,9R)-9-{[(tert-butoxy)carbonyl]amino}-2,10-dimethyl-6-
methylideneundecan-3-yl]carbamate (118b) 
 
Rf 0.4 (10% ethyl acetate in petroleum ether); mp 91-92 °C; νmax/cm
-1: 
2958, 1683, 1510, 1165; 1H NMR (400 MHz, CDCl3) δ ppm: 0.86 (6 H, d J 
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7.0 Hz, 2CHCH3CH3), 0.89 (6 H, d J 7.0 Hz, 2CHCH3CH3), 1.38-1.59 (2 H, 
m, 2CH(CH3)2), 1.43 (18 H, s, 2C(CH3)3), 1.57-1.62 (2 H, m, 
2CHAHBC=CH2), 1.68-1.75 (2 H, m, 2CHAHBC=CH2), 1.99-2.11 (4 H, m, 
2CH2CHN), 3.40-2.49 (2 H, m, 2CHN), 4.30 (2 H, d, J 10.0 Hz, 2NH), 4.72 
(2 H, s, C=CH2); 
13C NMR (100 MHz, CDCl3) δ ppm: 17.6, 19.1, 28.4, 
30.8, 32.2, 32.8, 55.4, 78.0, 109.0, 149.0, 156.3; Found MH+ 427.3517 
C24H47N2O4 requires MH
+ 427.3536; [α]D
22 -6 (c 1 in CHCl3).  
Reaction of methyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-4-iodobutanoate 
(109c) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
This reaction was done according to the general procedure A using (1.37 
g, 4 mmol) of 109c to give 117c (786 mg, 60%) as a colourless oil and 
118c (194 mg, 10%) as a white solid. 
Methyl (3R)-3-{[(tert-butoxy)carbonyl]amino}-6-(chloromethyl)hept-6-
enoate (117c) 
 
Rf 0.34 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2977, 1736, 
1690, 1505; 1H NMR (400 MHz, CDCl3) δ ppm: 1.42 (9 H, s, C(CH3)3), 
1.68 (2 H, q J 7.5 Hz, CH2CHN), 2.20-2.25 (2 H, m, CH2C=CH2), 2.51-2.57 
(2 H, m, CH2CO2CH3), 3.68 (3 H, s, CO2CH3), 3.88-3.92 (1 H, m, CHN), 
4.03 (2 H, s, CH2Cl), 4.96 (1 H, s, C=CHAHB), 4.93-5.1 (1 H, br, NH), 5.14 
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(1 H, s, C=CHAHB); 
13C NMR (100 MHz, CDCl3) δ ppm: 28.3, 29.5, 32.2, 
39.0, 47.0, 48.2, 51.7, 79.5, 114.9, 144.1, 155.3, 172.0; Found MH+ 
306.1457 C14H25
35ClNO4 requires MH
+ 306.1472; [α]D
20 +13.0 (c 1 in 
CHCl3).  
1,11-Dimethyl (3R,9R)-3,9-bis({[(tert-butoxy)carbonyl]amino})-6-
methylideneundecanedioate (118c) 
 
Rf 0.27 (20% ethyl acetate in petroleum ether); mp 54-55 °C; νmax/cm
-1: 
3332, 1737, 1707, 1681; 1H NMR (400 MHz, CDCl3) δ ppm: 1.42 (18 H, s, 
2C(CH3)3), 1.59-1.65 (4 H, m, 2CH2CHN), 2.0-2.17 (4 H, m, 2CH2C=CH2), 
2.49-2.55 (4 H, m, 2CH2CO2CH3), 3.67 (6 H, s, 2CO2CH3), 3.83-3.89 (2 H, 
m, 2CHN), 4.73 (2 H, s, C=CH2), 4.96 (2 H, d J 9.0 Hz, 2NH); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 28.3, 32.4, 32.5, 39.1, 47.3, 51.6, 79.3, 109.9, 
147.5, 155.3, 172.1; Found MH+ 487.3018 C24H43N2O8 requires MH
+ 
487.3019; [α]D
20 +15.0 (c 1 in CHCl3). 
Reaction of methyl (4S)-4-{[(tert-butoxy)carbonyl]amino}-5-iodopentanoate 
(109d) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
 This reaction was done according to the general procedure A using (1.42 
g, 4 mmol) of 109d to give 117d (764 mg, 60%) as a colourless oil and 
118d (266 mg, 13%) as a white solid. 
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Methyl (4R)-4-{[(tert-butoxy)carbonyl]amino}-7-(chloromethyl)oct-7-enoate 
(117d) 
 
Rf 0.41 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 2948, 1735, 
1686, 1518, 1164; 1H NMR (400 MHz, CDCl3) δ ppm: 1.45 (9 H, s, 
C(CH3)3), 1.58-1.65 (1 H, m, CHAHBCH2CO2CH3), 1.68-1.73 (2 H, m, 
CH2CHN), 1.87-1.95 (1 H, m, CHAHBCH2CO2CH3), 2.18-2.25 (2 H, m, 
CH2C=CH2), 2.38 (2 H, t J 7.5 Hz, CH2CO2CH3), 3.55-3.61 (1 H, m, CHN), 
3.67 (3 H, s, CO2CH3), 4.03 (2 H, s, CH2Cl), 4.31 (1 H, d J 9.0 Hz, NH) 
4.96 (1 H, d J 1.0 Hz, C=CHAHB), 5.13 (1 H, br, s, C=CHAHB); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 28.3, 29.3, 30.4, 30.8, 33.6, 48.3, 50.0, 51.7, 
79.2, 114.8, 144.4, 155.6, 174.0; Found MH+ 320.1618 C15H27
35ClNO4 
requires MH+ 320.1629; [α]D
22 -11 (c 1 in CHCl3). 
1,13-Dimethyl (4R,10R)-4,10-bis({[(tert-butoxy)carbonyl]amino})-7-
methylidenetridecanedioate (118d) 
 
Rf 0.28 (20% ethyl acetate in petroleum ether); mp 76-77 °C; νmax/cm
-1: 
2940, 1778, 1731, 1682, 1644, 1162; 1H NMR (400 MHz, CDCl3) δ ppm: 
1.45 (18 H, s, 2C(CH3)3), 1.56-1.63 (2 H, m, 2CHAHBCH2CO2CH3), 1.66-
1.73 (4 H, m, 2CH2CHN), 1.87-1.94 (2 H, m, 2CHAHBCH2CO2CH3), 2.04 (4 
H, t J 7.5 Hz, 2CH2C=CH2), 2.38 (4 H, t J 7.5 Hz, 2CH2CO2CH3), 3.52-3.59 
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(2 H, m, 2CHN), 3.67 (6 H, s, 2CO2CH3), 4.31 (2 H, d J 9.5 Hz, 2NH), 4.72 
(2 H, s, C=CH2), 
13C NMR (100 MHz, CDCl3) δ ppm: 28.4, 30.6, 30.8, 
32.3, 33.9, 50.2, 51.6, 77.3, 109.5, 148.5, 157.0, 174.5; Found MH+ 
515.3324 C26H47N2O8 requires MH
+ 515.3332; [α]D
22 -10 (c 1 in CHCl3). 
Reaction of 2,2,2-trifluoro-N-[(2S)-1-iodo-3-phenylpropan-2-yl]acetamide 
(110a) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
 
This reaction was done according to the general procedure A using (2.48 
g, 7 mmol) of 110a to give 120a (1.32 g, 60%) as a white solid and 121a 
(213 mg, 12%) as a white solid. 
N-[(2R)-5-(Chloromethyl)-1-phenylhex-5-en-2-yl]-2,2,2-trifluoroacetamide 
(120a) 
  
Rf 0.33 (10% ethyl acetate in petroleum ether); mp 58-59 °C; νmax/cm
-1: 
3296, 1694, 1644, 1555, 1161; 1H NMR (400 MHz, CDCl3) δ ppm: 1.64-
1.69 (1 H, m, CHAHBCHN), 1.80-1.87 (1 H, m, CHAHBCHN), 2.21-2.29 (2 
H, m, CH2C=CH2), 2.88-2.95 (2 H, m, CH2Ph), 4.0 (1 H, d J 12.0 Hz, 
CHAHBCl), 4.05 (1 H, d J 12.0 Hz, CHAHBCl), 4.20-4.29 (1 H, m, CHN), 
4.97 (1 H, s, C=CHAHB), 5.18 (1 H, s, C=CHAHB), 6.13 (1 H, d J 8.0 Hz, 
NH), 7.25-7.34 (5 H, m, Ph); 13C NMR (100 MHz, CDCl3) δ ppm: 29.3, 
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31.1, 40.2, 48.0, 50.9, 115.5, 115.8 (q J 293 Hz), 127.0, 128.6, 129.2, 
136.3, 147.2, 157.2 (q J 38.0 Hz); Found MH+ 320.1014 C15H18NOF3
35Cl 
requires MH+ 320.1029; [α]D
22 +11 (c 1 in CHCl3). 
2,2,2-Trifluoro-N-[(2R,8R)-5-methylidene-1,9-diphenyl-8-
(trifluoroacetamido)nonan-2-yl]acetamide (121a) 
 
Rf 0.26 (10% ethyl acetate in petroleum ether); mp 153-155 °C; νmax/cm
-1: 
3298, 1696, 1455; 1H NMR (400 MHz, CDCl3) δ ppm: 1.52-1.67 (2 H, m, 
2CHAHBCHN), 1.68-1.79 (2 H, m, 2CHAHBCHN), 2.05 (4 H, t J 7.5 Hz, 
2CH2C=CH2), 2.83 (2 H, dd J 14.0 and 6.5 Hz, 2CHAHBPh), 2.90 (2 H, dd 
J 14.0 and 6.5 Hz, 2CHAHBPh), 4.11-4.22 (2 H, m, 2CHN), 4.78 (2 H, s, 
CH2=C), 6.15 (2 H, d J 9.0 Hz, 2NH), 7.14-7.20 (4 H, m, Ph), 7.24-7.37 (6 
H, m, Ph); 13C NMR (100 MHz, CDCl3) δ ppm: 31.2, 31.9, 40.2, 50.8, 
111.0, 115.8 (q J 290 Hz), 127.1, 128.7, 129.2, 136.5, 146.5, 157.2 (q J 
38.0 Hz); Found MH+ 515.2109. C26H29N2O2F6 requires MH
+ 515.2133.; 
[α]D
22 +90 (c 1 in CHCl3).  
Reaction of 2,2,2-trifluoro-N-[(2S)-1-iodo-3-methylbutan-2-yl]acetamide 
(110b) with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
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This reaction was done according to the general procedure A using (1.23 
g, 4 mmol) of 110b to give 120b (647 mg, 60%) as a colourless oil and 
121b (100 mg, 12%) as a white solid. 
N-[(3R)-6-(Chloromethyl)-2-methylhept-6-en-3-yl]-2,2,2-trifluoroacetamide 
(120b) 
 
Rf 0.50 (5% ethyl acetate in petroleum ether); νmax/cm
-1: 3302, 1697, 
1555, 1155; 1H NMR (400 MHz, CDCl3) δ ppm: 0.92 (3 H, d J 6.5 Hz, 
CHCH3CH3), 0.95 (3 H, d J 6.5 Hz, CHCH3CH3), 1.52-1.58 (1 H, m, 
CHAHBCHN), 1.75-1.81 (1 H, m, CHAHBCHN), 1.81-1.87 (1 H, m, 
CH(CH3)2), 2.18-2.25 (2 H, m, CH2C=CH2), 3.82-3.88 (1 H, m,CHN), 4.03 
(2 H, s, CH2Cl), 4.97 (1 H, d J 1.0 Hz, C=CHAHB), 5.16 (1 H, d J 1.0 Hz, 
C=CHAHB), 5.98 (1 H, d J 8.0 Hz, NH); 
13C NMR (100 MHz, CDCl3) δ ppm: 
17.4, 19.1, 29.4, 29.7, 31.6, 48.1, 55.0, 115.3, 115.8 (q J 293 Hz), 143.8, 
157.2 (q J 38.0 Hz); Found MH+ 272.1019. C11H17
35ClF3NO requires MH
+ 
272.1029; [α]D
22 -20 (c 1 in CHCl3). 
N-[(3R,9R)-2,10-Dimethyl-6-methylidene-9-(trifluoroacetamido)undecan-3-
yl]-2,2,2-trifluoroacetamide (121b) 
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Rf 0.20 (5 % ethyl acetate in petroleum ether); mp 160-162 °C; νmax/cm
-1: 
3299, 1717, 1697.1556; 1H NMR (400 MHz, CDCl3) δ ppm: 0.91 (6 H, d J 
6.5 Hz, 2CHCH3CH3), 0.94 (6 H, d J 6.5 Hz, 2CHCH3CH3), 1.48-1.55 (2 H, 
m, 2CHAHBCHN), 1.70-1.77 (2 H, m, 2CHAHBCHN), 1.81-1.88 (2 H, m, 
2CH(CH3)2), 2.01 (4 H, t J 7.5 Hz, 2CH2C=CH2), 3.78-3.84 (2 H, m, 
2CHN), 4.78 (2 H, s, C=CH2), 6.07 (2 H, d J 9.5 Hz, 2NH); 
13C NMR (100 
MHz, CDCl3) δ ppm: 17.4, 19.1, 29.7, 31.6, 31.7, 55.0, 110.5, 115.3 (q J 
294 Hz), 143.8, 157.2 (q J 39.0 Hz); Found MH+ 419.2123. C18H29F6N2O2 
requires MH+ 419.2133; [α]D
22 -26 (c 1 in CHCl3). 
Reaction of methyl (3S)-4-iodo-3-(trifluoroacetamido)butanoate (110c) 
with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
This reaction was done according to the general procedure A using (1.35 
g, 4 mmol) of 110c to give 120c (678 mg, 57%) as a colourless oil and 
121c (115 mg, 12%) as a white solid. 
Methyl (3R)-6-(chloromethyl)-3-(trifluoroacetamido)hept-6-enoate (120c) 
 
Rf 0.60 (30% ethyl acetate in petroleum ether); νmax/cm
-1: 2931, 1702, 
1555, 1438, 1154; 1H NMR (400 MHz, CDCl3) δ ppm: 1.77-1.82 (1 H, m, 
CHAHBCHN), 1.86-1.93 (1 H, m, CHAHBCHN), 2.18 (1 H, br d J 8.0 Hz, 
CHAHBCO2CH3), 2.28 (1 H, br d J 8.0 Hz, CHAHBCO2CH3), 2.65 (2 H, d J 
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4.5 Hz, CH2C=CH2), 3.72 (3 H, s, CO2CH3), 4.03 (2 H, s, CH2Cl), 4.26 (1 
H, m, CHN), 4.98 (1 H, d J 1.0 Hz, C=CHAHB), 5.17 (1 H, br, s, C=CHAHB), 
7.24-7.31 (1 H, br, NH); 13C NMR (100 MHz, CDCl3) δ ppm: 29.3, 31.1, 
37.1, 46.4, 48.0, 52.0, 115.5, 116.0 (q J 289 Hz) 143.3, 156.8 (q J 38.0 
Hz), 171.8; Found MH+ 302.0776 C11H16
35ClF3NO3 requires MH
+ 
302.0771; [α]D
20 -1.0 (c 1 in CHCl3). 
1,11-Dimethyl(3R,9R)-6-methylidene-3,9-bis(trifluoroacetamido) 
undecanedioate (121c) 
 
Rf 0.33 (30% ethyl acetate in petroleum ether); mp 85-86 °C; νmax/cm
-1: 
2927, 1728, 1699, 1647, 1557, 1146; 1H NMR (400 MHz, CDCl3) δ ppm: 
1.66-1.73 (2 H, m, 2 CHAHBCHN), 1.75-1.84 (2 H, m, 2 CHAHBCHN), 2.05 
(4 H, t J 7.5, 2CH2CO2CH3), 2.60 (4 H, br, d J 5.0, 2CH2C=CH2), 3.72 (6 
H, s, 2 CO2CH3), 4.13-4.21 (2 H, m, 2CHN), 4.85 (2 H, s, C=CH2), 7.31 (2 
H, d J 9.0 Hz, 2NH); 13C NMR (100 MHz, CDCl3) δ ppm: 31.2, 32.0, 37.1, 
46.5, 52.0, 111.0, 115.9 (q, J 291 Hz), 145.8, 156.8 (q, J 38 Hz), 171.8; 
Found MH+ 479.1610 C18H25F6N2O6 requires MH
+ 479.1617; [α]D
22 -4.0 (c 
1 in CHCl3). 
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Reaction of methyl (4S)-5-iodo-4-(trifluoroacetamido)pentanoate (110d) 
with 3-chloro-2-(chloromethyl) prop-1-ene (41) 
This reaction was done according to the general procedure A using (1.40 
g, 4 mmol) of 110d to give 120d (694 mg, 55%) as a colourless oil and 
121d (212 mg, 21%) as a white solid. 
Methyl (4R)-7-(chloromethyl)-4-(trifluoroacetamido)oct-7-enoate (120d) 
 
Rf 0.4 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2953, 1700, 
1555, 1152; 1H NMR (400 MHz, CDCl3) δ ppm: 1.43-1.49 (2 H, m, 
CH2CHN), 1.80-1.87 (1 H, m, CHAHBCH2CO2CH3), 1.92-1.97 (1 H, m, 
CHAHBCH2CO2CH3), 2.22 (2 H, t J 8.0 Hz, CH2C=CH2), 2.32-2.39 (1 H, m, 
CHAHBCO2CH3), 2.41-2.48 (1 H, m, CHAHBCO2CH3), 3.67 (3 H, s, 
CO2CH3), 3.91-3.98 (1 H, m, CHN), 4.03 (2 H, s, CH2Cl), 4.97 (1 H, s, 
C=CHAHB), 5.15 (1 H, s, C=CHAHB), 6.71 (1 H, d J 7.5 Hz, NH); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 28.7, 29.0, 30.3, 32.3, 48.1, 50.1, 51.9, 114.4, 
115.6 (q J 292 Hz), 143.6, 157.2 (q J 38 Hz), 174.1; Found MH+ 316.0914 
C12H18F3
35ClNO3 requires MH
+ 316.0927; [α]D
22 -1.0 (c 1 in CHCl3). 
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1,13-Dimethyl (4R,10R)-7-methylidene-4,10-bis(trifluoroacetamido) 
tridecanedioate (121d) 
 
Rf 0.24 (40% ethyl acetate in petroleum ether); mp 89-90 °C; νmax/cm
-1: 
2949, 1735, 1694, 1641, 1555, 1179; 1H NMR (400 MHz, CDCl3) δ ppm: 
1.68 (4 H, q J 7.5 Hz, 2 CH2CHN), 1.77-1.83 (2 H, m, 2 
CHAHBCH2CO2CH3), 1.91-1.99 (2 H, m, 2 CHAHBCH2CO2CH3), 2.00-2.09 
(4 H, m, 2 CH2C=CH2), 2.32-2.39 (2 H, m, 2 CHAHBCO2CH3), 2.41-2.49 (2 
H, m, 2 CHAHBCO2CH3), 3.67 (6 H, s, 2 CO2CH3), 3.88-3.96 (2 H, m, 
2CHN), 4.78 (2 H, s, C=CH2), 6.84 (2 H, d J 8.0 Hz, 2NH); 
13C NMR (100 
MHz, CDCl3) δ ppm: 28.6, 30.3, 31.7, 32.2, 50.1, 51.9, 110.9, 115.6 (q J 
292 Hz), 146.5, 157.2 (q J 37 Hz), 174.1; Found MH+ 507.1931 
C20H29F6N2O6 requires MH
+ 507.1930; [α]D
22 -2.0 (c 1 in CHCl3). 
Methyl (2S)-5-(chloromethyl)-2-(trifluoroacetamido)hex-5-enoate (126) 
 
Trifluoroacetic acid (1.5 g, 13.1 eq) was added dropwise to a stirred 
solution of methyl (2S)-2-{[(tert-butoxy) carbonyl] amino}-5 
(chloromethyl)hex-5-enoate ent-94 (70 mg, 0.24 mmol) in 
dichloromethane (13 mL), and stirred for 30 min. The exesse of 
trifluoroacetic acid and dichloromethane removed under reduced pressure. 
The residue was dissolved in diethylether (1 mL) followed by addition of 
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trifluoroacetic anhydride (80 mg, 0.38 eq) and stirring at room temperutre. 
Triethylamine (75 mg, 0.74 mmol) was added dropwise to the reaction 
mixture for 1 h. Ethyl acetate was added and after washing by ammonium 
chloride, the organic layer was then concentrated, and purified via flash 
chromatography on silica using an eluant gradient of 10% ethyl acetate in 
petroleum ether to give the title compound as a colourless oil (48 mg, 
70%). 
Rf 0.27 (10% ethyl acetate in petrolumether); νmax/cm
-1: 3303, 2853, 1702, 
1546; 1H NMR (400 MHz, CDCl3) δ ppm: 1.91-2.01 (1 H, m, CHAHBCHN), 
2.10-2.16 (1 H, m, CHAHBCHN), 2.17-2.29 (2 H, m, CH2C=CH2), 3.81 (3 H, 
s, CO2CH3), 4.04 (2 H, s, CH2Cl), 4.59-4.71 (1 H, m, CHN), 5.0 (1 H, s, 
C=CHAHB), 5.19 (1 H, s, C=CHAHB), 6.97 (1 H, d J 6.5 Hz, NH); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 28.2, 29.7, 47.9, 52.2, 53.0, 115.8, 115.5 (q J 
291 Hz), 143.0, 156.8 (q J 42 Hz), 171.1; Found MH+ 288.0617 
C10H14NO3F3
35Cl requires MH+ 288.0614; [α]D
21 +25 (c 4 in CHCl3). 
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4.4 General Procedure B: Cyclization of allylic chlorides  
A two-necked round-bottomed flask fitted with a rubber septum, three-way 
tap and magnetic follower was flame-dried under vacuum and backfilled 
with nitrogen three times. The flask was charged with allylic chloride (1.0 
mmol) and dry DMF (0.8 mL). The mixture was stirred at room 
temperature until a colourless to pale yellow solution was obtained, at 
which point the flask was cooled to 0 °C. Sodium hydride (60 % dispersion 
in mineral oil, 1.2 eq) was added in one portion, and the reaction stirred at 
0 °C for 10 min, before being allowed to warm to room temperature and 
stirred for 1 h. Phosphate buffer solution (pH 7) (10 mL) was carefully 
added to the vessel via syringe, and the reaction mixture was transferred 
to a separatory funnel using (10 mL) ethyl acetate. The aqueous layer was 
extracted further with (10 mL) ethyl acetate, and the combined organic 
layers washed with (5 mL) water and (5 mL) brine, dried over magnesium 
sulfate and the solvent removed under reduced pressure. The residue was 
purified by flash chromatography on silica, using ethyl acetate in 
petroleum ether. 
1-tert-Butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-dicarboxylate (ent-
37) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-5-(chloromethyl)hex-
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5-enoate ent-94 (1.45 g, 5 mmol) as the starting material to give the title 
compound. The product was a colorless oil (1.1 g, 85%). 
Rf 0.39 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 2930, 1743, 
1694, 1448; 1H NMR (400 MHz, CDCl3), exhibits strongly rotameric 
behaviour δ ppm: 1.40 (9 H, s, C(CH3)3), 1.45 (9 H, s, C(CH3)3), 1.68-1.84 
(1 H, m, CHAHBCH), 1.97-2.10 (1 H, m, CHAHBCH), 2.15-2.30 (2 H, m, 
CH2C=CH2), 3.76-3.59 (1 H, m, CHAHBN), 3.72 (3 H, s, CO2CH3), 4.46-
4.26 (1 H, m, CHAHBN), 4.98-4.69 (2 H, m, C=CH2), 4.98-4.69 (1 H, m, 
CHN); 13C NMR (100 MHz, CDCl3) δ ppm: 27.2, 28.3, 28.9, 29.1, 46.8, 
48.1, 52.1, 53.5, 54.2, 80.2, 109.9, 110.2, 141.5, 141.8, 155.1, 155.5, 
172.2, 172.5; Found MH+ 256.1539 C13H22NO4 requires MH
+ 256.1549; 
[α]D
22 -59 (c 1 in CHCl3). 
1-tert-Butyl 2-methyl (2R)-5-methylidenepiperidine-1,2-dicarboxylate (37) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-5-(chloromethyl)hex-
5-enoate 94 (583 mg, 2 mmol) as the starting material to give the title 
compound. The product was a colourless oil (413 mg, 81%). 
[α]D
22 57 (c 1 in CHCl3).  
tert-Butyl (2R)-2-benzyl-5-methylidenepiperidine-1-carboxylate (119a) 
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The title compound was synthesised according to the general procedure 
B, using tert-butyl N-[(2R)-5-(chloromethyl)-1-phenylhex-5-en-2-
yl]carbamate 117a (1.61 g, 5 mmol) as the starting material to give the title 
compound. The product was a colorless oil (1.22 g, 85%).  
Rf 0.31 (5% ethyl acetate in petroleum ether); νmax/cm
-1: 1740, 1692, 
1448; 1H NMR (400 MHz, CDCl3) δ ppm: 1.45 (9 H, s, C(CH3)3), 1.66-1.73 
(2 H, m, CH2CH2C=CH2), 2.30 (1 H, dt, J 4.0 and 14.5 Hz, CHAHBC=CH2), 
2.47-2.53 (1 H, m, CHAHBC=CH2), 2.88-2.94 (1 H, m, CHAHBPh), 3.05 (1 
H, dd, J 7.5 and 3.5 Hz, CHAHBPh), 3.67 (1 H, d, J 14.5 Hz, CHAHBN), 
4.47-4.55 (1 H, br, CHN), 4.47-4.55 (1 H, br, CHAHBN), 4.85 (1 H, s, 
C=CHAHB), 4.95 (1 H, s, C=CHAHB), 7.31-7.42 (5 H, m,  Ph); 
13C NMR 
(500 MHz, CDCl3) δ ppm: 27.5, 28.3, 29.6, 36.5, 45.0, 52.3, 79.3, 109.4, 
126.2, 128.3, 128.9, 138.9, 142.8, 154.6; Found MH+ 288.1967. 
C18H26NO2 requires MH
+ 288.1964.; [α]D
22 -33.0 (c 1 in CHCl3), GC: 
Chiraldex-PM, H2 at 1.4 mL/ min, 140 °C, retention time:  37.7 min, ee 
98%. 
tert-Butyl (2S)-2-benzyl-5-methylidenepiperidine-1-carboxylate (ent-119a) 
 
The title compound was synthesised according to the general procedure 
B, using tert-butyl N-[(2S)-5-(chloromethyl)-1-phenylhex-5-en-2-
yl]carbamate ent-117a (323.8 mg, 1 mmol) as the starting material to the 
title compound. The product was as colorless oil. [α]D
22 +34.0 (c 1 in 
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CHCl3), GC: Chiraldex-PM, H2 at 1.4 mL/ min, 140 °C, retention time:  39.5 
min, ee 99%. 
tert-Butyl (2R)-5-methylidene-2-(propan-2-yl)piperidine-1-carboxylate 
(119b) 
 
The title compound was synthesised according to the general procedure 
B, using tert-butyl N-[(3R)-6-(chloromethyl)-2-methylhept-6-en-3-
yl]carbamate 117b (551.6 mg, 2 mmol) as the starting material to give the 
title compound. The product was a colourless oil (344 mg, 72%).  
Rf 0.35 (5% ethyl acetate in petroleum ether); νmax/cm
-1: 1689, 1454; 1H 
NMR (400 MHz, CDCl3) δ ppm: 0.86 (3 H, d J 6.5 Hz, CHCH3CH3), 0.95 (3 
H, d J 6.5 Hz, CHCH3CH3), 1.43 (9 H, s, C(CH3)3), 1.57-1.66 (1 H, m, 
CHAHBCHN), 1.77-1.83 (1 H, m, CHAHBCHN), 1.98-2.1 (1 H, m, 
CHCH3CH3), 2.14 (1 H, dt J 14.0 and 4.0 Hz, CHAHBC=CH2), 2.28 (1 H, t J 
14.0 Hz, CHAHBC=CH2), 3.35 (1 H, d J 15.0 Hz, CHAHBN), 3.71-3.80 (1 H, 
br, CHN), 4.36-4.44 (1 H, br, CHAHBN), 4.70 (1 H, s, C=CHAHB), 4.77 (1 H, 
s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) δ ppm: 19.4, 19.8, 26.7, 27.8, 
28.4, 29.6, 45.0, 56.7, 79.2, 108.8, 143.3, 155.1; Found MH+ 240.1960 
C14H26NO2 requires MH
+ 240.1960; [α]D
22 -17.0 (c 1 in CHCl3). 
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tert-Butyl(2R)-2-(2-methoxy-2-oxoethyl)-5-methylidenepiperidine-1-
carboxylate (119c) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (3R)-3-{[(tert-butoxy)carbonyl]amino}-6-
(chloromethyl)hept-6-enoate 117c (611.5 mg, 2 mmol) as the starting 
material to give the title compound. The product was a colorless oil (431 
mg, 80%).  
Rf 0.51 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2973, 1737, 
1689, 1403, 1159; 1H NMR (400 MHz, CDCl3) δ ppm: 1.43 (9 H, s, 
C(CH3)3), 1.61-1.69 (1 H, m, CHAHBCHN), 1.74-1.79 (1 H, m, 
CHAHBCHN), 2.21-2.28 (2 H, m, CH2C=CH2), 2.54 (1 H, dd J 14.0 and 8.0 
Hz, CHAHBCO2CH3), 2.65 (1 H, dd J 14.0 and 7.0 Hz, CHAHBCO2CH3), 
3.47 (1 H, d J 15.0 Hz, CHAHBN), 3.66 (3 H, s, CO2CH3), 4.30-4.39 (1 H, 
br, CHAHBN), 4.61-4.71 (1 H, br, CHN), 4.75 (1 H, s, C=CHAHB), 4.82 (1 H, 
s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) δ ppm: 27.4, 28.2, 28.3, 28.7, 
35.5, 47.9, 51.7, 79.8, 109.7, 142.2, 154.4, 171.6; Found MH+ 270.1693 
C14H24NO4 requires MH
+ 270.1705; [α]D
22 +3.0 (c 1 in CHCl3). 
tert-Butyl(2R)-2-(3-methoxy-3-oxopropyl)-5-methylidenepiperidine-1-
carboxylate (119d) 
 
 132 
 
The title compound was synthesised according to the general procedure 
B, using methyl (4R)-4-{[(tert-butoxy)carbonyl]amino}-7-(chloromethyl)oct-
7-enoate 117d (639.5 mg, 2 mmol) as the starting material to give the title 
compound.The product was a colorless oil (453 mg, 80%).  
Rf 0.55 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2930, 1737, 
1687, 1409, 1153; 1H NMR (400 MHz, CDCl3) δ ppm: 1.44 (9 H, s, 
C(CH3)3), 1.58-1.66 (1 H, m, CHAHBCH2CO2CH3), 1.70-1.77 (1 H, m, 
CHAHBCH2CO2CH3), 2.03-2.11 (1 H, m, CHAHBCH2C=CH), 2.15-2.22 (1 H, 
m, CHAHBC=CH2), 2.31-2.39 (1 H, m, CHAHBC=CH2), 2.31-2.39 (2 H, m, 
CH2CO2CH3), 3.40 (1 H, d J 15.0 Hz, CHAHBN), 3.67 (3 H, s, CO2CH3), 
4.20-2.28 (1 H, br, CHN), 4.31-4.39 (1 H, br, CHAHBN), 4.67-4.75 (1 H, s, 
C=CHAHB), 4.80 (1 H, s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) δ ppm: 
25.1, 27.7, 28.3, 30.3, 30.9, 49.8, 51.5, 68.1, 79.6, 109.3, 142.8, 154.8, 
173.7; Found MH+ 284.1760 C15H26NO4 requires MH
+ 284.1862; [α]D
22 
+20 (c 1 in CHCl3). 
1-[(2R)-2-Benzyl-5-methylidenepiperidin-1-yl]-2,2,2-trifluoroethan-1-one 
(122a) 
 
The title compound was synthesised according to the general procedure 
B, using N-[(2R)-5-(chloromethyl)-1-phenylhex-5-en-2-yl]-2,2,2-
trifluoroacetamide 120a (1.6 g, 5 mmol) as the starting material to give the 
title compound. The product was as colourless crystal (850 mg, 60%).  
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Rf 0.45 (5% ethyl acetate in petroleum ether); mp 181-183 °C; νmax/cm
-1: 
2937, 1675, 1451, 1272, 1186; 1H NMR (400 MHz, CDCl3) exhibits 
strongly rotameric behaviour (1.3 : 1), major rotamer δ ppm: 1.66-1.74 (2 
H, m, CH2CHN), 2.28-2.36 (1 H, m, CHAHBC=CH2), 2.51-2.59 (1 H, m, 
CHAHBC=CH2), 2.94-3.1 (2 H, m, CH2Ph), 3.89 (1 H, d J 15.0 Hz, 
CHAHBN), 4.22 (1 H, d J 15.0 Hz, CHAHBN), 4.85-4.93 (1 H, m, CHN), 4.89 
(1 H, s, C=CHAHB), 4.92 (1 H, s, C=CHAHB), 7.25-7.33 (5 H, m, Ph); minor 
rotamer δ ppm: 1.66-1.74 (2 H, m, CH2CHN), 2.28-2.36 (1 H, m, 
CHAHBC=CH2), 2.51-2.59 (1 H, m, CHAHBC=CH2), 2.94-3.1 (2 H, m, 
CH2Ph), 3.18 (1 H, dd J 14.0 and 10.0 Hz, CHAHBPh), 3.69 (1 H, d J 14.5 
Hz, CHAHBN), 4.27-4.35 (1 H, m, CHN), 4.91 (1 H, m, CHAHBN), 4.91 (1 H, 
m, C=CHAHB), 5.0 (1 H, s, C=CHAHB), 7.25-7.33 (5 H, m, Ph); 
1H NMR at 
353 K (500 MHz, d6-DMSO) δ ppm: 1.60-1.69 (1 H, m, CHAHBCHN), 1.70-
1.80 (1 H, m, CHAHBCH2N), 2.21-2.29 (1 H, m, CHAHBC=CH2), 2.55-2.63 
(1 H, m, CHAHBC=CH2), 2.95-3.1 (2 H, m , CH2Ph), 4.0-4.1 (2 H, m,  
CH2N), 4.68-4.76 (1 H, m, CHN), 4.87 (1 H, s, C=CHAHB), 4.91 (1 H, s, 
C=CHAHB), 7.25-7.33  (5 H, m, Ph); 
13C NMR (125 MHz, CDCl3) major 
rotamer δ ppm: 26.6, 27.2, 35.9, 54.8, 57.6, 112.1, 116.7 (q J 292 Hz), 
126.8, 128.6, 129.0, 137.2, 140.7, 155.8 (q J 38.0 Hz), minor rotamer δ 
ppm: 26.6, 27.4, 36.6, 45.0, 52.0, 111.2, 116.7 (q J 292 Hz), 127.0, 128.2, 
129.1, 136.1, 140.3, 155.8 (q J 38.0 Hz), Found MH+ 284.1249 
C15H17F3NO requires MH
+ 284.1262; [α]D
22 -31.0 (c 1 in CHCl3). 
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2,2,2-Trifluoro-1-[(2R)-5-methylidene-2-(propan-2-yl)piperidin-1-yl]ethan-1-
one (122b)  
 
The title compound was synthesised according to the general procedure 
B, using (R)- N-[(3R)-6-(chloromethyl)-2-methylhept-6-en-3-yl]-2,2,2-
trifluoroacetamide 120b  (543.5 mg, 2 mmol) as the starting material to 
give the title compound. The product was a colourless oil (258 mg, 55%).  
Rf 0.76 (5% ethyl acetate in petroleum ether); νmax/cm
-1: 1687, 1447, 
1188; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour (2 : 
1), major rotamer δ ppm: 0.87 (3 H, d J 6.5 Hz, CHCH3CH3), 1.0 (3 H, d J 
6.5 Hz, CHCH3CH3), 1.59-1.74 (1 H, m, CHCH3CH3), 1.90-2.05 (1 H, m, 
CHAHBCHN), 2.13-2.22 (1 H, m, CHAHBCHN), 2.22-2.31 (1 H, m, 
CHAHBC=CH2), 2.32-2.48 (1 H, m, CHAHBC=CH2), 3.74 (1 H, d J 15.0 Hz, 
CHAHBN), 4.17 (1 H, d J 15.0 Hz, CHAHBN), 4.25-4.33 (1 H, m, CHN), 
4.80-4.84 (m, 1 H, CHAHB=C), 4.84-4.87 (m, 1 H, CHAHB=C); minor 
rotamer δ ppm: 0.87 (3 H, d J 6.5 Hz, CHCH3CH3), 1.0 (3 H, d J 6.5 Hz, 
CHCH3CH3), 1.59-1.74 (1 H, m, CHCH3CH3), 1.90-2.05 (1 H, m, 
CHAHBCHN), 2.13-2.22 (1 H, m, CHAHBCHN), 2.22-2.31 (1 H, m, 
CHAHBC=CH2), 2.32-2.48 (1 H, m, CHAHBC=CH2), 3.41 (1 H, d J 15.0 Hz, 
CHAHBN), 3.52-3.60 (1 H, m, CHN), 4.80-4.84 (1 H, m, CHAHBN), 4.84-
4.87 (1 H, m, CHAHB=C), 4.91 (1 H, d J 1.5 Hz, CHAHB=C); 
13C NMR (100 
MHz, CDCl3) major rotamer δ ppm: 18.8, 19.4, 26.0, 26.2, 27.5, 44.9, 
56.5, 110.8, 121.3 (q J 290 Hz),  140.6 156.1 (q J 38.0 Hz); minor 
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rotamer δ ppm: 18.8, 19.8, 27.5, 27.9,  28.0, 47.4, 59.5, 111.8, 121.3 (q J 
290 Hz), 141.1, 156.1 (q J 38.0 Hz); Found MH+ 236.1255 C11H17F3NO 
requires MH+ 236.1262; [α]D
19 -15.4 (c 4.67 in CHCl3).   
Methyl 2-[(2R)-5-methylidene-1(trifluoroacetyl)piperidin-2-yl]acetate (122c) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (3R)-6-(chloromethyl)-3-(trifluoroacetamido)hept-6-enoate 
120c (620 mg, 2 mmol) as the starting material to give the title compound. 
The product was as colourless oil (326 mg, 60%).  
Rf 0.52 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 1736, 1682, 
1438, 1269; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
behaviour (1.5 : 1), major rotamer δ ppm: 1.81-1.89 (2 H, m, CH2CHN), 
2.30-2.41 (2 H, m, CH2C=CH2), 2.64 (1 H, dd J 15.0 and 7.5 Hz, 
CHAHBCO2CH3), 2.74 (1 H, dd J 15.0 and 7.5 Hz, CHAHBCO2CH3) 3.66 (3 
H, s, CO2CH3), 3.87 (1 H, d J 15.0 Hz, CHAHBN), 4.20 (1 H, d J 15.0 Hz, 
CHAHBN), 4.87 (1 H, s, C=CHAHB), 4.90 (1 H, s, C=CHAHB), 4.97-5.1 (1 H, 
m, CHN); minor rotamer δ ppm: 1.81-1.89 (2 H, m, CH2CHN), 2.30-2.41 
(2 H, m, CH2C=CH2), 2.70 (1 H, dd J 15.0 and 7.5 Hz, CHAHBCO2CH3), 
2.88 (1 H, dd J 15.0 and 7.5 Hz, CHAHBCO2CH3), 3.48 (1 H, d J 15.0 Hz, 
CHAHBN), 3.70 (3 H, s, CO2CH3), 4.57-4.63 (1 H, m, CHN), 4.83 (1 H, d J 
15.0 Hz, CHAHBN), 4.87 (1 H, s, C=CHAHB), 4.95 (1 H, s, C=CHAHB); 
1H 
NMR at 353 K (125 MHz, d6-DMSO) δ ppm: 1.69-1.81 (2 H, m, CH2CHN), 
2.20-2.32 (1 H, m, CHAHBC=CH2), 2.41-2.52 (1 H, m, CHAHBC=CH2), 2.80 
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(2 H, m, CH2CO2CH3), 4.60 (3 H, s, CO2CH3), 3.94-4.10 (1 H, m, 
CHAHBN), 4.11-4.22 (1 H, m, CHAHBN), 4.85 (1 H, s, C=CHAHB), 4.90 (1 
H, s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) major rotamer δ ppm: 27.9, 
34.7, 47.14, 47.18, 47.8, 51.9, 111.5, 116.5 (q J 288 Hz), 140.1, 157.2 (q J 
40 Hz), 170.6; minor rotamer δ ppm: 27.1, 29.4, 35.4, 44.9, 49.8, 52.1, 
112.4, 116.6 (q J 288 Hz), 139.7, 157.2 (q J 40 Hz), 170.6; Found MH+ 
266.1006 C11H15F3NO3 requires MH
+ 266.1004; [α]D
22 +5 (c 1 in CHCl3). 
Methyl (2E)-6-[(trifluoroacetamido)methyl]hepta-2,6-dienoate (123) 
 
The title compound is obtained as a by-product at preparing the previous 
compound as a colorless crystal (82 mg, 15%).  
Rf 0.32 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 3293, 1697, 
1653, 1555, 1435; 1H NMR (400 MHz, CDCl3) δ ppm: 2.19 (2 H, t J 7.5 Hz, 
CH2C=CH2), 2.39 (2 H, qd J 7.5 and 1.5 Hz, CH2CH=CHCO2CH3), 3.71 (3 
H, s, CO2CH3), 3.93 (2 H, d J 6.0 Hz, CH2NH), 4.97 (2 H, d J 7.0 Hz, 
C=CH2), 5.84 (1 H, dt J 15.5 and 1.5 Hz, CH=CHCO2CH3), 6.48-6.55 (1 H, 
br, NH), 6.95 (1 H, dt J 15.5 and 7.0 Hz, CH=CHCO2CH3); 
13C NMR (100 
MHz, CDCl3) δ ppm: 29.8, 32.0, 44.0, 51.4, 112.7, 114.0 (q J 80 Hz), 
121.7, 142.3, 147.6, 157.2 (q J 40 Hz), 166.8; Found MH+ 266.1012 
C11H15F3NO3 requires MH
+ 266.1004. 
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Methyl 3-[(2R)-5-methylidene-1-(trifluoroacetyl)piperidin-2-yl]propanoate 
(122d) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (4R)-7-(chloromethyl)-4-(trifluoroacetamido)oct-7-enoate 
120d (637 mg, 2 mmol) as the starting material to give the title compound. 
The product was a colourless oil (446 mg, 79%).  
Rf 0.38 (20% ethyl acetate in petroleum ether); νmax/cm
-1: 2926, 1736, 
1681, 1438, 1364, 1178; 1H NMR (400 MHz, CDCl3) exhibits strongly 
rotameric behaviour (1.5 : 1), major rotamer δ ppm: 1.77-1.91 (2 H, m, 
CH2CHN), 1.77-1.91 (2 H, m, CH2CH2CO2CH3), 2.25-2.40 (2 H, m, 
CH2CO2CH3), 2.25-2.40 (2 H, m, CH2C=CH2), 3.67 (3 H, s, CO2CH3), 3.82 
(1 H, d J 15.0 Hz, CHAHBN), 4.16 (1 H, d J 15.0 Hz, CHAHBN), 4.72 (1 H, 
m, CHN), 4.86 (1 H, s, C=CHAHB), 4.90 (1 H, s, C=CHAHB); minor 
rotamer δ ppm: 1.77-1.91 (2 H, m, CH2CH2N), 1.77-1.91 (2 H, m, 
CH2CH2CO2CH3), 2.25-2.40 (2 H, m, CH2CO2CH3), 2.25-2.40 (2 H, m, 
CH2C=CH2), 3.48 (1 H, d J 15.0 Hz, CHAHBN), 3.68 (3 H, s, CO2CH3), 4.10 
(1 H, m, CHN), 4.81 (1 H, d J 15.0 Hz, CHAHBN), 4.86 (1 H, s, C=CHAHB), 
4.93 (1 H, s, C=CHAHB); 
1H NMR at 353 K (125 MHz, d6-DMSO) δ ppm: 
1.63-1.76 (2 H, m, CH2CHN), 1.90-2.1 (2 H, m, CH2CH2CO2CH3), 2.22-
2.40 (2 H, m, CH2C=CH2), 2.43-2.55 (2 H, m, CH2CO2CH3), 3.59 (3 H, s, 
CO2CH3), 3.90-3.99 (1 H, m, CHAHBN), 4.0-4.13 (1 H, m, CHAHBN), 4.84 
(1 H, s, C=CHAHB), 4.87 (1 H, s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) 
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major rotamer δ ppm: 27.5, 28.5,  34.9, 47.2, 47.3, 47.8, 52.0, 111.6, 
116.0 (q J 290 Hz), 140.6, 157.9 (q J 41 Hz), 170.9; minor rotamer δ 
ppm: 27.2, 28.2, 29.6, 35.8, 45.0, 49.8, 52.3, 112.4, 116.0 (q J 290 Hz), 
139.7, 157.9 (q J 41 Hz), 170.6;  Found MH+ 280.1154 C12H17F3NO3 
requires MH+ 280.1161; [α]D
22 +48 (c 1.0 in CHCl3). 
Methyl (2S)-5-methylidene-1-(trifluoroacetyl)piperidine-2-carboxylate (127) 
 
The title compound was synthesised according to the general procedure 
B, using methyl (2S)-5-(chloromethyl)-2-(trifluoroacetamido)hex-5-enoate 
126 (72 mg, 0.25 mmol) as the starting material to give the title compound. 
The product was as colourless oil (40 mg, 64%). 
Alternatively, trifluoroacetic acid acid (12.4 g, 110.5 mmol) was added 
dropwise to the stirred solution of 1-tert-butyl 2-methyl (2S)-5-
methylidenepiperidine-1,2-dicarboxylate ent-37 (562 mg, 2.2 mmol) in 
dichloromethane (100 mL), and the reaction mixture stirred for a further 20 
min. At this time, the solvent and excess trifluoroacetic acid were removed 
under reduced pressure. The residue was dissolved in diethyl ether (4 
mL), and adding triethylamine (467 mg, 4.62 mmol), then trifluoroacetic 
anhydride (508 mg, 2.42 mmol, 1.1 eq)  was added dropwise. The mixture 
was stirred for 1 h, and washed with 1 M hydrochloric acid the organic 
layer was concentrated and column chromatography using 10% ethyl 
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acetate in petroleum ether to produce the title compound as a colourless 
oil (441 mg, 80%).  
Rf 0.35 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 2959, 1743, 
1691, 1442; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
behaviour (3 : 1), major rotamer δ ppm: 1.77-1.91 (1 H, m, CHAHBCHN), 
2.11-2.25 (1 H, m, CHAHBC=CH2), 2.37-2.46 (1 H, m, CHAHBCHN), 2.37-
2.46 (1 H, m, CHAHBC=CH2), 3.78 (3 H, s, CO2CH3), 3.99 (1 H, d J 14.5 
Hz, CHAHBN), 4.29 (1 H, d J 14.5 Hz, CHAHBN), 4.88 (1 H, d J 1.5 Hz, 
C=CHAHB), 4.92 (1 H, d J 1.5 Hz, C=CHAHB), 5.25 (1 H, dd J 6.5 and 3.0 
Hz, CHN); minor rotamer δ ppm: 1.77-1.91 (1 H, m, CHAHBCHN), 2.11-
2.25 (1 H, m, CHAHBC=CH2), 2.37-2.46 (1 H, m, CHAHBCHN), 2.37-2.46 (1 
H, m, CHAHBC=CH2), 3.65 (1 H, d J 15.5 Hz, CHAHBN), 3.79 (3 H, s, 
CO2CH3), 5.25 (1 H, m, CHN) 4.79 (1 H, d J 15.5 Hz, CHAHBN), 4.88 (1 H, 
d J 1.5 Hz, C=CHAHB), 4.95 (1 H, d J 1.5 Hz, C=CHAHB); 
13C NMR (125 
MHz, CDCl3) δ ppm major rotamer: 26.7, 28.9, 47.1, 52.7, 53.3, 112.0, 
116.3 (q J 279 Hz), 139.2, 156.5 (q J 27 Hz), 170.0; minor rotamer: 28.0, 
28.9, 49.2, 52.9, 55.5, 112.4, 116.3 (q J 279 Hz), 139.4, 156.5 (q J 27 Hz), 
170.0; Found MH+ 252.0839 C10H13F3NO3 requires MH
+ 252.0848; [α]D
19 -
39.0 (c 1 in CHCl3). 
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4.5 Indolizidine Synthesis 
tert-Butyl (2S)-2-(iodomethyl)pyrrolidine-1-carboxylate 130 and (5S)-5-
(iodomethyl)pyrrolidin-2-one 142 were prepared according to the literature 
method.  
(2S)-Pyrrolidin-2-ylmethanol (131)89 
 
 
tert-Butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (132)100 
 
 
tert-Butyl (2S)-2-(iodomethyl)pyrrolidine-1-carboxylate (130)101 
 
 
(5S)-5-(Hydroxymethyl)pyrrolidin-2-one (140)102 
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[(2S)-5-Oxopyrrolidin-2-yl]methyl 4-methylbenzene-1-sulfonate (141)102 
 
 
(5S)-5-(Iodomethyl)pyrrolidin-2-one (142)102 
 
 
tert-Butyl (2R)-2-[3-(chloromethyl)but-3-en-1-yl]pyrrolidine-1-carboxylate 
(135) 
 
A two-necked round bottom flask, fitted with a three-way tap and rubber 
septum, was flame-dried, evacuated and back-filled with nitrogen three 
times. The flask was charged with a magnetic follower and zinc powder 
(390 mg, 6 mmol, 2.0 eq), and again evacuated and back-filled with 
nitrogen three times, with continuous stirring. Dry DMF (3 mL) was added 
via syringe, and the heterogeneous mixture stirred vigorously. Iodine (195 
mg, 0.75 mmol) was added by rapid removal and replacement of the 
three-way tap under a stream of nitrogen, turning the solvent yellow. The 
mixture was stirred for 1-2 mins, until the solvent had become colourless.. 
During the activation period, a separate two necked round bottomed flask 
fitted with a three-way tap was flame-dried under vacuum, and back filled 
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with nitrogen three times. This flask was charged with a magnetic follower 
and CuBr.DMS (60 mg, 0.3 mmol, 0.1 eq), and gently heated under 
vacuum until the CuBr.DMS changed appearance from a brown to light 
green powder. The flask was allowed to cool, before adding dry DMF (2.4 
mL) and 3-chloro-2-(chloromethyl)prop-1-ene 41 (1.2 mL, 12 mmol, 4.0 
eq) via syringe. The mixture was stirred at room temperature, at which 
point the (S)-tert-butyl 2-(iodomethyl)pyrrolidine-1-carboxylate 130 (933 
mg, 3 mmol) was added by rapid removal of the three-way tap under a 
stream of nitrogen to the activated zinc and the allyl dichloride and 
CuBr.DMS mixture was added via syringe quickly, and was stirred at room 
temperature for 1 h. The reaction mixture was transferred to a separatory 
funnel with (30 mL) ethyl acetate, and washed with (15 mL) saturated 
sodium thiosulfate solution, (15 mL) water and (15 mL) brine. The organic 
layer was dried over magnesium sulfate, filtered, and the solvent removed 
under reduced pressure. The residue was purified by flash 
chromatography on silica, using 10% diethylether in petroleum ether to 
provide the title compound as colourless oil (491 mg, 60%). 
Rf 0.35 (10% diethyl ether in petroleum ether); νmax/cm
-1: 1686, 1652, 
1478; 1H NMR (400 MHz, CDCl3) δ ppm: 1.45 (9 H, s, C(CH3)3), 1.60-1.71 
(2 H, m, CH2CH2N), 1.74-2.01 (2 H, m, CH2CH), 1.74-2.01 (2 H, m, 
CH2CH), 2.05-2.27 (2 H, m, CH2C=CH2), 3.26-3.44 (2 H, m, CH2N), 3.69-
3.82 (1 H, br, CHN), 4.06 (2 H, s, CH2Cl), 4.97 (1 H, s, C=CHAHB), 5.11 (1 
H, s, C=CHAHB); 
13C NMR (125 MHz, CDCl3) major rotamer δ ppm: 23.1, 
28.4, 29.7, 30.9, 32.2, 46.3, 48.3, 56.8, 79.0, 114.4, 144.7, 154.6; Found 
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MH+ 274.1584 C14H25
35ClNO2 requires MH
+ 274.1574; [α]D
21 -31 (c 1.0 in 
CHCl3). 
tert-Butyl (2R)-2-{5-[(2R)-1-[(tert-butoxy)carbonyl]pyrrolidin-2-yl]-3- 
methylidenepentyl}pyrrolidine-1-carboxylate (136) 
 
Rf 0.15 (10% diethyl ether in petroleum ether); νmax/cm
-1: 2971, 1692, 
1393 1H NMR (400 MHz, CDCl3) δ-ppm: 1.45 (18 H, s, 2C(CH3)3), 1.52-
1.69 (4 H, m, 2 CH2CH2), 1.52-1.69 (4 H, m, 2 CH2CH2), 1.73-1.95 (4 H, 
m, 2 CH2CH), 1.95-2.07 (4 H, m, 2 CH2C=CH2), 3.21-3.47 (4 H, m, 2 
CH2N), 3.64-3.86 (2 H, br, 2 CHN), 4.72 (2 H, s, CH2=C); 
13C NMR (125 
MHz, CDCl3): 28.5, 29.6, 30.3, 32.8, 46.2, 56.8, 57.0, 78.9, 108.9, 148.9, 
154.6; Found MH+ 423.3209 C24H43N2O4 requires MH
+ 423.3223; [α]D
24 -
45 (c 1.33 in CHCl3).  
Reaction of (5S)-5-iodomethyl)pyrrolidin-2-one (142) with 3-chloro-2-
(chloromethyl) prop-1-ene (41) 
 
This reaction was done according to the general procedure A using (112 
mg, 0.5 mmol) of 142 to give 143 (78 mg, 84%) as a white solid. 
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(5R)-5-[3-(Chloromethyl)but-3-en-1-yl]pyrrolidin-2-one (143) 
 
Rf 0.16 (ethyl acetate); mp 62-64 °C; νmax/cm
-1: 3219, 2931, 1690, 1444; 
1H NMR (400 MHz, CDCl3) δ ppm: 1.61-1.82 (2 H, m, CH2CH2CO), 2.14-
2.26 (2 H, m, CH2C=CH2), 2.14-2.26 (2 H, m, CH2CHN), 2.27-2.41 (2 H, 
m, CH2CO), 3.65-3.73 (1 H, m, CHN), 4.04 (2 H, s, CH2Cl), 4.99 (1 H, s, 
CHAHB=C), 5.16 (1 H, s, CHAHB=C), 6.40-6.25 (1 H, br, NH); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 27.2, 29.3, 30.0, 34.4, 48.1, 54.0, 115.2, 143.9, 
178.1; Found MH+ 188.0833 C9H15
35ClNO requires MH+ 188.0842; [α]D
24 
+8.6 (c 2.33 in CHCl3). 
(8aR)-6-Methylidene-octahydroindolizin-3-one (43) 
 
Potassium carbonate (830 mg, 6.0 mmol) was added to methyl 3-[(2R)-5-
methylidene-1-(trifluoroacetyl)piperidin-2-yl] propanoate 122d (320 mg, 
1.15 mmol) in methanol (45 mL) and water (2.5 mL), the reaction was 
heated at reflux for 2 h, The residue was purified by flash chromatography 
on silica, using 80% ethyl acetate in petroleum ether to yield the title 
compound as a colourless oil (147 mg, 58%). 
Alternative, sodium borohydride (102 mg, 2.7 mmol, 3.0 eq) was added to 
methyl 3-[(2R)-5-methylidene-1-(trifluoroacetyl)piperidin-2-yl] propanoate 
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122d (250 mg, 0.9 mmol) in methanol (9 mL), the reaction was heated at 
reflux for 3 days. Removing the methanol on rotary vapour and The 
residue was dissolved in (15 mL) ethyl acetate, washing by (10 mL) water 
and (10 mL) brine, the organic layer was concentrated to produce the title 
compound as colourless oil (117 mg, 88%). 
Alternative method, the title compound was synthesised according to the 
general procedure B, using (5R)-5-[3-(chloromethyl)but-3-en-1-
yl]pyrrolidin-2-one 143 (56 mg, 0.3 mmol) as the starting material to give 
the title compound. The product was a colourless oil (29 mg, 65%). 
Rf 0.47 (ethyl acetate); νmax/cm
-1: 1666, 1453, 1420; 1H NMR (400 MHz, 
CDCl3) δ ppm: 1.26 (1 H, qd J 12.5 and 4.0 Hz, CHAHBCH), 1.52-1.65 (1 
H, m, CHAHBCH), 1.96 (1 H, dq J 13.0 and 3.5 Hz, CHAHBCH2CO), 2.13-
2.27 (1 H, m, CHAHBCH2CO), 2.13-2.27 (1 H, m, CHAHBC=CH2), 2.33-2.47 
(1 H, m, CHAHBC=CH2), 2.33-2.47 (2 H, m, CH2CO), 3.30 (1 H, d J 14.5 
Hz, CHAHBN), 3.48-3.58 (1 H, m, CHN), 4.49 (1 H, d J 14.5 Hz, CHAHBN), 
4.80 (1 H, d J 2.0 Hz, CHAHB=C), 4.88 (1 H, d J 2.0 Hz, CHAHB=C); 
13C 
NMR (100 MHz, CDCl3) δ ppm: 24.9, 30.6, 32.2, 34.0, 46.1, 56.7, 110.9, 
140.8, 173.3; Found MH+ 151.0994 C9H13NO requires MH
+ 151.0997; 
[α]D
19 -38 (c 1.0 in CHCl3). 
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(8aR)-6-Methylidene-octahydroindolizine (128) 
 
Trifluoroacetic acid (9.6 g, 85.5 mmol) was added dropwise to the stirred 
solution of (R)-tert-butyl 2-(3-(chloromethyl)but-3-enyl)pyrrolidine-1-
carboxylate 135 (468 mg, 1.7 mmol) in dichloromethane (80 mL), and the 
reaction mixture stirred for a further 20 min. At this time, the solvent and 
excess trifluoroacetic acid was removed under reduced to produce a 
brown oil (655 mg, 2.39 mmol). The flask was flame-dried under vacuum 
and back-filled with nitrogen three times, dry DMF (2.5 mL) was added. 
The mixture was stirred at room temperature at which point the flask was 
cooled to 0 °C. Sodium hydride (60% dispersion in mineral oil, 235 mg, 2.1 
eq) was added in one portion, and the reaction stirred at 0 °C for 10 min, 
before being allowed to warm to room temperature and stirred for 1 h. 
Water (20 mL) was carefully added to the vessel via syringe, and the 
reaction mixture was transferred to a separatory funnel using ethyl 
acetate. The aqueous layer was extracted further with ethyl acetate, and 
the combined organic layers washed with water and brine, dried over 
MgSO4 and the solvent removed under reduced pressure. 
Alternative, lithium aluminium hydride (43 mg, 1.13 mmol) was added to a 
solution of (8aR)-6-methylidene-octahydroindolizin-3-one 43 (45 mg, 0.3 
mmol) in (2 mL) of ether at 0 °C under nitrogen. The resulting suspension 
was refluxed for 3 h, and cooled to 0 °C, and water (0.04 mL), 15% 
sodium hydroxide (0.04 mL), water (0.128 mL) were sequentially added. 
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The resulting suspension was stirred for 20 min, filtered through Celite, 
and concentrated to produce the title compound as colourless oil (30 mg, 
75%). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.64-1.76 (2 H, m, CH2), 1.78-1.97 (5 
H, m), 2.01-2.18 (2 H, m, CH2N), 2.34-2.41 (1 H, m), 2.63 (1 H, d J 12.0 
Hz, CHAHBN), 3.00-3.12 (1 H, m, CHN), 3.49 (1 H, d J 12.0 Hz, CHAHBN),   
tert-Butyl (2S)-2-(hydroxymethyl)-5-methylidenepiperidine-1 carboxylate 
(ent-146)108 
 
Lithium aluminium hydride (25 mg, 0.65 mmol, 0.75 eq) was added to 
stirred solution of 1-tert-butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-
dicarboxylate ent-37 (223 mg, 0.87 mmol) in diethyl ether (2 mL) at 0 °C 
for 10 min then 1 h at room tempurture under nitrogen. Water (10 mL) was 
carefully added to quench the reaction and the reaction mixture was 
transferred to a separatory funnel using (15 mL) ethyl acetate and washing 
by (10 mL) brine, dried over magnesium sulfate and the solvent removed 
under reduced pressure to give the title compound as a colourless oil (183 
mg, 93%) without any further purification.  
Rf 0.17 (50% ethyl acetate in petroleum ether); νmax/cm
-1: 3446 (br), 2976, 
1697; ); 1H NMR (400 MHz, CDCl3) δ ppm: 1.45 (9 H, s, C(CH3)3), 1.65-
1.82 (2 H, m, CH2CHN), 2.15-2.33 (2 H, m, CH2C=CH2), 3.56 (1 H, d J 
15.0 Hz, CHAHBN), 3.66 (1 H, d J 15.0 Hz, CHAHBN), 3.79 (1 H, t J 10.5 
Hz, OH), 4.21-4.36 (2 H, m, CH2OH), 4.76 (1 H, s, C=CHAHB), 4.83 (1 H, 
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s, C=CHAHB); 
13C NMR (100 MHz, CDCl3) δ ppm: 25.5, 27.9, 28.4, 46.0, 
52.9, 62.6, 80.1, 109.5, 142.5, 172.0; Found MH+ 228.1600 C12H22NO3 
requires MH+ 228.1600; [α]D
19 -12 (c 1.0 in CHCl3). 
tert-Butyl (2R)-2-(hydroxymethyl)-5-methylidenepiperidine-1 carboxylate 
(146)108 
 
 
(8aS)-6-Methylidene-hexahydro-1H-[1,3]oxazolo[3,4-a]pyridin-3-one (ent-
147) 
 
Sodium hydride (60 % dispersion in mineral oil, 20 mg, 1 eq) was added to 
stirred solution of tert-butyl (2S)-2-(hydroxymethyl)-5-
methylidenepiperidine-1 carboxylate (112 mg, 0.5 mmol) in (2 mL) of 
tetrahydrofuran at 0 °C for 10 min and then at room tempurter for 2 h. 
Water was carefully added and the reaction mixture was transferred to a 
separatory funnel using ethyl acetate. The aqueous layer was extracted 
further with ethyl acetate, and the combined organic layers washed with 
water and brine, dried over MgSO4 and the solvent removed under 
reduced pressure. The residue was purified by flash chromatography on 
silica, using 50% ethyl acetate in petroleum ether to produce the title 
compound as a colourless oil (65 mg, 85%).  
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Rf 0.28 (50% ethyl acetate in petroleum ether); νmax/cm
-1: 2924, 1745, 
1421; 1H NMR (400 MHz, CDCl3) δ ppm: 1.44-1.56 (1 H, m, CHAHBCHN), 
1.92-1.99 (1 H, m, CHAHBCHN), 2.17-2.28 (1 H, m, CHAHBC=CH2), 2.47-
2.54 (1 H, m, CHAHBC=CH2), 3.54 (1 H, dd J 14.5 and 1.5 Hz, CHAHBN), 
3.76-3.85 (1 H, m, CHN), 3.92 (1 H, dd J 9.0 and 6.0 Hz, CHAHBO), 4.28 
(1 H, dd J 14.5 and 1.0 Hz, CHAHBN), 4.45 (1 H, dd J 9.0 and 8.5 Hz, 
CHAHBO), 4.86-4.89 (1 H, m, C=CHAHB), 4.93-4.96 (1 H, m, C=CHAHB); 
13C NMR (100 MHz, CDCl3) δ-ppm: 31.2, 31.5, 47.2, 54.0, 57.7, 116.7, 
139.8, 179.1; Found MH+ 154.0873 C8H12NO2 requires MH
+ 154.0868; 
[α]D
19 -10 (c 1.0 in CHCl3).  
(8aR)-6-Methylidene-hexahydro-1H-[1,3]oxazolo[3,4-a]pyridin-3-one (ent-
147) 
 
The spectroscopic data is the same as 147, Found MH+ 154.0877 
C8H12NO2 requires MH
+ 154.091; [α]D
19 12 (c 1.0 in CHCl3). 
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4.6 General procedure C: Reduction of 5-methylenepiperidines 
A two-necked round bottomed flask, fitted with a rubber septum, three-way 
tap and magnetic follower was flame-dried under vacuum and back-filled 
with nitrogen three times. Palladium on carbon (10% w/w, 0.1 eq) was 
added to the flask, which was again evacuated and back-filled with 
nitrogen three times. Piperidine (1 eq) was added to the flask as a solution 
in ethyl acetate (20 mL), and then a balloon of hydrogen was attached to 
the three-way tap. The flask was evacuated until the reaction mixture 
began to boil, and then back-filled with hydrogen. This procedure was 
repeated three more times, and the reaction stirred at room temperature 
for overnight. At this time, the mixture was filtered through Celite® and the 
solvent removed from the filtrate under reduced pressure. The residue 
was purified by flash chromatography. 
Hydrogenation of methyl 2-[(2R)-5-methylidene-1(trifluoroacetyl)piperidin-
2-yl] acetate 127 
 
This reaction was done according to the general procedure C using (251 
mg, 1 mmol) of 127 to give 149b and 149a each as colourless oil. 
Chromatography gave 149b (50 mg, 20%), a mixed fraction of 149b and 
149a (113 mg, 45%) and 149a (70 mg, 28%). The ratio of trans : cis (1 : 1) 
determined by 1H-NMR spectroscopy of the crude product. 
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Methyl (2S,5S)-5-methyl-1-(trifluoroacetyl)piperidine-2-carboxylate (149b) 
 
Rf 0.53 (20% diethyl ether in petroleum ether); νmax/cm
-1: 2958, 1747, 
1696, 1450; 1H NMR (400 MHz, CDCl3) Exhibits strongly rotameric 
behaviour, major rotamer δ-ppm: 0.93 (3 H, d J 3.5 Hz, CHCH3), 0.99-
1.13 (1 H, m, CHCH3), 1.75-1.68 (1 H, m, CHAHBCHN), 1.72-1.80 (2 H, m, 
CH2CHCH3), 2.31-2.40 (1 H, m, CHAHBCHN), 2.91 (1 H, dd J 14.0 and 
12.0 Hz, CHA(ax)CHB(eq)N), 3.76 (3 H, s, CO2CH3), 3.80 (1 H, dd J 12.0 and 
4.5 Hz, CHA(ax)HB(eq)N), 5.25 (1 H, d J 6.0 Hz, CH(eq)N), minor rotamer δ-
ppm: 0.92 (3 H, d J 3.5 Hz, CHCH3), 0.99-1.13 (1 H, m, CHCH3), 1.75-
1.68 (1 H, m, CHAHBCHN), 1.72-1.80 (2 H, m, CH2CHCH3), 2.31-2.40 (1 
H, m, CHAHBCHN), 2.55 (1 H, dd J 14.0 and 13.0 Hz, CHA(ax)CHB(eq)N), 
3.78 (3 H, s, CO2CH3), 4.40 (1 H, dd J 13.0 and 2.0 Hz, CHA(ax)HB(eq)N), 
4.69 (1 H, d J 5.5 Hz, CH(eq)N); 
13C NMR (500 MHz, CDCl3) major 
rotamer δ-ppm: 19.0, 26.3, 29.4, 31.1, 50.0, 52.6, 116.1 (q J 280 Hz), 
156.7 (q J 38 Hz), 170.0; minor rotamer δ-ppm: 18.8, 27.5, 29.3, 30.9, 
47.5, 52.8, 116.1 (q J 280 Hz), 156.7 (q J 38 Hz), 170.1; Found MH+ 
254.1002. C10H15F3NO3 requires MH
+ 254.1004.; [α]D
19  -45 (c 0.67 in 
CHCl3). 
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Methyl (2S,5R)-5-methyl-1-(trifluoroacetyl)piperidine-2-carboxylate (149a) 
 
Rf 0.48 (20% diethyl ether in petroleum ether); νmax/cm
-1: 2959, 1746, 
1693, 1452; 1H NMR (400 MHz, CDCl3) Exhibits strongly rotameric 
behaviour, major rotamer δ-ppm: 1.03 (3 H, d J 7.0 Hz, CHCH3), 1.44-
1.55 (1 H, m, CHCH3), 1.54-1.73 (2 H, m, CH2CHCH3), 1.92-2.09 (1 H, m, 
CHAHBCHN), 2.11-2.21 (1 H, m, CHAHBCHN), 3.51 (1 H, dd J 14.0 and 3.5 
Hz, CHA(ax)HB(eq)N), 3.64 (1 H, d J 14.0 Hz, CHA(ax)HB(eq)N), 3.76 (3 H, s, 
CHCH3), 5.17 (1 H, d J 6.5 Hz, CH(eq)N), minor rotamer δ-ppm: 1.0 (3 H, 
d J 7.5 Hz, CHCH3), 1.44-1.55 (1 H, m, CHCH3), 1.54-1.73 (2 H, m, 
CH2CHCH3), 1.92-2.09 (1 H, m, CHAHBCHN), 2.11-2.21 (1 H, m, 
CHAHBCHN), 3.12 (1 H, dd J 14.0 and 3.0 Hz, CHA(ax)HB(eq)N), 3.78 (3 H, 
s, CHCH3), 4.22 (1 H, d J 14.0 Hz, CHA(ax)HB(eq)N), 4.68 (1 H, d J 5.5 Hz, 
CH(eq)N); 
13C NMR (500 MHz, CDCl3) major rotamer δ-ppm: 15.8, 21.8, 
26.7, 30.9, 48.5, 53.5, 117.3 (q, J 281 Hz), 157.6 (q J 39 Hz), 170.2; 
minor rotamer δ-ppm: 18.8, 22.9, 26.5, 30.3, 46.1, 52.8, 117.1 (q J 281 
Hz), 157.6 (q J 39 Hz), 170.6; Found MH+ 254.0999. C10H15F3NO3 
requires MH+ 254.1004.; [α]D
19  -52.5 (c 1.33 in CHCl3). 
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Hydrogenation of 1-[(2R)-2-Benzyl-5-methylidenepiperidin-1-yl]-2,2,2-
trifluoroethan-1-one 122a  
 
This reaction was done according to the general procedure C using (283 
mg, 1 mmol) of 122a to give 150c, 150b and 150a each as colourless oil. 
Chromatography gave 150c (42 mg, 15%), 150b (27 mg, 10%) a mixed 
fraction of 150b and 150a (100 mg, 35%) and 150a (70 mg, 25%). The 
ratio of trans : cis (7 : 1) determined by 1H-NMR spectroscopy of the crude 
product. 
1-[(2R)-2-Benzyl-5-methyl-1,2,3,4-tetrahydropyridin-1-yl]-2,2,2-
trifluoroethan-1-one (150c) 
 
Rf 0.58 (10% diethyl ether in petrolum ether); νmax/cm
-1: 1916, 1667, 1426;  
1H NMR (500 MHz, CDCl3) exhibits strongly rotameric behaviour, major 
rotamer δ ppm: 1.55-1.80 (2 H, m, CH2CHN), 1.81 (3 H, s, CH3), 1.90-
2.06 (1 H, m, CHAHBC=C), 2.22-2.34 (1 H, m, CHAHBC=C), 2.70 (1 H, dd J 
13.5 and 10.0 Hz, CHAHBPh), 2.88 (1 H, dd J 13.5 and 6.0 Hz, CHAHBPh), 
4.75-4.83 (1 H, m, CHN), 6.48 (1 H, s, CH=C), 7.18-7.38 (5 H, m, Ph); 
minor rotamer δ ppm: 1.55-1.80 (2 H, m, CH2CHN), 1.81 (3 H, s, CH3), 
1.90-2.06 (1 H, m, CHAHBC=C), 2.22-2.34 (1 H, m, CHAHBC=C), 2.70 (1 
H, dd J 13.5 and 10.0 Hz, CHAHBPh), 2.88 (1 H, dd J 13.5 and 6.0 Hz, 
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CHAHBPh), 4.28-4.36 (1 H, m, CHN), 6.88 (1 H, s, CH=C), 7.18-7.38 (5 H, 
m, Ph); 13C NMR (100 MHz, CDCl3) major rotamer δ ppm: 21.1, 22.1, 
23.3, 35.8, 51.0, 115.4, 116.1 (q J 288 Hz), 116.6, 126.9, 128.7, 129.2, 
137.5, 157.1 (q J 39 Hz);  minor rotamer δ ppm: 20.9, 22.6, 23.4, 37.0, 
53.2, 116.1 (q J 288 Hz), 118.5, 120.4, 126.7, 128.5, 129.0, 141.1, 157.1 
(q J 39 Hz); Found MH+ 284.1265 C15H17F3NO requires MH
+ 284.1262; 
[α]D
19  +45 (c 2.67 in CHCl3).    
1-[(2R,5R)-2-Benzyl-5-methylpiperidin-1-yl]-2,2,2-trifluoroethan-1-one 
(150b) 
 
Rf 0.46 (10% diethyl ether in petrolum ether); νmax/cm
-1: 2931, 1685, 1196; 
1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, major 
rotamer δ ppm: 1.0 (3 H, d J 6.5 Hz, CH3CH), 1.41-1.75 (2 H, m, 
CH2CHN), 1.41-1.75 (2 H, m, CH2CHCH3), 1.41-1.75 (1 H, m, CH3CH), 
2.85-2.96 (2 H, m, CH2Ph), 3.09 (1 H, dd J 14.0 and 10.0 Hz, 
CHA(ax)HB(eq)N), 3.72 (1 H, dd J 14.0 and 2.0 Hz, CHA(ax)HB(eq)N), 4.0 (1 H, 
appr.q J 7.0 Hz, CH(eq)N), 7.17-7.4 (5 H, m, Ph); minor rotamer δ ppm: 
1.03 (3 H, d J 6.5 Hz, CH3CH), 1.41-1.75 (2 H, m, CH2CHN), 1.41-1.75 (2 
H, m, CH2CHCH3), 1.41-1.75 (1 H, m, CH3CH), 2.64 (1 H, dd J 13.5 and 
12.5 Hz, CHA(ax)HB(eq)N), 2.85-2.96 (2 H, m, CH2Ph), 4.18-4.26 (1 H, m, 
CH(eq)N), 4.44 (1 H, dd J 12.5 and 4.0 Hz, CHA(ax)HB(eq)N), 7.17-7.4 (5 H, 
m, Ph); 13C NMR (100 MHz, CDCl3) major rotamer δ ppm: 19.0, 26.1, 
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27.3, 31.3, 35.5, 45.2, 51.0, 126.6, 128.5, 129.0, 137.5, 116.1 (q J 288 
Hz), 157.1 (q J 39 Hz); minor rotamer δ ppm: 19.2, 26.6, 27.6, 31.9, 36.5, 
47.9, 54.6, 126.9, 128.7, 129.1, 137.5, 116.1 (q J 288 Hz), 157.1 (q J 39 
Hz); Found MH+ 286.1424 C15H19F3NO requires MH
+ 286.1419; [α]D
19  -37 
(c 2.67 in CHCl3). 
1-[(2R,5S)-2-Benzyl-5-methylpiperidin-1-yl]-2,2,2-trifluoroethan-1-one 
(150a) 
 
Rf 0.37 (10% diethyl ether in petrolum ether); νmax/cm
-1: 2940, 1683, 1194; 
1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, major 
rotamer δ ppm: 1.03 (3 H, d J 7.0 Hz, CH3CH), 1.37-1.53 (1 H, m, 
CHAHBCHN), 1.37-1.53 (1 H, m, CHAHBCHCH3), 1.75-1.88 (1 H, m, 
CHAHBCHCH3), 1.97-2.12 (1 H, m, CHAHBCHN), 2.11-2.21 (1 H, m, 
CH3CH), 2.89-2.95 (2 H, m, CH2Ph), 3.50 (1 H, dd J 14.5 and 3.0 Hz, 
CHA(ax)HB(eq)N), 3.59 (1 H, d J 14.5 Hz, CHA(ax)HB(eq)N), 4.85 (1 H, appr.q J 
7.0 Hz, CH(eq)N), 7.15-7.37 (5 H, m, Ph); minor rotamer δ ppm: 1.04 (3 H, 
d J 7.0 Hz, CH3CH), 1.37-1.53 (1 H, m, CHAHBCHN), 1.37-1.53 (1 H, m, 
CHAHBCHCH3), 1.75-1.88 (1 H, m, CHAHBCHCH3), 1.97-2.12 (1 H, m, 
CHAHBCHN), 2.11-2.21 (1 H, m, CH3CH), 2.89-2.95 (2 H, m, CH2Ph), 3.24 
(1 H, dd J 14.0 and 2.0 Hz, CHA(ax)HB(eq)N), 4.17-4.26 (1 H, m, CH(eq)N), 
4.32 (1 H, d J 14.0 Hz, CHA(ax)HB(eq)N), 7.15-7.37 (5 H, m, Ph); 
13C NMR 
(100 MHz, CDCl3) major rotamer δ ppm: 16.1, 20.8, 24.6, 27.6, 35.7, 
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46.2, 52.0, 116.4 (q J 288 Hz), 126.6, 128.5, 129.1, 137.5, 157.1 (q J 39 
Hz); minor rotamer δ ppm: 15.9, 21.0, 24.3, 27.8, 36.6, 43.5, 55.2, 116.4 
(q J 288 Hz), 126.9, 128.7, 129.2, 137.5, 157.1 (q J 39 Hz); Found MH+ 
286.1413 C15H19F3NO requires MH
+ 286.1419; [α]D
19  -33.3 (c 4.5 in 
CHCl3). 
Hydrogenation of 2,2,2-Trifluoro-1-[(2R)-5-methylidene-2-(propan-2-
yl)piperidin-1-yl]ethan-1-one 122b  
 
This reaction was done according to the general procedure C using (102 
mg, 0.43 mmol) of 122b to give 151b and 151a  each as colourless oil. 
Chromatography gave two an inseparable mixture of 151b and 151a (76 
mg, 75%). The ratio of trans : cis (4 : 1) determined by 1H-NMR 
spectroscopy of the crude product. 
1H NMR (500 MHz, CDCl3) exhibits strongly rotameric behaviour, major 
diastereoisomer δ ppm: 0.81 and 0.83 (3 H, d J 7.0 Hz, CH3CH for each 
rotamer), 0.96 and 0.97 (3 H, d J 7.0 Hz, CHCH3CH3 for each rotamer), 
1.0 and 1.05 (3 H, d J 7.0 Hz, CHCH3CH3 for each rotamer), 1.34-1.41 (1 
H, m, CHAHBCHN), 1.65-1.70 (1 H, m, CHAHBCHN), 1.75-1.90 (2 H, m, 
CH2CHCH3), 1.95-2.0 and 2.0-2.10 (1 H, m, CH3CH for each rotamer), 
2.10-2.20 and 2.20-2.30 (1 H, m, CHCH3CH3 for each rotamer), 2.95 and 
3.32 (1 H, dd J 13.5 and 3.5 Hz, 14.0 and 4.0 Hz, CHA(ax)HB(eq)N for each 
rotamer), 3.47 and 4.25 (1 H, m, CHN for each rotamer), 3.53 and 4.21 (1 
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H, d J 13.5 Hz, 14.0 Hz, CHA(ax)HB(eq)N for each rotamer); minor 
diastereoisomer: 2.36 and 2.70 (1 H, dd J 13.5 and 13.5 Hz, and 14.0 
and 11.5 Hz, CHA(ax)HB(eq)N for each rotamer), 3.65 and 4.31 (1 H, d J 13.5 
Hz, and 14.0 Hz, CHA(ax)HB(eq)N for each rotamer); 
13C NMR (125 MHz, 
CDCl3) δ ppm: 16.1, 18.6, 19.7, 20.0, 20.1, 21.5, 24.7, 25.6, 27.6, 28.0, 
43.5, 46.1, 56.6, 59.9, 117.1 (q J 288 Hz), 158.0 (q J 40 Hz). 
Hydrogenation of methyl 2-[(2R)-5-methylidene-1(trifluoroacetyl)piperidin-
2-yl] acetate 122c 
 
This reaction was done according to the general procedure C using (267 
mg, 1 mmol) of 122c to give 152b and 152a each as colourless oil. 
Chromatography gave 152b (428 mg, 18%), a mixed fraction of 152b and 
152a (112 mg, 42%) and 152a (53 mg, 20%). The ratio of trans : cis (2.5 : 
1) determined by 1H-NMR spectroscopy of the crude product. 
Methyl 2-[(2R,5R)-5-methyl-1-(trifluoroacetyl)piperidin-2-yl]acetate (152b) 
 
Rf 0.38 (15% ethyl acetate in petroleum ether); νmax/cm
-1: 2928, 1742, 
1656; 1H NMR (500 MHz, CDCl3) exhibits strongly rotameric behaviour, 
major rotamer δ ppm: 0.96 (3 H, d J 4.0 Hz, CH3CH), 1.19-1.37 (2 H, m, 
CH2CHCH3), 1.53-1.66 (1 H, m, CHCH3), 1.67-1.80 (2 H, m, CH2CHN), 
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2.56 (1 H, dd J 15.0 and 8.0 Hz, CHAHBCO2CH3), 2.65 (1 H, dd J 15.0 and 
7.5 Hz, CHAHBCO2CH3), 2.79 (1 H, dd J 15.0 and 12.0 Hz, CHA(ax)HB(eq)N), 
3.65 (3 H, s, CO2CH3), 3.70 (1 H, d J 12.0 Hz, CHA(ax)HB(eq)N), 5.1 (1 H, m 
CH(eq)N), minor rotamer δ ppm: 0.94 (3 H, d J 4.0 Hz, CH3CH), 1.19-1.37 
(2 H, m, CH2CHCH3), 1.53-1.66 (1 H, m, CHCH3), 1.67-1.80 (2 H, m, 
CH2CHN), 2.41 (1 H, dd J 15.0 and 12.0 Hz, CHA(ax)HB(eq)N), 2.56 (1 H, dd 
J 15.0 and 8.0 Hz, CHAHBCO2CH3), 2.83 (1 H, dd J 15.0 and 6.5 Hz, 
CHAHBCO2CH3), 3.69 (3 H, s, CO2CH3), 4.37 (1 H, dd J 12.0 and 4.0 Hz, 
CHA(ax)HB(eq)N), 4.51-4.60 (1 H, m CHN); 
13C NMR (100 MHz, CDCl3) 
major rotamer δ ppm: 18.9, 27.3, 27.8, 31.1, 34.4, 46.7, 47.7, 51.9, 116.1 
(q J 285 Hz), 157.0 (q J 39 Hz), 173.3, minor rotamer δ ppm: 19.2, 27.5, 
27.9, 31.8, 35.3, 46.9, 47.8, 52.3, 116.1 (q J 285 Hz), 157.0 (q J 39 Hz), 
173.3, Found MH+ 268.1157 C11H17F3NO3 requires MH
+ 268.1161; [α]D
22  -
40 (c 1.0 in CHCl3). 
Methyl 2-[(2R,5S)-5-methyl-1-(trifluoroacetyl)piperidin-2-yl]acetate (152a) 
 
Rf 0.33 (15% ethyl acetate in petrplum ether); νmax/cm
-1: 2946, 1737, 
1681, 1454; 1H NMR (500 MHz, CDCl3) exhibits strongly rotameric 
behaviour, major rotamer δ ppm: 1.03 (3 H, d J 7.5 Hz, CH3CH), 1.40-
1.50 (1 H, m, CHAHBCHCH3), 1.50-1.55 (1 H, m CHAHBCHN), 1.83-1.95 (1 
H, m, CHAHBCHCH3), 1.95-2.05 (1 H, m, CHAHBCHN), 2.05-2.15 (1 H, m, 
CH3CH), 2.60 (1 H, dd J 14.5 and 8.0 Hz, CHAHBCO2CH3), 2.73 (1 H, dd J 
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14.5 and 8.0 Hz, CHAHBCO2CH3), 3.45 (1 H, dd J 14.0 and 3.5 Hz, 
CHA(ax)HB(eq)N), 3.57 (1 H, d J 14.0 Hz, CHA(ax)HB(eq)N), 3.67 (3 H, s, 
CO2CH3), 5.05 (1 H, q J 6.5 Hz, CH(eq)N); minor rotamer δ ppm: 1.03 (3 
H, d J 7.5 Hz, CH3CH), 1.40-1.50 (1 H, m, CHAHBCHCH3), 1.50-1.55 (1 H, 
m CHAHBCHN), 1.83-1.95 (1 H, m, CHAHBCHCH3), 1.95-2.05 (1 H, m, 
CHAHBCHN), 2.05-2.15 (1 H, m, CH3CH), 2.63 (1 H, dd J 15.5 and 8.0 Hz, 
CHAHBCO2CH3), 2.88 (1 H, dd J 15.5 and 9.0 Hz, CHAHBCO2CH3), 3.02 (1 
H, dd J 14.0 and 2.5 Hz, CHA(ax)HB(eq)N), 3.71 (3 H, s, CO2CH3), 4.26 (1 H, 
d J 14.0 Hz, CHA(ax)HB(eq)N), 4.57-4.6 (1 H, m, CHN); 
1H NMR at 303 K 
(500 MHz, CDCl3 ) δ ppm: 1.04 (3 H, d J 7.0 Hz, CH3CH), 1.44 (1 H, d J 
10.0 Hz, CHAHBCHCH3), 1.57 (1 H, d J 15.5 Hz, CHAHBCHN), 1.85-1.97 (1 
H, m, CHAHBCHCH3), 1.97-2.16 (1 H, m, CHAHBCHN), 1.97-2.16 (1 H, m, 
CH3CH), 2.52-2.79 (2 H, m, CH2CO2CH3), 3.52 (1 H, d J 4.5 Hz, 
CHA(ax)HB(eq)N), 3.69 (3 H, s, CO2CH3), 4.43 (1 H, d J 16.0 Hz, 
CHA(ax)HB(eq)N), 4.87-5.13 (1 H, m, CHN);  
13C NMR (100 MHz, CDCl3) 
major rotamer δ ppm: 16.1, 24.8, 27.5, 34.6, 46.3, 48.0, 51.9, 116.5 (q J 
288 Hz), 140.1, 157.2 (q J 40 Hz), 170.6; minor rotamer δ ppm: 15.7, 
24.3, 27.5, 35.4, 43.5, 48.0, 51.9, 116.6 (q J 288 Hz), 139.7, 157.2 (q J 40 
Hz), 170.6; Found MH+ 268.1157 C11H17F3NO3 requires MH
+ 268.1161; 
[α]D
22  +20 (c 1.0 in CHCl3). 
Hydrogenation of methyl 3-[(2R)-5-methylidene-1-(trifluoroacetyl)piperidin-
2-yl]propanoate 122d 
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This reaction was done according to the general procedure C using (279 
mg, 1 mmol) of 122d to give 153b and 153a each as colourless oil. 
Chromatography gave 153b (47 mg, 17%), a mixed fraction of 153b and 
153a (106 mg, 38%) and 153a (70 mg, 25%). The ratio of trans : cis (2.5 : 
1) determined by 1H-NMR spectroscopy of the crude product. 
Methyl 3-[(2R,5R)-5-methyl-1-(trifluoroacetyl)piperidin-2-yl]propanoate 
(153b) 
 
Rf 0.35 (30% diethyl ether in petroleum ether); νmax/cm
-1: 2953, 1739, 
1684; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, 
major rotamer δ ppm: 0.94 (3 H, d J 5.5 Hz, CH3CH), 1.21-1.39 (2 H, m, 
CH3CHCH2), 1.60-1.65 (1 H, m, CH3CH), 1.70-1.85 (2 H, m, CH2CHN), 
1.84-1.99 (1 H, m, CHAHBCH2CO2CH3), 2.08-2.21 (1 H, m, 
CHAHBCH2CO2CH3), 2.21-2.39 (2 H, m, CH2CO2CH3), 3.79 (1 H, dd J 12.5 
and 11.5 Hz, CHA(ax)HB(eq)N), 3.64 (1 H, dd J 12.5 and 2.0 Hz, 
CHA(ax)HB(eq)N), 3.66 (3 H, s, CO2CH3), 4.62-4.75 (1 H, m, CHN); minor 
rotamer δ ppm: 0.93 (3 H, d J 5.5 Hz, CH3CH), 1.21-1.39 (2 H, m, 
CH2CHCH3), 1.60-1.65 (1 H, m, CH3CH), 1.70-1.85 (2 H, m, CH2CHN), 
1.84-1.99 (1 H, m, CHAHBCH2CO2CH3), 2.08-2.21 (1 H, m, 
CHAHBCH2CO2CH3), 2.21-2.39 (2 H, m, CH2CO2CH3), 2.54 (1 H, dd J 14.5 
and 13.0 Hz, CHA(ax)H(eq)N), 3.67 (3 H, s, CO2CH3), 4.31 (1 H, dd J 13.0 
and 4.0 Hz, CHA(ax)HB(eq)N), 3.99-4.08 (1 H, m, CHN); 
13C NMR (100 MHz, 
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CDCl3) major rotamer δ ppm: 15.5, 22.9, 25.4, 27.9, 28.3, 30.3, 48.9, 
51.7, 52.8, 116.6 (q J 291 Hz), 157.2 (q J 40 Hz), 173.3; minor rotamer δ 
ppm: 15.7, 23.1, 26.2, 28.0, 28.9, 31.3, 44.5, 51.8, 52.2, 116.6 (q J 291 
Hz), 157.2 (q J 40 Hz), 173.3; Found MH+ 282.1328 C12H19F3NO3 requires 
MH+ 282.1317; [α]D
22 +51 (c 1.0 in CHCl3). 
Methyl 3-[(2R,5S)-5-methyl-1-(trifluoroacetyl)piperidin-2-yl]propanoate 
(153a) 
 
Rf 0.29 (30% diethyl ether in petroleum ether);
 νmax/cm
-1: 2946, 1736, 
1678, 1439, 1365; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
behaviour, major rotamer δ ppm: 1.00 (3 H, d J 7.0 Hz, CH3CH), 1.35-
1.42 (1 H, m, CHAHBCH2CO2CH3), 1.42-1.52 (1 H, m, CH2CHAHBCH), 
1.74-1.86 (1 H, m CHAHBCHN), 1.86-2.10 (1 H, m, CHAHBCHN), 1.86-2.10 
(2 H, m, CH2CO2CH3), 1.86-2.10 (1 H, m, CH3CH), 2.13-2.38 (2 H, m, 
CH2CO2CH3), 3.40 (1 H, dd J 14.0 and 3.5 Hz, CHA(ax)HB(eq)N), 3.53 (1 H, 
d J 14.0 Hz, CHA(ax)HB(eq)N), 3.66 (3 H, s, CO2CH3), 4.64-4.73 (1 H, m, 
CHN); minor rotamer δ ppm: 1.00 (3 H, d J 7.0 Hz, CH3CH), 1.35-1.42 (1 
H, m, CHAHBCHCH3), 1.42-1.52 (1 H, m, CHAHBCHCH3), 1.74-1.86 (1 H, 
m CHNCHAHB), 1.86-2.10 (1 H, m, CHNCHAHB), 1.86-2.10 (2 H, m, 
CH2CH2CO2CH3), 1.86-2.10 (1 H, m, CH3CH), 2.13-2.38 (2 H, m, 
CH2CO2CH3), 3.03 (1 H, dd J 14.0 and 2.50 Hz, CHA(ax)HB(eq)N), 3.67 (3 H, 
s, CO2CH3), 3.99-4.07 (1 H, m, CHN), 4.21 (1 H, d J 14.0 Hz, 
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CHA(ax)HB(eq)N); 
13C NMR (100 MHz, CDCl3) major rotamer δ ppm: 15.8, 
19.2,  22.9, 24.6, 27.5, 29.7, 45.6, 50.0, 51.7, 116.1 (q J 290 Hz), 157.2 (q 
J 40 Hz), 173.4, minor rotamer δ ppm: 16.1, 20.1, 23.7, 24.7, 27.9, 30.3, 
42.8, 50.3, 52.7, 116.1 (q J 290 Hz), 157.2 (q J 40 Hz), 173.4; Found MH+ 
282.1328 C12H19F3NO3 requires MH
+ 282.1317; [α]D
22 +44 (c 1.0 in CHCl3). 
Hydrogenation of 1-tert-Butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-
dicarboxylate ent-37 
 
This reaction was done according to the general procedure C using (255 
mg, 1 mmol) of ent-37 to give 154b and 154a each as colourless oil. 
Chromatography gave 154b (79 mg, 31%), a mixed fraction of 154b and 
154a (120 mg, 47%) and 154a (43 mg, 17%). The ratio of cis : trans (3 : 1) 
determined by 1H-NMR spectroscopy of the crude product. 
1-tert-Butyl 2-methyl (2S,5S)-5-methylpiperidine-1,2-dicarboxylate (154b) 
 
Rf 0.45 (25% diethyl ether in petroleum ether); νmax/cm
-1: 1745, 1702, 
1393; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, 
first rotamer δ-ppm: 0.87 (3 H, d J 3.0 Hz, CH3CH), 1.43 (9 H, s, 
C(CH3)3), 1.55-1.76 (2 H, m, CH2CHN), 1.77-1.96 (2 H, m, CH2CH), 2.16-
2.27 (1 H, m, CH3CH), 2.41 (1 H, dd J 13.5 and 12.5 Hz, CHA(ax)HB(eq)N), 
3.71 (3 H, s, CO2CH3), 3.84 (1 H, dd J 12.5 and 4.5 Hz, CHA(ax)HB(eq)N), 
4.72 (1 H, d J 5.5 Hz, CH(eq)N); second rotamer δ-ppm: 0.85 (3 H, d J 3.0 
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Hz, CH3CH), 1.44 (9 H, s, C(CH3)3), 1.55-1.76 (2 H, m, CH2CHN), 1.77-
1.96 (2 H, m, CH2CH), 2.16-2.27 (1 H, m, CH3CH), 2.54 (1 H, dd J 13.5 
and 12.5 Hz, CHA(ax)HB(eq)N), 3.73 (3 H, s, CO2CH3), 3.99 (1 H, dd J 12.5 
and 4.5 Hz, CHA(ax)HB(eq)N), 4.0 (1 H, d J 5.5 Hz, CH(eq)N); 
13C NMR (400 
MHz, CDCl3) first rotamer δ ppm: 19.1, 26.7, 28.2, 29.4, 30.4, 47.9, 52.0, 
81.9, 157.3; second rotamer δ ppm: 19.1, 26.5, 28.3, 29.6, 30.6, 48.9, 
53.1, 81.9, 157.3; Found MH+ 258.1696. C13H24NO4 requires MH
+ 
258.1705.; [α]D
21  -25 (c 2.0 in CHCl3). 
1-tert-Butyl 2-methyl (2S,5R)-5-methylpiperidine-1,2-dicarboxylate (154a) 
 
Rf 0.41 (25% diethyl ether in petroleum ether); νmax/cm
-1: 1750, 1703, 
1363; 1H NMR (400 MHz, CDCl3) δ-ppm: 0.98 (3 H, d J 7.0 Hz, CH3CH), 
1.45 (9 H, s, C(CH3)3), 1.50-1.63 (2 H, m, CH2CHN), 1.80-1.91 (1 H, m, 
CH3CH), 1.91-1.99 (2 H, m, CH2CH), 3.16 (1 H, d J 13.5 Hz, 
CHA(ax)HB(eq)N), 3.60 (1 H, d J 13.5 Hz, CHA(ax)HB(eq)N), 3.72 (3 H, s, 
CO2CH3), 4.58-4.87 (1 H, br, CH(eq)N); Found MH
+ 258.1698. C13H24NO4 
requires MH+ 258.1705.; [α]D
21  -5 (c 2.0 in CHCl3). 
 
Hydrogenation of tert-butyl (2R)-2-benzyl-5-methylidenepiperidine-1-
carboxylate (119a) 
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This reaction was done according to the general procedure C using (286 
mg, 1 mmol) of 119a to give 148c, 148b and 148a each as colourless oil. 
Chromatography gave 148c (28 mg, 10%), 148b (28 mg, 10%) a mixed 
fraction of 148b and 148a (156 mg, 55%) and 148a (42 mg, 15%). The 
ratio of trans : cis (3 : 1) determined by 1H-NMR spectroscopy of the crude 
product.    
tert-Butyl (2R)-2-benzyl-5-methyl-1,2,3,4-tetrahydropyridine-1-carboxylate 
(148c)  
 
Rf 0.53 (10% diethyl ether in petroleum ether), νmax/cm
-1: 2920, 1693, 
1453, 1393, 1365; 1H NMR (500 MHz, CDCl3) exhibits strongly rotameric 
behaviour, major rotamer δ ppm: 1.35 (9 H, s, C(CH3)3), 1.53-1.62 (1 H, 
m, CHAHBCHN), 1.64-1.69 (1 H, m, CHAHBCHN), 1.71 (3 H, s, CH3), 1.76-
1.87 (1 H, m, CHAHBC=CH), 2.08-2.20 (1 H, m, CHAHBC=CH), 2.56-2.59 
(1 H, m, CHAHBPh), 2.80 (1 H, dd J 12.5, 6.0 Hz, CHAHBPh), 4.26-4.32 (1 
H, m, CHN), 6.67 (1 H, s, CH=C), 7.03-7.14 (5 H, m, Ph); minor rotamer 
δ ppm: 1.44 (9 H, s, C(CH3)3), 1.53-1.62 (1 H, m, CHAHBCHN), 1.64-1.69 
(1 H, m, CHAHBCHN), 1.71 (3 H, s, CH3), 1.76-1.87 (1 H, m, 
CHAHBC=CH), 2.08-2.20 (1 H, m, CHAHBC=CH), 2.56-2.59 (1 H, m, 
CHAHBPh), 2.80 (1 H, dd J 12.5 and 6.0 Hz, CHAHBPh), 4.41-4.48 (1 H, m, 
CHN), 6.50 (1 H, s, CH=C), 7.12-7.25 (5 H, m, Ph); 1H NMR at 373 K (500 
MHz, d6-DMSO) δ ppm: 1.34 (9 H, s, C(CH3)3), 1.54-1.63 (1 H, m, 
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CHAHBCHN), 1.65-1.68 (1 H, m, CHAHBCHN), 1.69 (3 H, s, CH3), 1.81 (1 
H, dd J 18.0 and 6.0 Hz, CHAHBC=CH), 2.11-2.22 (1 H, m, CHAHBC=CH), 
2.61 (1 H, dd J 13.5 and 8.5 Hz, CHAHBPh), 2.71 (1 H, dd J 13.5 and 7.0 
Hz, CHAHBPh), 4.27-4.35 (1 H, m, CHN), 6.52 (1 H, s, CH=C), 7.13-7.30 
(5 H, m, Ph); 13C NMR (100 MHz, CDCl3) major rotamer δ ppm: 20.9, 
22.6, 23.1, 28.1, 36.5, 50.4, 80.0, 113, 118.6, 126.2, 128.2, 129.3, 149.0, 
156; minor rotamer δ ppm: 20.9, 22.9, 23.6, 28.3, 37.1, 51.7, 80.0, 114.0, 
119.0, 126.2, 128.4, 129.3, 149.5, 156.0; Found MH+ 288.1952 C18H26NO2 
requires MH+ 288.1964; [α]D
24  +7 (c 1.0 in CHCl3). 
tert-Butyl (2R,5R)-2-benzyl-5-methylpiperidine-1-carboxylate (148b) 
 
Rf 0.33 (10% diethyl ether in petroleum ether); νmax/cm
-1: 2927, 1689, 
1158; 1H NMR (400 MHz, CDCl3) δ ppm: 0.95 (3 H, d J 6.5 Hz, CH3CH), 
1.23-1.45 (2 H, m, CH2CHN), 1.23-1.45 (2 H, m, CH2CHCH3), 1.58-1.62 (1 
H, m, CH3CH), 2.51 (1 H, dd J 14.0 and 12.0 Hz, CHA(ax)HB(eq)N), 2.65-
2.77 (1 H, m, CHAHBPh), 2.77-2.94 (1 H, m, CHAHBPh), 4.08 (1 H, d J 12.0 
Hz, CHA(ax)HB(eq)N), 4.31-4.42 (1 H, br, CH(eq)N), 7.15-7.35 (5 H, m, Ph); 
13C NMR (100 MHz, CDCl3) δ ppm: 17.1, 19.3, 27.8, 28.2, 31.2, 46.1, 
65.8, 72.3, 79.1, 126.1, 128.3, 129.2, 136.2, 157.1; Found MH+ 290.2125 
C18H28NO2 requires MH
+ 290.2120; [α]D
19  -30 (c 1.67 in CHCl3). 
 
 
 166 
 
tert-Butyl (2R,5S)-2-benzyl-5-methylpiperidine-1-carboxylate (148a) 
 
Rf 0.26 (10% diethyl ether in petroleum ether); νmax/cm
-1: 2933, 1688, 
1172; 1H NMR (400 MHz, CDCl3) δ ppm: 1.01 (3 H, d J 7.0 Hz, CH3CH), 
1.30-1.39 (1 H, m, CHAHBCHN), 1.36 (9 H, s, C(CH3)3), 1.59-1.62 (1 H, m, 
CHAHBCHCH3), 1.72-1.84 (1 H, m, CHAHBCHN), 1.86-1.99 (1 H, m, 
CHAHBCHCH3), 1.86-1.99 (1 H, m, CH3CH), 2.78 (1 H, dd J 13.0 and 8.5 
Hz, CHAHBPh), 2.92 (1 H, dd J 13.0 and 7.5 Hz, CHAHBPh), 3.14 (1 H, dd 
J 13.5 and 3.5 Hz, CHA(ax)HB(eq)N), 3.78 (1 H, d J 13.5 Hz, CHA(ax)HB(eq)N), 
4.35 (1 H, appr.q J 7.5 Hz, CH(eq)N), 7.16-7.32 (5 H, m, Ph); 
13C NMR (100 
MHz, CDCl3) δ ppm: 16.6, 21.8, 25.0, 27.7, 28.3, 36.3, 43.9, 52.3, 78.9, 
126.0, 128.3, 129.2, 139.3, 155.5; Found MH+ 290.2132 C18H28NO2 
requires MH+ 290.2120; [α]D
19  -32.9 (c 4.25 in CHCl3). 
Hydrogenation of tert-butyl (2R)-5-methylidene-2-(propan-2-yl)piperidine-
1-carboxylate 119b  
 
This reaction was done according to the general procedure C using (167 
mg, 0.69 mmol) of 119b to give 155c, 155b and 155a  each as colourless 
oil. Chromatography gave 155c (15 mg, 9%), and two inseparable 155b 
and 155a (129 mg, 78%). The ratio of trans : cis (1.5 : 1) determined by 
1H-NMR spectroscopy of the crude product. 
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tert-Butyl (2R)-5-methyl-2-(propan-2-yl)-1,2,3,4-tetrahydropyridine-
1carboxylate (155c) 
 
Rf 0.47 (2.5% diethyl ether in petroleum ether) νmax/cm
-1: 2965, 1695, 
1455, 1395, 1365, 1155; 1H NMR (500 MHz, CDCl3) exhibits strongly 
rotameric behaviour, first rotamer δ ppm: 0.84 (3 H, d J 6.0 Hz, 
CHCH3CH3), 0.97 (3 H, d J 6.0 Hz, CHCH3CH3), 1.47 (9 H, s, C(CH3)3), 
1.62-1.66 (1 H, m, CHCH3CH3), 1.64 (3 H, s, CH3), 1.77 (2 H, dd J 17.0 
and 5.5 Hz CH2CHN), 1.89-2.02 (2 H, m, CH2C=CH), 3.90 (1 H, d J 10.0 
Hz, CHN), 6.43 (1 H, s, CH=C), second rotamer δ ppm: 0.84 (3 H, d J 6.0 
Hz, CHCH3CH3), 0.97 (3 H, d J 6.0 Hz, CHCH3CH3), 1.47 (9 H, s, 
C(CH3)3), 1.62-1.66 (1 H, m, CHCH3CH3), 1.64 (3 H, s, CH3), 1.77 (2 H, dd 
J 17.0 and 5.5 Hz, CH2CHN), 1.89-2.02 (2 H, m, CH2C=CH), 3.74 (1 H, d J 
10.0 Hz, CHN), 6.59 (1 H, s, CH=C); 13C NMR (100 MHz, CDCl3) δ ppm 
first rotamer: 19.2, 19.7, 20.8, 23.0, 23.3, 28.3, 54.6, 79.9, 114.4, 119.2, 
152.2, second rotamer: 19.2, 19.3, 19.7, 23.3, 23.5, 27.7, 56.0, 79.9, 
115.4, 118.0, 157.0; Found MH+ 240.1960. C14H26NO2 requires MH
+ 
240.1964.; [α]D
24  +156 (c 1.0 in CHCl3). 
tert-Butyl (2R)-5-methyl-2-(propan-2-yl)piperidine-1-carboxylate 
(155b/155a) 
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Rf 0.35 (2.5% diethyl ether in petroleum ether); 
1H NMR (500 MHz, CDCl3) 
major diastereoisomer δ ppm: 0.82 (6 H, d J 7.0 Hz, (CH3)2CH), 0.87 (3 
H, d J 6.5 Hz, CH3CH), 1.24 (1 H, m, CHAHBCHCH3), 1.43 (9 H, s, (CH3)3), 
1.50 (1 H, m, CHAHBCHCH3), 1.70-1.76 (2 H, m, CH2CHN), 1.78-1.82 (1 
H, m, CH(CH3)2), 2.03-2.09 (1 H, m, CHCH3), 2.89 (1 H, dd J 13.5 and 3.5 
Hz, CHA(ax)HB(eq)N), 3.73 (1 H, d J 13.5 Hz, CHA(ax)HB(eq)N), 3.80-3.83 (1 H, 
m, CHN); minor diastereoisomer: 0.8 (6 H, d J 6.5 Hz, (CH3)2CH), 0.97 
(3 H, d J 7.0 Hz, CH3CH), 1.10-1.18 (1 H, m, CHAHBCHCH3), 1.43 (9 H, s, 
(CH3)3), 1.45-1.51 (1 H, m, CHAHBCHCH3), 1.70-1.76 (2 H, m, CH2CHN), 
1.78-1.82 (1 H, m, CH(CH3)2), 2.03-2.09 (1 H, m, CHCH3), 3.65 (1 H, dd J 
11.5 and 4.0 Hz, CHA(ax)HB(eq)N), 3.71-3.73 (1 H, m, CHA(ax)HB(eq)N), 3.98-
4.03 (1 H, m, CHN); 13C NMR (125 MHz, CDCl3) δ ppm: 16.6, 18.9, 19.2, 
19.4, 20.0, 20.2, 20.5, 25.2, 25.9, 26.0, 26.3, 27.8, 27.9, 28.4, 31.1, 31.4, 
44.0, 45.3, 46.7, 55.4, 56.8, 78.7, 78.9, 155.2, 155.9; Found MH+ 
242.2131 C14H28NO2 requires MH
+ 242.2120.   
Hydrogenation of tert-butyl (2R)-2-(2-methoxy-2-oxoethyl)-5-methylidene 
piperidine-1-carboxylate 119c 
 
This reaction was done according to the general procedure C using (269 
mg, 1 mmol) of 119c to give 156c, 156b and 156a  each as colourless oil. 
Chromatography gave 156c (26 mg, 10%), 156b (47 mg, 15%) a mixed 
fraction of 156b and 156a (133 mg, 49%) and 156a (51 mg, 19%). The 
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ratio of trans : cis (1.5 : 1) determined by 1H-NMR spectroscopy of the 
crude product.    
tert-Butyl (2R)-2-(2-methoxy-2-oxoethyl)-5-methyl-1,2,3,4 
tetrahydropyridine-1-carboxylate (156c) 
 
Rf 0.57 (30% diethyl ether in petroleum ether); νmax/cm
-1: 1740, 1698, 
1680; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, 
major rotamer δ ppm: 1.18 (3 H, s, CH3C=CH), 1.47 (9 H, s, C(CH3)3), 
1.75-1.83 (2 H, m, CH3CCH2), 1.85-1.92 (1 H, m, CHAHBCHN), 1.97-2.10 
(1 H, m, CHAHBCHN), 2.51 (1 H, dd J 13.5 and 7.0 Hz, CHAHBCO2CH3), 
2.36 (1 H, dd J 13.5 and 8.5 Hz, CHAHBCO2CH3), 3.66 (3 H, s, CO2CH3), 
4.64-4.72 (1 H, m, CHN), 6.43 (1 H, s, C=CHN); minor rotamer δ ppm: 
1.25 (3 H, s, CH3C=CH), 1.47 (9 H, s, C(CH3)3), 1.75-1.83 (2 H, m, 
CH3CCH2), 1.85-1.92 (1 H, m, CHAHBCHN), 1.97-2.10 (1 H, m, 
CHAHBCHN), 2.39-2.47 (2 H, m, CH2CO2CH3), 3.68 (3 H, s, CO2CH3), 
4.51-4.60 (1 H, m, CHN), 6.58 (1 H, s, C=CHN); 13C NMR (100 MHz, 
CDCl3) major rotamer δ ppm: 21.2, 23.1, 24.6, 28.3, 35.7, 46.2, 51.8, 
80.6, 114.1, 119.6, 152.5, 168.6; minor rotamer δ ppm: 21.0, 24.4, 24.6, 
28.9, 36.3, 46.2, 52.7, 80.6, 114.1, 119.6, 152.5, 168.6; Found MH+ 
270.1711 C14H24NO4 requires MH
+ 270.1705; [α]D
21  +50 (c 1.0 in CHCl3).    
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tert-Butyl (2R,5R)-2-(2-methoxy-2-oxoethyl)-5-methylpiperidine-1-
carboxylate (156b) 
 
Rf 0.50 (30% diethyl ether in petroleum ether); νmax/cm
-1: 1740, 1693, 
1435; ; 1H NMR (400 MHz, CDCl3) δ ppm: 0.88 (3 H, d J 6.5 Hz, CH3CH), 
1.08-1.33 (2 H, m, CH2CHCH3), 1.40-1.44 (1 H, m, CHAHBCHN), 1.44 (9 
H, s, C(CH3)3), 1.54-1.62 (1 H, m, CHAHBCHN), 1.63-1.71 (1 H, m, 
CH3CH), 2.47 (1 H, dd J 14.5 and 8.0 Hz, CHAHBCO2CH3), 2.56 (1 H, dd J 
14.5 and 7.5 Hz, CHAHBCO2CH3), 3.65 (3 H, s, CO2CH3), 3.77 (1 H, d J 
12.0 Hz, CHA(ax)HB(eq)N), 4.01 (1 H, d J 12.0 Hz, CHA(ax)HB(eq)N), 3.60-4.73 
(1 H, m, CHN); 13C NMR (100 MHz, CDCl3) δ ppm: 17.4, 19.2, 25.2, 27.7, 
28.4, 32.1, 44.6, 49.1, 51.6, 81.9, 151.2, 173.4; Found MH+ 272.1853 
C14H26NO4 requires MH
+ 272.1862.  
tert-Butyl (2R,5S)-2-(2-methoxy-2-oxoethyl)-5-methylpiperidine-1-
carboxylate (156a) 
 
Rf 0.44 (30% diethyl ether in petroleum ether); νmax/cm
-1: 1740, 1691, 
1414; 1H NMR (400 MHz, CDCl3) δ ppm: 0.97 (3 H, d J 7.0 Hz, CH3CH), 
1.27-1.39 (2 H, m, CH2CHCH3), 1.44 (9 H, s, (CH3)3), 1.70-1.82 (2 H, m, 
CH2CHN), 1.82-1.96 (1 H, m, CHCH3), 2.51 (1 H, dd J 14.0 and 8.0 Hz, 
CHAHBCO2CH3), 2.62 (1 H, dd J 14.0 and 7.5 Hz, CHAHBCO2CH3), 3.02 (1 
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H, dd J 13.5 and 3.5 Hz, CHA(ax)HB(eq)N), 3.65 (3 H, s, CO2CH3), 3.67 (1 H, 
d J 13.5 Hz, CHA(ax)HB(eq)N), 4.64 (1 H, q J 7.0 Hz, CHN); 
13C NMR (100 
MHz, CDCl3) δ ppm: 16.6, 23.1, 25.1, 27.6, 28.4, 35.5, 44.3, 48.1, 51.6, 
79.4, 152.3, 171.8; Found MH+ 272.1854 C14H26NO4 requires MH
+ 
272.1862; [α]D
21  +30 (c 1.0 in CHCl3). 
Hydrogenation of tert-butyl (2R)-2-(3-methoxy-3-oxopropyl)-5 methylidene 
piperidine-1-carboxylate 119d 
 
This reaction was done according to the general procedure C using (283 
mg, 1 mmol) of 119d to give 157c, 157b and 157a  each as colourless oil. 
Chromatography gave 157c (28 mg, 10%), 157b (45 mg, 16%) a mixed 
fraction of 157b and 157a (133 mg, 47%) and 157a (60 mg, 21%). The 
ratio of trans : cis (1.5 : 1) determined by 1H-NMR spectroscopy of the 
crude product. 
tert-Butyl (2R)-2-(3-methoxy-3-oxopropyl)-5-methyl-1,2,3,4-
tetrahydropyridine-1-carboxylate (157c) 
 
Rf 0.55 (30% diethyl ether in petrolum ether); νmax/cm
-1: 2943, 1742, 1696, 
1397; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric behaviour, 
first rotamer δ ppm: 1.24 (3 H, s, CH3C=CH), 1.47 (9 H, s, C(CH3)3), 
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1.57-1.63 (2 H, m, CH2C=CH), 1.72-1.81 (1 H, m, CHAHBCH2CO2CH3), 
1.81-1.87 (1 H, m, CHAHBCH2CO2CH3), 1.95-2.10 (1 H, m, CHAHBCHN), 
2.23-2.45 (1 H, m, CHAHBCHN), 2.23-2.45 (2 H, m, CH2CO2CH3), 3.66 (3 
H, s, CO2CH3), 4.25-4.34 (1 H, m, CHN), 6.40 (1 H, s, C=CHN); second 
rotamer δ ppm: 1.24 (3 H, s, CH3C=CH), 1.47 (9 H, s, C(CH3)3), 1.57-1.63 
(2 H, m, CH2C=CH), 1.72-1.81 (1 H, m, CHAHBCH2CO2CH3), 1.81-1.87 (1 
H, m, CHAHBCH2CO2CH3), 1.95-2.10 (1 H, m, CHAHBCHN), 2.23-2.45 (1 
H, m, CHAHBCHN), 2.23-2.45 (2 H, m, CH2CO2CH3), 3.67 (3 H, s, 
CO2CH3), 4.13-4.21 (1 H, m, CHN), 6.55 (1 H, s, C=CHN); 
13C NMR (100 
MHz, CDCl3) first rotamer δ ppm: 20.9, 22.9, 25.3, 28.3, 29.7, 31.0, 48.1, 
51.5, 80.4, 113.1, 118.5, 152.3, 168.1; second rotamer δ ppm: 20.9, 
23.1, 24.9, 28.9, 29.9, 31.2, 49.2, 51.8, 80.4, 113.7, 118.9, 152.3, 168.1; 
Found MH+ 284.1852 C15H26NO4 requires MH
+ 284.1862; [α]D
21  +20 (c 1.0 
in CHCl3). 
tert-Butyl (2R,5R)-2-(3-methoxy-3-oxopropyl)-5-methylpiperidine-1-
carboxylate (157b) 
 
Rf 0.49 (30% diethyl ether in petroleum ether); νmax/cm
-1: 2936, 1740, 
1689 1H NMR (400 MHz, CDCl3) δ ppm: 0.86 (3 H, d J 7.0 Hz, CH3CH), 
1.14-1.34 (2 H, m, CH2CHCH3), 1.44 (9 H, s, (CH3)3), 1.51-1.73 (2 H, m, 
CH2), 1.96-2.11 (1 H, m, CH3CH), 2.20-2.42 (2 H, m, CH2CO2CH3), 2.20-
2.42 (2 H, m, CH2CHN), 3.66 (3 H, s, CO2CH3), 3.78 (1 H, d J 13.0 Hz, 
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CHA(ax)HB(eq)N), 3.99 (1 H, d J 13.0 Hz, CHA(ax)HB(eq)N), 4.13-4.21 (1 H, br, 
CHN); 13C NMR (100 MHz, CDCl3) δ ppm: 17.9, 19.2, 25.0, 26.8, 28.4, 
29.4, 30.9, 31.7, 48.1, 51.5, 80.2, 155.2, 178.0; Found MH+ 286.2007 
C15H28NO4 requires MH
+ 286.2018; [α]D
21  +30 (c 0.67 in CHCl3). 
tert-Butyl (2R,5S)-2-(3-methoxy-3-oxopropyl)-5-methylpiperidine-1-
carboxylate (157a) 
 
Rf 0.42 (30% diethyl ether in petrolum ether); νmax/cm
-1: 2940, 1746, 1689; 
1H NMR (400 MHz, CDCl3) δ ppm: 0.96 (3 H, d J 7.0 Hz, CH3CH), 1.23-
1.34 (2 H, m, CH2CHCH3), 1.43 (9 H, s, (CH3)3), 1.60-1.70 (2 H, m, 
CH2CHN), 1.74-1.91 (1 H, m, CHCH3), 1.74-1.91 (1 H, m, CHAHBCHN), 
2.02-2.16 (1 H, m, CHAHBCHN), 2.20-2.35 (2 H, m, CH2CO2CH3 ), 2.95 (1 
H, dd J 13.5 and 3.0 Hz, CHA(ax)HB(eq)N), 3.69 (1 H, d J 13.5, 
CHA(ax)HB(eq)N), 3.65 (3 H, s, CO2CH3), 4.17- 4.27 (1 H, m, CHN); 
13C NMR 
(100 MHz, CDCl3) δ ppm: 16.3, 23.4, 25.1, 25.2, 27.8, 28.4, 30.9, 43.6, 
49.9, 51.5, 79.1, 155.2, 178.0; Found MH+ 286.2005 C15H28NO4 requires 
MH+ 286.2018; [α]D
21  +30 (c 1.0 in CHCl3). 
Hydrogenation of (8aR)-6-methylidene-octahydroindolizin-3-one 43  
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This reaction was done according to the general procedure C using (22 
mg, 0.15 mmol) of 43 to give 158b and 158a  each as colourless oil. 
Chromatography gave an in separable 158b and 158a (56 mg, 92%). The 
ratio of trans : cis (1 : 5) determined by 1H-NMR spectroscopy of the crude 
product. 
Rf 0.11 (90% ethyl acetate in petroleum ether); νmax/cm
-1: 2929, 1681, 
1423; cis-diastereoisomer 159b 1H NMR (400 MHz, CDCl3) δ ppm: 0.96 
(3 H, d J 7.5 Hz, CH3CH), 1.37-1.52 (2 H, m, CH2CHN), 1.54-1.72 (2 H, m, 
CH2CHCH3), 1.54-1.72 (1 H, m, CHAHBCH2CO), 1.95-2.10 (1 H, m, 
CH3CH), 2.14-2.26 (1 H, m, CHAHBCH2CO), 2.31-2.44 (2 H, m, CH2CO), 
2.81 (1 H, dd J 13.0 and 4.0 Hz, CHA(ax)HB(eq)N), 3.39 (1 H, dtd J 11.5, 7.0 
and 3.0 Hz, CHN), 3.83 (1 H, ddd J 13.0, 1.5 and 1.5 Hz, CHA(ax)HB(eq)N); 
13C NMR (100 MHz, CDCl3) δ ppm: 16.3, 25.3, 26.6, 27.8, 29.4, 30.3, 
45.5, 57.5, 164.0; trans-diastereoisomer 159a 1H NMR (400 MHz, 
CDCl3) δ ppm: 0.91 (3 H, d J 7.0 Hz, CH3CH), 1.04-1.23 (2 H, m, 
CH2CHCH3), 1.54-1.72 (1 H, m, CHAHBCH2CO), 1.77-1.91 (2 H, m, 
CH2CHN), 1.59-2.10 (1 H, m, CH3CH), 2.14-2.26 (1 H, m, CHAHBCH2CO), 
2.31-2.44 (1 H, m, CHAHBN), 3.32-3.44 (1 H, m, CHN), 4.06 (1 H, ddd J 
13.0, 5.0 and 2.0 Hz, CHAHBN); 
13C NMR (100 MHz, CDCl3) δ ppm: 18.9, 
24.9, 30.5, 30.6, 32.5, 33.4, 47.0, 56.9, 166.5; Found MH+ 154.1232 
C9H16NO requires MH
+ 154.1232. 
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(6S,8aR)-6-Methyl-octahydroindolizin-3-one (158a) 
 
Sodium borohydride (18 mg, 0.69 mmol, 3.0 eq) was added to methyl 3-
[(2R,5S)-5-methyl-1-(trifluoroacetyl)piperidin-2-yl]propanoate 153a (67 mg, 
0.23 mmol) in methanol (3 mL), the reaction was heated at reflux for 3 
days. Removing the methanol on rotary vapour and The residue was 
dissolved in (5 mL) ethyl acetate, washing by (3 mL) water and (3 mL) 
brine, the organic layer was concentrated to produce the title compound 
as colorless oil (60 mg, 90%). 
νmax/cm
-1: 1682, 1442; 1H NMR (400 MHz, CDCl3) δ ppm: 0.78-0.89 (1 H, 
m, CHAHBCHN), 0.9 (3 H, d J 7.0 Hz, CH3CH), 1.03-1.26 (1 H, m, 
CHAHBCHN), 1.03-1.26 (2 H, m, COCH2CH2CHN), 1.40-1.52 (1 H, m, 
CHCH3), 1.52-1.61 (1 H, m, CHAHBCHCH3), 1.76-1.90 (2 H, m, CH2CO), 
2.13-2.23 (1 H, m, CHAHBCHCH3), 2.41 (1 H, dd J 13.0 and 12.5 Hz, 
CHA(ax)HB(eq)N), 3.41 (1 H, ddd J 11.5, 7.0 and 3.5 Hz, CHN), 4.05 (1 H, 
ddd J 13.0, 5.0 and 2.0 Hz, CHA(ax)HB(eq)N); 
13C NMR (100 MHz, CDCl3) δ 
ppm: 18.9, 29.7, 30.5, 31.9, 32.5, 46.9, 56.8, 173.3; Found MH+ 154.1229. 
C9H16NO requires MH
+ 154.1232; [α]D
22 +5 (c 4.0 in CHCl3).    
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Hydrogenation of (8aR)-6-methylidene-hexahydro-1H-[1,3]oxazolo[3,4-
a]pyridin-3-one 147  
 
This reaction was done according to the general procedure C using (22 
mg, 0.15 mmol) of 147 to give 159b and 159a each as colourless oil. 
Chromatography gave an in separable 159b and 159a (22 mg, 95%). The 
ratio of trans : cis (1 : 7) determined by 1H-NMR spectroscopy of the crude 
product. 
Rf 0.35 (70% ethyl acetate in petroleum ether); νmax/cm
-1: 2929, 1747, 
1425; cis-diastereoisomer 160b 1H NMR (400 MHz, CDCl3) δ ppm: 1.03 
(3 H, d J 7.5 Hz, CH3CH), 1.53-1.70 (2 H, m, CH2CHCH3), 1.53-1.70 (2 H, 
m, CH2CHN), 1.89-2.06 (1 H, m, CH3CH), 3.0 (1 H, dd J 13.0 and 4.0 Hz, 
CHA(ax)HB(eq)N), 3.56 (1 H, d J 13.0 Hz, CHA(ax)HB(eq)N), 3.59-3.65 (1 H, m, 
CHN), 3.90 (1 H, dd J 8.5 and 7.5 Hz, CHAHBO), 4.42 (1 H, d J 8.5 Hz, 
CHAHBO) trans-diastereoisomer 159a 0.90 (3 H, d J 7 Hz, CH3CH), 
1.53-1.70 (2 H, m, CH2CHCH3), 1.53-1.70 (2 H, m, CH2CHN), 1.78-1.89 (1 
H, m, CH3CH), 2.4 (1 H, dd J 13.0 and 11.5 Hz, CHA(ax)HB(eq)N), 3.59-3.65 
(1 H, m, CHN), 3.81 (1 H, ddd J 13.0, 5.0 and 1.5 Hz, CHA(ax)HB(eq)N), 3.88 
(1 H, dd J 8.5 and 7 Hz, CHAHBO), 4.39 (1 H, dd J 8.5 and zero, CHAHBO); 
13C NMR (100 MHz, CDCl3) δ ppm: 16.3, 18.7, 25.0, 26.6, 28.3, 30.3, 
30.6, 31.5, 46.5, 54.1, 54.6, 68.0, 68.3, 157.9, 160.0; Found MH+ 
156.1022. C8H14NO2 requires MH
+ 156.1025. 
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4.7 General procedure D: Heck Reaction 
A 10 mL one-necked round bottomed flask, reflux condenser, magnetic 
stirrer bar, and three-way tap, was flame dried under vacuum and back-
filled with nitrogen three times. The flask was then charged with Pd(OAc)2 
(10.8 mg, 0.05 mmol, 0.05 eq), and an aryl iodide (9.5 mmol, 10 eq) and 
back-filled with nitrogen. Methylene piperidine (1.0 mmol), triethylamine 
(2.5 mmol, 2.5 eq) and acetonitrile (7.5 mL) were then added to the flask 
via syringe, and the reaction mixture was stirred at reflux for 20 h. The 
flask was then removed from the heat source and allowed to cool to room 
temperature, and transferring the reaction mixture into a single necked 
round bottom flask using methanol, and removal of the solvent under 
reduced pressure. Flash chromatography on silica, using an eluant 
gradient of ethyl acetate in petroleum ether. 
1-tert-Butyl 2-methyl (2S)-5-benzyl-1,2,3,4-tetrahydropyridine-1,2-
dicarboxylate (160) 
 
The title compound was synthesised according to the general procedure 
D, using 1-tert-butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-
dicarboxylate ent-37 (255 mg, 1 mmol) as the starting material to give the 
title compound (268 mg, 81%) as a colourless oil.  
Rf 0.5 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 1747, 1701, 
1672, 1475, 1452; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
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behaviour, first rotamer δ ppm: 1.48 (9 H, s, C(CH3)3), 1.75-1.93 (2 H, m, 
CH2C=CH), 1.75-1.93 (1 H, m, CHAHBCHN), 2.22-2.35 (1 H, m, 
CHAHBCHN), 3.31 (2 H, s,CH2Ph), 3.72 (3 H, s, CO2CH3), 4.70-4.75 (1 m, 
CHN), 6.74 (1 H, s, CH=C), 7.16-7.24 (3 H, m, Ph), 7.24-7.34 (2 H, m, Ph); 
second rotamer δ ppm: 1.53 (9 H, s, C(CH3)3), 1.75-1.93 (2 H, m, 
CH2C=CH), 1.75-1.93 (1 H, m, CHAHBCHN), 2.22-2.35 (1 H, m, 
CHAHBCHN), 3.31 (2 H, s ,CH2Ph), 3.73 (3 H, s, CO2CH3), 4.87-4.91 (1 m, 
CHN), 6.93 (1 H, s, CH=C), 7.16-7.24 (3 H, m, Ph), 7.24-7.34 (2 H, m, Ph); 
13C NMR (100 MHz, CDCl3) δ ppm first rotamer: 21.3, 23.6, 28.2, 41.4, 
52.1, 52.7, 81.1, 115.8, 120.8, 126.0, 128.2, 128.6, 139.7, 152.4, 171.7, 
second rotamer: 21.7, 23.9, 28.3, 41.5, 25.2, 53.9, 81.3, 116.4, 121.4, 
126.1, 128.5, 128.6, 139.7, 152.9, 172.2; Found MH+ 332.1860 C19H26NO4 
requires MH+ 332.1862; [α]D
21 -26 (c 1.0 in CHCl3). 
1-tert-Butyl 2-methyl (2S)-5-[(2-methoxyphenyl)methyl]-1,2,3,4  
tetrahydropyridine -1,2-dicarboxylate (161) 
 
The title compound was synthesised according to the general procedure 
D, using 1-tert-butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-
dicarboxylate ent-37 (255 mg, 1 mmol) as the starting material to give the 
title compound (273 mg, 76%) as a colourless oil.  
Rf (10% ethyl acetate in petroleum ether); νmax/cm
-1: 1751, 1698, 1588, 
1586, 1492, 1456; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
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behaviour, first rotamer δ ppm: 1.45 (9 H, s, C(CH3)3), 1.79-1.91 (2 H, m, 
CH2C=CH), 1.79-1.91 (1 H, m, CHAHBCHN), 2.19-2.35 (1 H, m, 
CHAHBCHN), 3.25-3.35 (2 H, m, CH2Ar), 3.70 (3 H, s, OCH3), 3.80 (3 H, s, 
CO2CH3), 4.67-4.72 (1 H, m, CHN), 6.69 (1 H, s, CH=C), 6.80-6.87 (3 H, 
m, Ar), 7.09 (1 H, dd J 7.5 and 1.5 Hz, Ar), 7.13-7.21 (1 H, m, Ar); second 
rotamer δ ppm: 1.49 (9 H, s, C(CH3)3), 1.79-1.91 (2 H, m, CH2C=CH), 
1.79-1.91 (1 H, m, CHAHBCHN), 2.19-2.35 (1 H, m, CHAHBCHN), 3.25-
3.35 (2 H, m, CH2Ar), 3.71 (3 H, s, OCH3), 3.81 (3 H, s, CO2CH3), 4.84-
4.88 (1 H, m, CHN), 6.80-6.87 (3 H, m, Ar), 6.88 (1 H, s, CH=C), 7.09 (1 
H, dd J 7.5 and 1.5 Hz, Ar), 7.13-7.21 (1 H, m, Ar); 13C NMR (100 MHz, 
CDCl3) δ ppm first rotamer: 21.6, 23.7, 28.2, 34.3, 52.1, 52.7, 55.3, 80.9, 
110.3, 115.4, 120.4, 121.3, 127.1, 128.2, 129.5, 152.3, 157.5, 171.7; 
second rotamer: 21.9, 24.0, 28.3, 34.4, 52.2, 52.7, 53.9, 81.1, 110.3, 
116.2, 120.7, 127.2, 128.2, 129.7, 141.1, 152.5, 157.5, 172.1; Found MH+ 
362.1958 C20H28NO5 requires MH
+ 362.1967; [α]D
21 -39 (c 1.0 in CHCl3). 
1-tert-Butyl 2-methyl (2S)-5-[(3-methoxyphenyl)methyl]-1,2,3,4-
tetrahydropyridine-1,2-dicarboxylate (162) 
 
The title compound was synthesised according to the general procedure 
D, using 1-tert-butyl 2-methyl (2S)-5-methylidenepiperidine-1,2-
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dicarboxylate ent-37 (255 mg, 1 mmol) as the starting material to give the 
title compound (288 mg, 80%) as a colourless oil.  
Rf 0.25 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 1749, 1701, 
1672, 1597, 1584, 1486; 1H NMR (400 MHz, CDCl3) exhibits strongly 
rotameric behaviour, first rotamer δ ppm: 1.46 (9 H, s, C(CH3)3), 1.72-
1.91 (2 H, m, CH2C=CH), 1.72-1.91 (1 H, m, CHAHBCHN), 2.19-2.32 (1 H, 
m, CHAHBCHN), 3.22-3.32 (2 H, m, CH2Ar), 3.70 (3 H, s, OCH3), 3.78 (3 
H, s, CO2CH3), 4.67-4.72 (1 H, m, CHN), 6.70-6.67 (3 H, m, Ar), 6.77 (1 H, 
s, CH=C), 7.14-7.22 (1 H, m, Ar); second rotamer δ ppm: 1.51 (9 H, s, 
C(CH3)3), 1.72-1.91 (2 H, m, CH2C=CH), 1.72-1.91 (1 H, m, CHAHBCHN), 
2.19-2.32 (1 H, m, CHAHBCHN), 3.22-3.32 (2 H, m, CH2Ar), 3.71 (3 H, s, 
OCH3), 3.79 (3 H, s, CO2CH3), 4.85-4.90 (1 H, m, CHN), 6.70-6.67 (3 H, 
m, Ar), 6.91 (1 H, s, CH=C), 7.14-7.22 (1 H, m, Ar); 13C NMR (100 MHz, 
CDCl3) δ ppm first rotamer: 21.3, 23.6, 28.2, 41.4, 52.1, 52.7, 55.1, 81.1, 
111.3, 114.1, 115.5, 120.9, 121.1, 129.1, 141.4, 152.4, 159.7, 171.6; 
second rotamer: 21.6, 23.9, 28.3, 41.5, 52.2, 53.9, 55.1, 81.3, 111.5, 
114.3, 116.2, 121.0, 121.5, 129.2, 141.5, 152.7, 160.1, 172.0; Found MH+ 
362.1958 C20H28NO5 requires MH
+ 362.1967; [α]D
21 -28 (c 1.0 in CHCl3). 
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Methyl(2S)-5-benzyl-1-(trifluoroacetyl)-1,2,3,4-tetrahydropyridine-2 
carboxylate (163) 
 
The title compound was prepared according to the general procedure D, 
using (S)-methyl 5-methylene-1-(2,2,2-trifluoroacetyl)piperidine-2-
carboxylate 127 (292 mg, 1.16 mmol) as the starting material to give the 
title compound (265 mg, 70%) as a colorless oil. 
Rf 0.4 (10% ethyl acetate in petroleum ether); νmax/cm
-1: 2320, 1748, 
1697, 1495; 1H NMR (400 MHz, CDCl3) exhibits strongly rotameric 
behaviour, major rotamer δ ppm: 1.85-2.03 (2 H, m, CH2C=CH2), 1.85-
2.03 (1 H, m, CHAHBCH), 2.38-2.49 (1 H, m, CHAHBCH), 3.34 (2 H, s, 
CH2Ph), 3.75 (3 H, s, CO2CH3), 5.14-5.20 (1 H, br, CHN), 6.66 (1 H, s, 
C=CHN), 7.12-7.38 (5 H, m, Ph); minor rotamer δ ppm: 1.85-2.03 (2 H, 
m, CH2C=CH2), 1.85-2.03 (1 H, m, CHAHBCH), 2.38-2.49 (1 H, m, 
CHAHBCH), 3.38 (2 H, s, CH2Ph), 3.75 (3 H, s, CO2CH3), 4.84-4.88 (1 H, 
br, CHN), 6.45 (1 H, s, C=CHN), 7.12-7.38 (5 H, m, Ph); 13C NMR (100 
MHz, CDCl3) δ ppm major rotamer: 21.8, 23.0, 30.1,  41.4, 52.9, 116.2 (q 
J 219 Hz), 118.7, 123.3, 126.5, 128.5, 128.6, 138.1, 154.8 (q J 41 Hz), 
169.4; minor rotamer: 22.1, 24.1, 41.5, 52.9, 54.6, 116.2 (q J 219 Hz), 
118.7, 125.0, 126.6, 128.5, 128.6, 138.5, 154.8 (q J 41 Hz), 169.7; Found 
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MH+ 328.1174 C16H17F3NO3 requires MH
+ 328.1161; [α]D
24 -45 (c 2.0 in 
CHCl3).           
tert-Butyl (2R)-2,5-dibenzyl-1,2,3,4-tetrahydropyridine-1-carboxylate (164) 
 
The title compound was synthesised according to the general procedure 
D, using tert-butyl (2R)-2-benzyl-5-methylidenepiperidine-1-carboxylate 
119a ( 287 mg, 1 mmol) as the starting material to give the title compound 
(261 mg, 72%) as a colourless oil.  
Rf 0.71 (5% ethyl acetate in petroleum ether); νmax/cm
-1: 1694, 1600, 
1476, 1453, 1395, 1366, 1347, 1322; 1H NMR (400 MHz, CDCl3) exhibits 
strongly rotameric behaviour, major rotamer δ ppm: 1.41 (9 H, s, 
C(CH3)3), 1.55-1.73 (2 H, m, CH2CH), 1.74-1.87 (1 H, m, CHAHBC=CH), 
1.98-2.12 (1 H, m, CHAHBC=CH), 2.53-2.65 (1 H, m, CHCHAHBPh), 2.79-
2.91 (1 H, m, CHCHAHBPh), 3.31-3.43 (2 H, s, CH2Ph), 4.30-4.38 (1 H, m, 
CHN), 6.91 (1 H, s, CH=C), 7.15-730 (10 H, m, 2 Ph); minor rotamer: 
1.49 (9 H, s, C(CH3)3), 1.55-1.73 (2 H, m, CH2CH), 1.74-1.87 (1 H, m, 
CHAHBC=CH), 1.98-2.12 (1 H, m, CHAHBC=CH), 2.53-2.65 (1 H, m, 
CHCHAHBPh), 2.79-2.91 (1 H, m, CHCHAHBPh), 3.31-3.43 (2 H, s, 
CH2Ph), 4.47-4.53 (1 H, m, CHN), 6.69 (1 H, s, CH=C), 7.15-7.30 (10 H, 
m, 2 Ph); 13C NMR (100 MHz, CDCl3) δ ppm major rotamer: 20.6, 23.5, 
28.2, 36.6, 41.9, 50.6, 80.3, 116.8, 117.1, 120.2, 126.1, 127.1, 128.3, 
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128.6, 128.7, 129.3, 138.9, 152.7; minor rotamer: 20.8, 22.7, 28.3, 37.2, 
41.9, 42.3, 51.9, 81.5, 116.8, 117.1, 126.1, 127.1, 128.3, 128.6, 128.7, 
129.3, 140.6, 152.7; Found MH+ 364.2276 C24H30NO2 requires MH
+ 
364.2277; [α]D
19 +12 (c 1.0 in CHCl3).  
1-[(2R)-2,5-Dibenzyl-1,2,3,4-tetrahydropyridin-1-yl]-2,2,2-trifluoroethan-1-
one (165) 
 
The title compound was synthesised according to the general procedure 
D, using 1-[(2R)-2-Benzyl-5-methylidenepiperidin-1-yl]-2,2,2-trifluoroethan-
1-one 122a ( 283. mg, 1 mmol) as the starting material to give the title 
compound (280 mg, 78%) as a colourless oil.  
Rf 0.57 (5% diethyl ether in petroleum ether); νmax/cm
-1: 1685, 1602, 1494, 
1453, 1424, 1228, 1191, 1136; 1H NMR (400 MHz, CDCl3) exhibits 
strongly rotameric behaviour, major rotamer δ ppm: 1.63-1.83 (2 H, m, 
CH2CH), 1.95 (1 H, dd J 18.0 and 6.0 Hz, CHAHBC=CH), 2.08-2.23 (1 H, 
m, CHAHBC=CH), 2.66 (1 H, dd J 13.5 and 9.5 Hz, CHCHAHBPh), 2.88 (1 
H, dd J 13.5 and 6.0 Hz, CHCHAHBPh), 3.41 (2 H, s, CH2Ph), 4.76-4.83 (1 
H, m, CHN), 6.60 (1 H, s, C=CH), 7.20-7.40 (10 H, m, 10 Ph); minor 
rotamer: 1.63-1.83 (2 H, m, CH2CH), 1.95 (1 H, dd J 18.0 and 6.0 Hz, 
CHAHBC=CH), 2.08-2.23 (1 H, m, CHAHBC=CH), 2.66 (1 H, dd J 13.5 and 
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9.5 Hz, CHCHAHBPh), 2.88 (1 H, dd J 13.5 and 6.0 Hz, CHCHAHBPh), 
3.46 (2 H, d J 5.0 Hz, CH2Ph), 4.30-4.38 (1 H, m, CHN), 7.09 (1 H, s, 
C=CH), 7.20-7.40 (10 H, m, 2 Ph); 13C NMR (100 MHz, CDCl3) δ ppm 
major rotamer: 21.2, 22.1, 35.8, 41.8, 51.2, 115.0 (q J 90 Hz), 118.0, 
123.7, 125.3, 126.6, 126.7, 128.5, 128.7, 129.0, 129.2, 137.3, 157.9 (q J 
50 Hz), minor rotamer: 21.2, 22.5, 37.0, 41.8, 53.4, 115.0 (q J 90 Hz), 
118.4, 123.6, 124.6, 126.7, 126.6, 126.7, 128.6, 128.7, 129.2, 138.5, 
157.9 (q J 50 Hz); Found MH+ 360.1580 C21H21F3NO requires MH
+ 
360.1575; [α]D
19 +77 (c 1.0 in CHCl3).  
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4.8 General procedure E: Hydrogenation of Heck reaction 
products 
A two-necked round-bottomed flask, equipped with a rubber septum, 
three-way   tap and magnetic follower, was flame-dried under vacuum and 
back-filled with nitrogen three times. The flask was charged with platinum 
supported on activated carbon (1% w/w, 0.1 eq), and then evacuated and 
back-filled with nitrogen three times. A solution of the Heck reaction 
product (1.0 mmol) in methanol (17 mL) was added to the flask via 
syringe, and the reaction mixture stirred vigorously. A balloon of hydrogen 
was fitted to the three-way tap, and the reaction vessel evacuated until the 
solvent began to boil, at which point it was back-filled with hydrogen, and 
this process was repeated three times. The reaction mixture was stirred 
vigorously at room temperature for 48 h, then filtered through celite using 
methanol. The solvent was then removed from the filtrate under reduced 
pressure and the residue purified via flash chromatography on silica. 
Hydrogenation of 1-tert-butyl 2-methyl (2S)-5-benzyl-1,2,3,4-
tetrahydropyridine-1,2-dicarboxylate 160 
 
This reaction was done according to the general procedure E using (130 
mg, 0.39 mmol) of 160 to give 167b and 167a as inseparable 
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diastereoisomers (84 mg, 65%) as a colourless oil. The ratio of cis : trans 
(4 : 1) determined by 1H-NMR spectroscopy of the crude product. 
Rf 0.45 (15% diethyl ether in petroleum ether), νmax/cm
-1: 2930, 1744, 
1698, 1392; 1H NMR (400 MHz, CDCl3) δ ppm: 0.78-1.10 (1 H, m), 1.44 (9 
H, s, C(CH3)3), 1.98-1.79 (3 H, m), 2.17-2.29 (1 H, m, CHAHBCHN), 2.38-
2.47 (1 H, m, CHAHBCHN), 2.51-2.62 (2 H, m, CH2Ph), 2.67 (1 H of major 
isomer of one rotamer, app. t J 12.5 Hz, CHAHBN), 2.77 (1 H of minor 
isomer of one rotamer, dd J 14.0 and 8.5 Hz, CHAHBN), 3.12 (1 H of minor 
isomer of other rotamer, dd J 13.0 and 4.0 Hz, CHAHBN), 3.75 (3 H, s, 
CO2CH3), 3.77 (3 H, s, CO2CH3), 3.89 (1 H of minor isomer of one 
rotamer, d J 4.5 Hz, CHAHBN), 3.93 (1 H of major isomer of one rotamer, 
dd J 14.0 and 4.0 Hz, CHAHBN), 4.03 (1 H of minor isomer of other 
rotamer, d J 4.5 Hz, CHAHBN), 4.08 (1 H of major rotamer of other 
rotamer, dd J 13.0 and 4.0 Hz, CHAHBN), 4.74 (1 H of major isomer of one 
rotamer, d J 5.0 Hz, CHN), 4.86 (1 H of minor isomer of one rotamer, d J 
6.5 Hz, CHN), 4.92 (1 H of major isomer of other rotamer, d J 5.0 Hz, 
CHN), 5.10 (1 H of minor isomer of other rotamer, d J 6.5 Hz, CHN), 7.11-
7.33 (5 H, m, Ph); 13C NMR (100 MHz, CDCl3) many signals was observed 
due to rotameric behaviour, and the presence of diastereoisomers δ ppm: 
26.6, 26.7, 27.1, 27.3, 28.3, 31.2, 35.4, 37.4, 37.6, 40.5, 40.7, 46.5, 47.5, 
52.0, 53.4, 54.6, 80.0, 128.2, 128.9, 129.0, 139.6, 155.4, 155.5, 172.3, 
172.8; Found MH+ 334.2023. C19H28NO4 requires MH
+ 334.2018. 
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Hydrogenation of 1-tert-butyl 2-methyl (2S)-5-[(2-methoxyphenyl)methyl]-
1,2,3,4 tetrahydropyridine -1,2-dicarboxylate 161 
 
This reaction was done according to the general procedure E using (141 
mg, 0.39 mmol) of 161 to give 168b and 168a as inseparable 
diastereoisomers (78 mg, 55%) as a colourless oil. The ratio of cis : trans 
(4 : 1) determined by 1H-NMR spectroscopy of the crude product. 
Rf 0.28 (25% diethyl ether in petroleum ether), νmax/cm
-1: 2930, 1741, 
1690, 1493; 1H NMR (400 MHz, CDCl3) δ ppm: 0.8-1.01 (2 H, m, CH2CH), 
1.41 (9 H of major isomer, s, C(CH3)3), 1.46 (9 H of minor isomer, s, 
C(CH3)3), 1.55-1.80 (1 H, m, CHCH2Ph), 2.15-2.25 (1 H, m, CHAHBCHN), 
2.37-2.46 (1 H, m, CHAHBCHN), 2.48-2.57 (2 H, m, CH2Ph), 2.65 (1 H of 
major isomer of one rotamer, app. t J 12.5 Hz, CHAHBN), 3.07 (1 H of 
minor isomer of one rotamer, dd J 13.5 and 4.0 Hz, CHAHBN), 3.26-3.30 (1 
H of major isomer of other rotamer, m, CHAHBN), 3.71 (3 H of minor 
isomer, s, CO2CH3), 3.72 (3 H of major isomer of one rotamer, s, 
CO2CH3), 3.74 (3 H of major isomer of other rotamer, s, CO2CH3), 3.78 (3 
H of major isomer of one rotamer, s, OCH3), 3.79 (3 H of minor isomer, s, 
CO2CH3), 3.81 (3 H of major isomer of other rotamer, s, CO2CH3), 3.88 ( 1 
H of major isomer of one rotamer, dd J 13.5 and 4.0 Hz, CHAHBN), 4.03 ( 
1 H of major isomer of other rotamer, dd J 13.5 and 4.5 Hz, CHAHBN), 
4.70 (1 H of major isomer of one rotamer, d J 5.0 Hz, CHN), 4.88 (1 H of 
 188 
 
major isomer of other rotamer, d J 5.0 Hz, CHN), 4.91 (1 H of minor 
isomer, d J 6.0 Hz, CHN), 6.79-6.90 (2 H, m, Ph), 7.02-7.08 (1 H, m, Ph), 
7.13-7.21 (1 H, m, Ph); 13C NMR (100 MHz, CDCl3) many signals was 
observed due to rotameric behaviour, and the presence of 
diastereoisomers δ ppm: 26.6, 26.7, 27.2, 27.5, 28.3, 34.6, 34.9, 35.8, 
36.2, 46.7, 47.7, 52.0, 53.5, 54.6, 55.2, 79.9, 110.2, 120.2, 127.3, 130.6, 
130.8, 157.7, 175.3; Found MH+ 364.2115. C20H30NO5 requires MH
+ 
364.2124. 
Hydrogenation of 1-tert-butyl 2-methyl (2S)-5-[(3-methoxyphenyl)methyl]-
1,2,3,4-tetrahydropyridine-1,2-dicarboxylate 162 
 
This reaction was done according to the general procedure E using (141 
mg, 0.39 mmol) of 162 to give 169b and 169a as inseparable 
diastereoisomers (81 mg, 57%) as a colourless oil. The ratio of cis : trans 
(4 : 1) determined by 1H-NMR spectroscopy of the crude product. 
Rf 0.3 (25% diethyl ether in petroleum ether), νmax/cm
-1: 2928, 1745, 1697, 
1499; 1H NMR (400 MHz, CDCl3) δ ppm: 0.81-1.02 (2 H, m, CH2CH), 1.41 
(9 H of major isomer, s, C(CH3)3), 1.42 (9 H of minor isomer, s, C(CH3)3), 
1.56-1.75 (1 H, m, CHCH2Ph), 2.15-2.26 (1 H, m, CHAHBCHN), 2.33-2.41 
(1 H, m, CHAHBCHN), 2.47-2.59 (2 H, m, CH2Ph), 2.65 (1 H of major 
isomer of one rotamer, app. t J 12.5 Hz, CHAHBN), 3.08 (1 H of minor 
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isomer of one rotamer, dd J 14.0 and 4.0 Hz, CHAHBN), 3.26-3.30 (1 H of 
major isomer of other rotamer, m, CHAHBN), 3.68 (3 H of minor isomer, s, 
CO2CH3), 3.70 (3 H of major isomer of one rotamer, s, CO2CH3), 3.73 (3 H 
of major isomer of other rotamer, s, CO2CH3), 3.75 (3 H of major isomer of 
one rotamer, s, OCH3), 3.80 (3 H of minor isomer, s, CO2CH3), 3.82 (3 H 
of major isomer of other rotamer, s, CO2CH3), 3.91 ( 1 H of major isomer 
of one rotamer, dd J 13.0 and 4.0 Hz, CHAHBN), 4.05 ( 1 H of major 
isomer of other rotamer, dd J 13.0 and 3.5 Hz, CHAHBN), 4.72 (1 H of 
major isomer of one rotamer, d J 6.0 Hz, CHN), 4.83 (1 H of major isomer 
of other rotamer, d J 6.0 Hz, CHN), 4.90 (1 H of minor isomer, d J 6.0 Hz, 
CHN), 6.64-6.78 (2 H, m, Ph), 6.86-6.96 (1 H, m, Ph), 7.14-7.22 (1 H, m, 
Ph); 13C NMR (100 MHz, CDCl3) many signals was observed due to 
rotameric behaviour, and the presence of diastereoisomers δ ppm: 26.7, 
27.3, 28.3, 37.3, 37.5, 40.5, 46.5, 47.5, 52.0, 53.4, 54.5, 55.1, 77.3, 
111.32, 114.7, 121.4, 129.2, 131.8, 157.7, 175.3; Found MH+ 364.2134. 
C20H30NO5 requires MH
+ 364.2124.    
Hydrogenation of tert-butyl (2R)-2,5-dibenzyl-1,2,3,4-tetrahydropyridine-1-
carboxylate 164 
 
This reaction was done according to the general procedure E using (120 
mg, 0.33 mmol) of 164 to give 166a and 166b as partly separable 
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diastereoisomers (81 mg, 57%) as a colourless oil. The separated yield of 
166a (29 mg, 24%). The ratio of trans : cis (6 : 1) determined by 1H-NMR 
spectroscopy of the crude product. 
tert-Butyl (2R,5R)-2,5-dibenzylpiperidine-1-carboxylate (166a) 
 
νmax/cm
-1: 2928, 1686, 1414; 1H NMR (400 MHz, CDCl3) δ ppm: 1.24-1.38 
(1 H, m, CHAHBCH), 1.41-1.50 (1 H, m, CHAHBCH), 1.78-1.89 (2 H, m, 
CH2CHN), 1.95-2.04 (1 H, m, CHCH2Ph), 2.60 (1 H, dd J 13.0 and 7.0 Hz, 
CHAHBPh), 2.73-2.84 (2 H, m, CH2Ph), 2.93 (1 H dd J 13.0 7.5 Hz, 
CHAHBPh), 3.08 (1 H, dd J 13.5 and 4.0 Hz, CHA(ax)HB(eq)N), 3.90 (1 H, d J 
13.5 Hz, CHA(ax)HB(eq)N), 4.44-4.54 (1 H, m, CHN), 7.17-7.24 (5 H, m, Ph), 
7.26-7.33 (5 H, m, Ph); 13C NMR (100 MHz, CDCl3) δ ppm: 28.4, 29.7, 
35.5, 36.9, 52.1, 61.1, 79.2, 125.8, 126.1, 128.2, 128.3, 129.2, 129.3, 
139.1, 141.0, 157.2; Found MH+ 366.2415. C24H32NO2 requires MH
+ 
366.2433; [α]D
23 -12 (c 1.67 in CHCl3).     
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4.9 General procedure F: Conjugate addition 
A two-necked round bottomed flask, fitted with a three-way tap and rubber 
septum was flame-dried, evacuated and back-filled with nitrogen three 
times. The flask was charged with a magnetic follower and zinc (2.0 eq), 
and again evacuated and back-filled with nitrogen three times, with 
continuous stirring. Dry DMF (1 mL) was added via syringe, and the 
heterogeneous mixture stirred vigorously. Iodine (0.25 mmol) was added 
by rapid removal and replacement of the three-way tap under nitrogen, 
turning the solvent yellow. The mixture was stirred for 1-2 min, until the 
solvent had become colourless. The alkyl iodide (1.0 mmol) was added by 
rapid removal of the three-way tap under a stream of nitrogen. The mixture 
was stirred, and an exothermic was observed. The mixture was stirred for 
a further 45 min, before cessation of stirring. The solid zinc dust was 
allowed to settle before transferring the reagent into a new reaction vessel 
via syringe. During the activation period, a separate two-necked round 
bottomed flask fitted with a three-way tap was flame-dried under vacuum, 
and back filled with nitrogen three times. This flask was charged with a 
magnetic follower and CuBr.DMS (0.1 eq), and gently heated under 
vacuum until the CuBr.DMS changed appearance from a brown to light 
green powder. The flask was allowed to cool, before adding dry DMF (0.5 
mL) and the organozinc iodide was transferred to the previous flask. A 
mixture of distilled trimethylsilyl chloride (2.0 eq), DMF (0.5 mL) and an 
enone (2.0 eq) in a vial was added dropwise via syringe on water bath for 
10 min and then at room temperature overnight. A (10 mL) ammonium 
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chloride was added to the reaction for 30 min and the reaction mixture was 
transferred to a separatory funnel with (15 mL) ethyl acetate, and washed 
with (10 mL) water and (10 mL) brine. The organic layer was dried over 
magnesium sulfate, filtered, and the solvent removed at reduced pressure. 
The residue was purified by flash chromatography on silica, using ethyl 
acetate in petroleum ether. 
Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxoheptanoate (170a) 
 
The title compound was synthesised according to the general procedure F 
using methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate 104 
(658 mg, 2 mmol) and methyl vinyl ketone (280 mg, 4 mmol, 2 eq) to give 
the title compound as colourless oil (257 mg, 47%). 
Rf 0.35 (30% ethyl acetate in petroleum ether); νmax/cm
-1: 3313, 1730, 
1705, 1515; 1H NMR (400 MHz, CDCl3) δ ppm: 1.43 (9 H, s, C(CH3)3), 
1.41-1.45 (2 H, m, CH2CH2CO), 1.41-1.45 (1 H, m, CHAHBCHN), 1.77-1.81 
(1 H, m, CHAHBCHN), 2.13 (3 H, s, CH3CO), 2.45-2.48 (2 H, m, CH2CO), 
3.73 (3 H, s, CO2CH3), 4.27-4.31 (1 H, m, CHN), 5.05 (1 H, d J 8.0 Hz, 
NH); 13C NMR (100 MHz, CDCl3) δ ppm: 19.3, 28.3, 29.9, 32.0, 42.7, 52.3, 
53.0, 80.0, 155.2, 173.0; Found MH+ 247.1644. C13H24NO5 requires MH
+ 
274.1654.; [α]D
17 +81 (c 1.0 in CHCl3). 
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Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxooctanoate (170b) 
 
The title compound was synthesised according to the general procedure F 
using methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate 104 
(658 mg, 2 mmol) and ethyl vinyl ketone (336 mg, 4 mmol, 2 eq) to give 
the title compound as colorless oil (258 mg, 45%).  
Rf 0.39 (30% ethyl acetate in petroleum ether); νmax/cm
-1: 3304, 1726, 
1709, 1520; 1H NMR (400 MHz, CDCl3) δ ppm: 1.03 (3 H, t J 7.5 Hz, 
CH3CH2), (9 H, s, C(CH3)3), 1.56-1.67 (2 H, m, CH2CH2CO), 1.56-1.67 (1 
H, m, CHAHBCHN), 1.70-1.83 (1 H, m, CHAHBCHN), 2.39 (2 H, q J 7.5 Hz, 
CH3CH2CO), 2.44 (2 H, t J 7.0 Hz, CH2CH2CO), 3.72 (3 H, s, CO2CH3), 
4.23-4.33 (1 H, m, CHN), 5.05 (1 H, d J 8.0 Hz, NH); 13C NMR (100 MHz, 
CDCl3) δ ppm: 7.7, 19.4, 28.3, 32.0, 35.9, 41.3, 52.3, 53.0, 79.0, 155.4, 
173.1, 210.0; Found MH+ 288.1811. C14H26NO5 requires MH
+ 288.1811.; 
[α]D
21 +20 (c 1.0 in CHCl3). 
Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxononanoate (170c) 
 
The title compound was synthesised according to the general procedure F 
using methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate 104 
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(658 mg, 2 mmol) and propyl vinyl ketone (392 mg, 4 mmol, 2 eq) to give 
the title compound as colorless oil (269 mg, 45%). 
Rf 0.35 (30% ethyl acetate in petroleum ether); νmax/cm
-1: 2956, 1730, 
1709, 1512;  1H NMR (400 MHz, CDCl3) δ ppm: 0.89 (3 H, t J 7.5 Hz, 
CH3CH2), 1.43 (9 H, s, C(CH3)3), 1.52-1.66 (2 H, m, CH2CH2CO), 1.52-
1.66 (2 H, m, CH2CH2CO), 1.56-1.67 (1 H, m, CHAHBCHN), 1.72-1.84 (1 
H, m, CHAHBCHN), 2.35 (2 H, t J 7.0 Hz, CH3CH2CH2CO), 2.39 (2 H, t J 
7.0 Hz, CH2CH2CO), 3.73 (3 H, s, CO2CH3), 4.23-4.34 (1 H, m, CHN), 
5.05 (1 H, d J 8.0 Hz, NH); 13C NMR (100 MHz, CDCl3) δ ppm: 13.7, 17.2, 
19.3, 28.3, 32.0, 41.7, 44.7, 52.3, 53.1, 80.1, 151.7, 173.4, 208.2; Found 
MH+ 302.1975. C15H28NO5 requires MH
+ 274.1654.; [α]D
23 +10 (c 1.0 in 
CHCl3). 
Methyl 4-{[(tert-butoxy)carbonyl]amino}-8-oxononanoate (172a) 
 
1H NMR (400 MHz, CDCl3) δ ppm: 1.32-1.50 (2 H, m, CH2CH2CO), 1.42 (9 
H, s, C(CH3)3), 1.52-1.69 (2 H, m, CH2CH), 1.52-1.69 (1 H, m, CHAHBCH), 
1.77-1.89 (1 H, m, CHAHBCH), 2.12 (3 H, s, CH3CO), 2.37 (2 H, t J 3.5 Hz, 
CH2CO), 2.40-2.54 (2 H, m, CH2CO2CH3), 3.49-3.62 (1 H, m, CHN), 3.66 
(3 H, s, CO2CH3), 4.30 (1 H, d J 9.5 Hz, NH); 
13C NMR (100 MHz, CDCl3) 
δ ppm: 19.8, 28.3, 29.9, 30.5, 30.8, 35.2, 43.5, 49.9, 51.8, 79.3, 155.7, 
173.9, 181.4.  
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Methyl 4-{[(tert-butoxy)carbonyl]amino}-8-oxodecanoate (172b) 
 
1H NMR (400 MHz, CDCl3) δ ppm: 1.09 (3 H, m, CH3CH2), 1.32-1.50 (2 H, 
m, CH2CH2CO), 1.42 (9 H, s, C(CH3)3), 1.53-1.71 (2 H, m, CH2CH), 1.53-
1.71 (1 H, m, CHAHBCH), 1.76-1.89 (1 H, m, CHAHBCH), 2.31-2.49  (2 H, 
m, CH2CO), 2.31-2.49 (2 H, m, CH2CO), 2.31-2.49 (2 H, m, CH2CO2CH3), 
3.49-3.61 (1 H, m, CHN), 3.66 (3 H, s, CO2CH3), 4.30 (1 H, d J 9.5 Hz, 
NH); 13C NMR (100 MHz, CDCl3) δ ppm: 19.9, 28.3, 29.9, 30.8, 32.3, 35.2, 
35.9, 43.5, 49.9, 51.6, 79.3, 155.7, 173.8, 181.2.  
Trifluoroacetic acid methyl (2S)-6-methyl-2,3,4,5-tetrahydropyridine-2 
carboxylate (174a) 
 
Trifluoroacetic acid (4.4 g, 39.2 mmol) was added dropwise to the stirred 
solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxoheptanoate 
170a (218 mg, 0.8 mmol) in dichloromethane (40 mL), and the reaction 
mixture stirred for a further 20 min. At this time, the solvent and excess 
trifluoroacetic acid was removed under reduced to produce the title 
compound as brown oil.  
νmax/cm
-1: 1748, 1666, 1519,1438; 1H NMR (400 MHz, CDCl3) δ ppm: 
1.78-1.98 (2 H, m, CH2CH2), 2.09-2.25 (2 H, m, CH2CH), 2.57 (3 H, s, 
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CH3C=N), 2.81 (2 H, t J 6.0 Hz, CH2C=N), 3.81 (3 H, s, CO2CH3), 4.68 (1 
H, td J 5.5 and 1.5 Hz, CHN), 11.60-11.75 (1 H, br, NH); 13C NMR (100 
MHz, CDCl3) δ ppm: 15.2, 22.4, 24.9, 31.8, 53.6, 56.4, 115.5 (q J 288 Hz), 
160.6 (q J 40 Hz), 167.7, 191.8; Found MH+ 156.1023. C8H14NO2 requires 
MH+ 156.1025. 
Trifluoroacetic acid methyl (2S)-6-ethyl-2,3,4,5-tetrahydropyridine-2-
carboxylate (174b) 
 
Trifluoroacetic acid (4.4 g, 39.2 mmol) was added dropwise to the stirred 
solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxooctanoate 
170b (230 mg, 0.8 mmol) in dichloromethane (40 mL), and the reaction 
mixture stirred for a further 20 min. At this time, the solvent and excess 
trifluoroacetic acid was removed under reduced to produce the title 
compound as brown oil.  
νmax/cm
-1: 2961, 1747, 1664, 1439; 1H NMR (400 MHz, CDCl3) δ ppm: 
1.32 (3 H, t J 7.5 Hz, CH3CH2), 1.77-1.88 (1 H, m, CHAHBCH), 1.88-1.99 
(1 H, m, CHAHBCH), 2.14-2.21 (2 H, m, CH2CH2CH), 2.75-2.92 (2 H, m, 
CH2C=N), 2.75-2.92 (2 H, m, CH2CH3), 3.81 (3 H, s, CO2CH3), 4.71 (1 H, t 
J 5.0 Hz, CHN); 13C NMR (100 MHz, CDCl3) δ ppm: 9.9, 14.9, 22.6, 29.3, 
31.7, 53.4, 56.2, 117.9 (q J 286 Hz), 160.7 (q J 38.5 Hz), 167.9, 195.8; 
Found MH+ 170.1185. C9H16NO2 requires MH
+ 170.1181.; [α]D
23 +36 (c 1.0 
in CHCl3).   
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Trifluoroacetic acid methyl (2S)-6-propyl-2,3,4,5-tetrahydropyridine-2-
carboxylate (174c) 
 
Trifluoroacetic acid (4.4 g, 39.2 mmol) was added dropwise to the stirred 
solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-6-oxononanoate 
170c (239 mg, 0.8 mmol) in dichloromethane (40 mL), and the reaction 
mixture stirred for a further 20 min. At this time, the solvent and excess 
trifluoroacetic acid was removed under reduced to produce the title 
compound as brown oil. 
νmax/cm
-1: 2969, 1750, 1660, 1450;  1H NMR (400 MHz, CDCl3) δ ppm: 
1.03 (3 H, t J 7.5 Hz, CH3CH2), 1.69-1.87 (1 H, m, CHAHBCH), 1.69-1.87 
(2 H, m, CH3CH2), 1.88-1.99 (1 H, m, CHAHBCH), 2.12-2.23 (2 H, m, 
CH2CH2CH), 2.69-2.84 (2 H, m, CH2C=N), 2.69-2.84 (2 H, m, 
CH2CH2CH3), 3.81 (3 H, s, CO2CH3), 4.73 (1 H, t J 5.0 Hz, CHN); 
13C 
NMR (100 MHz, CDCl3) δ ppm: 13.2, 15.0, 20.2, 22.6, 29.7, 39.9, 53.6, 
56.2, 114.0 (q J 300 Hz), 160.7 (q J 60 Hz), 167.9, 194.5; Found MH+ 
184.1335. C10H18NO2 requires MH
+ 184.1338.; [α]D
23 +50 (c 1.0 in CHCl3).  
Methyl (2S)-6-methylpiperidine-2-carboxylate (175a/175b) 
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Sodium borohydride (8.19 mg, 0.2 mmol, 1.0 eq) was added to a stirred 
solution of trifluoroacetic acid methyl (2S)-6-methyl-2,3,4,5-
tetrahydropyridine-2 carboxylate 174a (53.8 mg, 0.2 mmol, 1.0 eq) in 
methanol (8.5 mL) at -78 °C. The mixture was stirred for 1 h at -78 °C, and 
the reaction was quenched by addition of acetone (0.04 mL). After 
concentration, the resulting oil was dissolved in chloroform and methanol 
(10:1) (10 mL), washed with saturated ammonium sulfate solution, and 
dried over magnesium sulfate and concentrated on rotary evaporator to 
provide the title compound as colorless oil (27 mg, 85%).114 The ratio of 
cis : trans (6 : 1) determined by 1H-NMR spectroscopy of the crude 
product. 
νmax/cm
-1: 2973, 1711; cis diastereoisomer 175a: 1H NMR (400 MHz, 
CDCl3) δ ppm: 1.12 (3 H, d J 6.5 Hz, CH3CH), 1.0-1.15 ( 1 H, m, 
CHAHBCHCH3), 1.32-1.49 (2 H, m, CH2CH2CH), 1.72-1.83 (1 H, m, 
CHAHBCHCH3), 1.83-1.91 (1 H, m, CHAHBCHN), 1.96-2.02 (1 H, m, 
CHAHBCHN), 2.12-2.50 (1 H, br, NH), 2.67 (1 H, dqd J 12.0, 6.5 and 2.5 
Hz, CH3CH), 3.38 (1 H, dd J 11.5 and 3.0 Hz, NHCH(ax)CO2CH3), 3.71 (3 
H, s, CO2CH3); 
13C NMR (100 MHz, CDCl3) δ-ppm: 23.1, 28.2, 29.7, 31.2, 
52.0, 58.0, 59.9, 173.8. trans diastereoisomer 175b: 1H NMR (400 MHz, 
CDCl3) δ ppm: 1.15 (3 H, d J 6.5 Hz, CH3CH), 1.0-1.15 ( 1 H, m, 
CHAHBCHCH3), 1.32-1.49 (2 H, m, CH2CH2CH), 1.72-1.83 (1 H, m, 
CHAHBCHCH3), 1.83-1.91 (1 H, m, CHAHBCHN), 1.96-2.02 (1 H, m, 
CHAHBCHN), 2.12-2.50 (1 H, br, NH), 2.91-3.0 (1 H, m, CH3CH), 3.73 (3 
H, s, CO2CH3), 3.75-3.83 (1 H, m, NHCH(ax)CO2CH3); 
13C NMR (100 MHz, 
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CDCl3) δ ppm: 23.1, 23.7, 26.4, 28.2,  29.3, 29.7, 31.2, 46.0, 52.0, 55.1, 
57.2, 58.0, 59.9, 167.6, 173.8. Found MH+ 158.1183. C8H16NO2 requires 
MH+ 158.1181. 
Methyl (2S)-6-ethylpiperidine-2-carboxylate (176a/176b) 
 
Sodium borohydride (8.19 mg, 0.2 mmol, 1.0 eq) was added to a stirred 
solution of trifluoroacetic acid methyl (2S)-6-ethyl-2,3,4,5-
tetrahydropyridine-2-carboxylate 174b (56 mg, 0.2 mmol, 1.0 eq) in 
methanol (8.5 mL) at -78 °C. The mixture was stirred for 1 h at -78 °C, and 
the reaction was quenched by addition of acetone (0.04 mL). After 
concentration, the resulting oil was dissolved in chloroform and methanol 
(10:1) (10 mL), washed with saturated ammonium sulfate solution, and 
dried over magnesium sulfate and concentrated on rotary evaporator to 
provide the title compound as colorless oil (30 mg, 88%). The ratio of cis : 
trans (6 : 1) determined by 1H-NMR spectroscopy of the crude product. 
νmax/cm
-1: 3008, 2949, 1797, 1795, 1388, 1382; cis diastereoisomer 
176a: 1H NMR (400 MHz, CDCl3) δ ppm: 0.92 (3 H, t J 7.5 Hz, CH3CH2), 
0.97-1.09 (1 H, m, CHA(eq)HBCHCH2CH3), 1.36-1.51 (2 H, m, CH2CH2CH), 
1.36-1.51 (2 H, m, CH2CH3), 1.68 (1 H, d J 11.0 Hz, 
CHAHB(ax)CHCH2CH3), 1.83-1.91 (1 H, m, CHA(eq)HBCHN), 2.00-2.09 (1 H, 
m, CHAHB(ax)CHN), 2.17-2.27 (1 H, br, NH), 2.43 (1 H, dtd J 11.5 6.5 and 
2.5 Hz, CH3CH2CH(ax)), 3.36 (1 H, dd J 11.5 and 3.0 Hz, 
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NHCH(ax)CO2CH3), 3.71 (3 H, s, CO2CH3); trans diastereoisomer 176b: 
1H NMR (400 MHz, CDCl3) δ-ppm: 0.91 (3 H, t J 7.5 Hz, CH3CH2), 0.97-
1.09 (1 H, m, CHAHBCHCH2CH3), 1.36-1.51 (2 H, m, CH2CH2CH), 1.36-
1.51 (2 H, m, CH2CH3), 1.68 (1 H, m, CHAHBCHCH2CH3), 1.83-1.91 (1 H, 
m, CHAHBCHN), 2.00-2.09 (1 H, m, CHAHBCHN), 2.17-2.27 (1 H, br, NH), 
2.73-2.84 (1 H, br, CH3CH2CH), 3.75 (3 H, s, CO2CH3), 3.87-3.92 (1 H, br, 
NHCHCO2CH3); 
13C NMR (100 MHz, CDCl3) δ-ppm: 10.0, 10.3, 20.9, 
26.4, 29.2, 29.7, 31.2, 46.0, 51.9, 55.1, 57.2, 58.0, 59.3, 167.6, 173.6; 
Found MH+ 172.1330. C9H18NO2 requires MH
+ 172.1338. 
Methyl (2S)-6-propylpiperidine-2-carboxylate (177a/177b) 
 
Sodium borohydride (8.19 mg, 0.2 mmol, 1.0 eq) was added to a stirred 
solution of trifluoroacetic acid methyl (2S)-6-propyl-2,3,4,5-
tetrahydropyridine-2-carboxylate 174c (59 mg, 0.2 mmol, 1.0 eq) in 
methanol (8.5 mL) at -78 °C. The mixture was stirred for 1 h at -78 °C, and 
the reaction was quenched by addition of acetone (0.04 mL). After 
concentration, the resulting oil was dissolved in chloroform and methanol 
(10:1) (10 mL), washed with saturated ammonium sulfate solution, and 
dried over magnesium sulfate and concentrated on rotary evaporator to 
provide the title compound as colorless oil (28 mg, 89%). The ratio of cis : 
trans (6 : 1) determined by 1H-NMR spectroscopy of the crude product. 
νmax/cm
-1: 2958, 1740; cis diastereoisomer 177a: 1H NMR (400 MHz, 
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CDCl3) δ ppm: 0.85-.91 (2 H, m, CH3CH2CH2), 0.91 (3 H, t J 7.5 Hz, 
CH3CH2), 1.0-1.13 (1 H, m, CHA(eq)HBCHCH2CH2CH3), 1.29-1.49 (2 H, m, 
CH2CH2CH), 1.29-1.49 (2 H, m, CH2CH2CH3), 1.62 (1 H, d J 13.0 Hz, 
CHAHB(ax)CHCH2CH2CH3), 1.83-1.91 (1 H, m, CHA(eq)HBCHN), 1.97-2.05 
(1 H, m, CHAHB(ax)CHN), 2.17-2.27 (1 H, br, NH), 2.54 (1 H, dtd J 11.5 6.5 
and 2.5 Hz, CH3CH2CH2CH(ax)), 3.40 (1 H, dd J 11.5 and 3.0 Hz, 
NHCH(ax)CO2CH3), 3.71 (3 H, s, CO2CH3); trans diastereoisomer 177b: 
1H NMR (400 MHz, CDCl3) δ ppm: 0.85-.91 (2 H, m, CH3CH2CH2), 0.91 (3 
H, t J 7.5 Hz, CH3CH2), 1.0-1.13 (1 H, m, CHAHBCHCH2CH3), 1.29-1.49 (2 
H, m, CH2CH2CH), 1.29-1.49 (2 H, m, CH2CH2CH3), 1.58-1.64 (1 H, m, 
CHAHBCHCH2CH2CH3), 1.83-1.91 (1 H, m, CHAHBCHN), 1.97-2.05 (1 H, 
m, CHAHBCHN), 2.17-2.27 (1 H, br, NH), 2.73-2.84 (1 H, br, 
CH3CH2CH2CH), 3.76 (3 H, s, CO2CH3), 3.87-3.92 (1 H, br, 
NHCHCO2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 14.1, 14.2, 18.9, 
19.0, 24.1, 24.2, 28.9, 29.7, 31.2, 31.3, 38.6, 38.7, 52.0, 52.1, 56.3, 59.1, 
59.2, 177.5, 179.8; Found MH+ 186.1487. C10H20NO2 requires MH
+ 
186.1494.  
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